Heinz-Josef Lenz, M.D. Curriculum Vitae › wp-content › uploads › 2019 › 11 ›...

Heinz-Josef Lenz, M.D. Curriculum Vitae

USC Department of Medicine Page 52 of 173

Molecular Markers on early and Metastatic Disease: What should be ordered and

what are their prognostic and predictive roles? 3rd Invitation Satellite Symposium

on G.I. Cancer Sao Paulo Brazil 8/7/19

Immunotherapy in MSI-H colorectal cancer: What is the best sequence? How to

select drugs and combinations? Satellite Symposium on G.I. Cancer Sao Paulo

Brazil 8/8/19

Liquid biopsies or new developments. Satellite Symposium on G.I. Cancer Sao Paulo

Brazil 8/9/19

Continuum of Care in RASwt Metastatic Colorectal Cancer. “ConCiencia” Mendoza

Argentina 8/22/19

LATAM Multikinase Inhibitors mCRC. Barcelona. 9/26/2019

Molecular Landscape of mCRC. Grand Rounds. Emory University. Atlanta,

9/11/2019

Mechanisms of Action of Regorafenib. Satellite Symposium, ESMO, Barcelona,

9/28/2019

Next Generation Sequencing in mCRC: Novel Mutated Genes and their effect on

response to therapy. Oral presentation at ESMO 9/30/2019, Barcelona, Spain.

H. Bibliography:

Peer Reviewed

1. Jaschonek K, Einsele H, Schmitt H, Lenz H-J, Ehninger G: 8-Methoxypsoralen and

ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Lancet,

1:599, 1988.

2. Ehninger G, Lenz H-J: Stand der intraperitonealen chemotherapie. Z Gastroenterol

Verh, 24:196–198, 1989.

3. Lenz H-J, Brunner T, Dopfer R, Schlag H, Ehninger G: Kontinuierliche infusion von

natürlichem interleukin-2 zur behandlung maligner erkrankungen: phase I studie.

Onkologie, 13:429–433, 1990.

4. Lenz H-J, Jaschonek K, Schuler U, Steinke B, Ehninger G: Splenectomy for chronic

thrombotic thrombocytopenic purpura. Lancet 335:1593, 1990.

5. Lenz H-J, Schuler U, Hicking W, Ehninger G: Phase I trial of clebopride: a new

antiemetic for chemotherapy induced nausea and vomiting. Eur J Clin Pharmacol,

38:525, 1990.

6. Pawelec G, Schwulera U, Lenz H-J, Owsianowshi M, Bühring HJ, Schlag H,

Schneider E, Schaudt K, Ehninger G: Lymphokine release, suppressor cell generation,

cell surface markers and cytotoxic activity in cancer patients receiving natural

interleukin-2. Molecul Biother, 2:44–49, 1990.

7. Lenz H-J, Schuler U, Jaschonek K, Steinke B, Ehninger G, Waller HD: ZNS-

Manifestationen beim metastasierendem mammakarzinom. Tumor Diagnostik und

Therapie, 12:177–182, 1991.

8. Lenz H-J, Waller HD: Autoimmune hemolytic anemia in a patient with polycythemia

vera: first description. Acta Haematol, 85:111, 1991.



9. Pawelec G, Lenz H-J, Schneider E, Bühring HJ, Rehbein A, Baumgärtner P, Ehninger

G: Clinical trial of natural human lymphocyte-derived interleukin-2 in cancer patients:

effects on cytokine production and suppressor cell status. Biotherapy, 3:309–318, 1991.

10. Danenberg PV, Horikoshi T, Volkenandt M, Danenberg K, Lenz H-J, Shea LC, Dicker

AP, Simoneau A, Jones PA, Bertino JR: Detection of point mutations in human DNA

by analysis of RNA conformation polymorphism(s). Nucleic Acids Res, 20:573–579,

1992.

11. Lenz H-J, Schuler U, Hicking W, Ehninger G: Pharmacology of clebopride: a new

benzamide derivate. Drug Invest, 4:47–50, 1992.

12. Horikoshi T, Lenz H-J, Danenberg K, Koch O, Bertino JR, Danenberg PV:

Quantitation determination of the ratio of a mutated to normal ras genes in the blood of

leukemia patients by allele-specific PCR. Leuk Res, 18:693–702, 1994.

13. Koch OM, Probst M, Tiemann M, Jakob I, Volkenandt M, Wienecke R, Buer J,

Atzpodien J, Lenz H-J, Danenberg PV, Bertino JR, Parwaresch R: Detection of clonal

T-cell populations in gastrointestinal lymphomas by analysis of cRNA conformational

polymorphism of rearranged T-cell receptor gamma genes. Br J Haematol, 86:316–321,

1994.

14. Lenz H-J, Danenberg KD, Mano DJ, Danenberg PV: Incorporation of 5-fluorouracil

into U2 and U6 snRNA inhibits precursor mRNA splicing. J Biol Chem, 269:31962–

31968, 1994.

15. Lenz H-J, Danenberg KD, Schnieders B, Goeker E, Peters GJ, Garrow T, Shane B,

Bertino JR, Danenberg PV: Quantitative analysis of folylpolyglutamate synthetase gene

expression in tumor tissues by the polymerase chain reaction: marked variation of

expression among leukemia patients. Oncology Res, 6:329–335, 1994.

16. Schmittgen TD, Danenberg KD, Horikoshi T, Lenz H-J, Danenberg PV: Effect of 5-

fluoro- and 5-bromouracil-substitution on the translation of human thymidylate

synthase mRNA. J Biol Chem, 269:16269–16275, 1994.

17. Banerjee D, Lenz H-J, Schnieders B, Manno DJ, Ju JF, Spears CP, Hochhauser D,

Danenberg KD, Danenberg PV, Bertino JR: Transfection of wild type but not mutant

p53 induces early monocytic differentiation in HL-60 cells. Cell Growth Differ,

6:1405–1413, 1995.

18. Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV,

Leichman L: Thymidylate synthase gene and protein expression are associated and

correlate with response to 5-fluorouracil in human colorectal and gastric tumors.

Cancer Res, 55:1407–1412, 1995.

19. Leichman L, Lenz H-J, Leichman CG, Groshen S, Danenberg K, Baranda J, Spears

CP, Boswell W, Silberman H, Ortega A, Stain S, Beart R, Danenberg P: Quantitation of

intratumoral thymidylate synthase expression predicts for resistance to protracted

infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers:

preliminary report from an ongoing trial. Eur J Cancer, 31A:1306–1310, 1995.

20. Lenz H-J, Danenberg KD, Schnieders B, Banerjee D, Bertino JR, Leichman L,

Danenberg PV: Identification of mutations by RNA conformational polymorphism

“Bar Code” analysis. Genomics, 30:120–122, 1995.

21. Link KH, Kornmann M, Lenz H-J, Butzer U, Pillasch J, Safi F, Gansauge F,

Danenberg KD, Danenberg PV, Beger HG: Response prediction in hepatic artery



infusion with fluoropyrimidines using cell culture and thymidylate synthase

quantitation. Reg Cancer Treat, 8:115–121, 1995.

22. Wang S-J, Scavetta R, Lenz H-J, Danenberg KD, Danenberg PV, Schoenthal AH:

Gene amplification and multidrug-resistance induced by the phosphatase-inhibitory

tumor promoter okadaic acid. Carcinogenesis, 16:637–641, 1995.

23. Lenz H-J, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen J, Laine

L, Crookes P, Silberman J, Baranda J, Garcia Y, Li J, Leichman LP: Thymidylate

synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor

response and overall survival. J Clin Oncol, 14:176–182, 1996.

24. Formenti SC, Dunnington G, Uziely B, Lenz-H-J, Keren-Rosenberg S, Silberman H,

Spicer D, Denk M, Leichman CG, Groshen S, Watkins K, Muggia F, Florentine B,

Press M, Danenberg KD, Danenberg P: Original p53 status predicts for pathological

response in locally advanced breast cancer patients treated preoperatively with

continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys,

39:1059–1068, 1997.

25. Hayashi K, Metzger R, Salonga D, Danenberg K, Leichman LP, Fink U, Sendler A,

Kelsen D, Schwartz G, Groshen S, Lenz H-J, Danenberg PV: High frequency of

simultaneous loss of p16 and p16ß gene expression in squamous cell carcinoma of the

esophagus but not in adenocarcinoma of the esophagus or stomach. Oncogene,

15:1481–1488, 1997.

26. Kornmann M, Link KH, Lenz H-J, Pillasch J, Metzger R, Butzer U, Leder GH,

Weindel M, Safi F, Danenberg KD, Beger HG, Danenberg PV: Thymidylate synthase

is a predictor for response and resistance in hepatic artery infusion chemotherapy.

Cancer Lett, 118:29–35, 1997.

27. Leichman CG, Lenz H-J, Leichman LP, Danenberg KS, Baranda J, Groshen S,

Boswell W, Metzger R, Tan M, Danenberg PV: Quantitation of intratumoral

thymidylate synthase expression predicts for disseminated colorectal cancer response

and resistance to protracted-infusion of 5-FU and weekly leucovorin. J Clin Oncol,

15:3223–3229, 1997.

28. Lenz H-J, Leichman CG, Leichman LP, Metzger R, Danenberg KD, Hayashi K,

Danenberg PV, Groshen S: Molecular markers as indicators of response and outcome in

primary gastric cancer. Prog Gastric Cancer Re, 2:1295–1300, 1997.

29. Ju J, Kane SE, Lenz H-J, Danenberg KD, Chu E, Danenberg PV: Desensitization and

sensitization of cells to fluoropyrimidines with different antisenses directed against

thymidylate synthase messenger RNA. Clin Cancer Res 4:2229–2236, 1998.

30. Ju J-F, Banerjee D, Lenz H-J, Danenberg KD, Schmittgen TC, Spears CP, Schonthal

AJ, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV: Restoration of wild-type

p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res,

4:1315–1322, 1998.

31. Lenz H-J, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou

L, Xiong Y-P, Danenberg PV, Leichman LP: p53 and thymidylate synthase expression

in untreated stage II colon cancer: association with recurrence, survival, and site. Clin

Cancer Res, 4:1227–1234, 1998.

32. Lenz H-J, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee

D, Bertino JR, Groshen S, Leichman LP, Leichman CG: p53 Point mutations and



thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an

analysis of response and survival. Clin Cancer Res, 4:1243–1250, 1998.

33. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz H-

J, Groshen S, Leichman LP, Danenberg PV: High basal level gene expression of

thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal

tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res, 4:2371–

2376, 1998.

34. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz H-J, Hayashi K,

Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda

B, Leichman LP: ERCC1 mRNA levels complement thymidylate synthase mRNA

levels in predicting response and survival for gastric cancer patients receiving

combination cisplatin and 5-fluorouracil chemotherapy. J Clin Oncol, 16:309–316,

1998.

35. Yang L, Chiang Y, Lenz H-J, Danenberg KD, Spears CP, Gordon EM, Anderson WF,

Parekh D: Intercellular communication mediates the bystander effect during herpes

simplex thymidine kinase/gancyclovir based gene therapy of human gastrointestinal

tumor cells. Hum Gene Ther, 9:719–728, 1998.

36. Brabender J, Lenz H-J, Danenberg PV: Molekulare Marker als Grundlage für die

Chemotherapie? Chirurgie, 71:1433–1439, 2000.

37. Ladner RD, Lynch FJ, Groshen S, Xiong Y-P, Sherrod A, Caradonna SJ, Stoehlmacher

J, Lenz H-J: dUTP nucleotidohydrolase isoform expression in normal and neoplastic

tissues: association with survival and response to 5-fluorouracil in colorectal cancer.

Cancer Res, 60:3493–3503, 2000.

38. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz H-

J, Leichman CG, Leichman LP, Diasio RB, Danenberg PV: Colorectal tumors

responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine

dehydrogenase, thymidylate synthase and thymidine phosphorylase. Clin Cancer Res,

6:1322–1327, 2000.

39. Anton PA, Poles MA, Elliott J, Mao SH, McGowan I, Lenz H-J, Chen ISY: Sensitive

and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in

patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic

biopsies. J Virol Methods, 195:65–79, 2001.

40. Garcia AA, Leichman CG, Lenz H-J, Baranda J, Lujan R, Casagrande Y, Leichman

LP: Phase II trial of outpatient schedule of paclitaxel in patients with previously

untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Onco,l

31:275–278, 2001.

41. Lara Jr PN, Gandara DR, Longmate J, Gumerlock PH, Lau DHM, Edelman MJ,

Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz H-J,

Doroshow JH: Activity of high-dose toremifene plus cisplatin in platinum-treated non-

small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer

Chemother Pharmacol, 48:22–28, 2001.

42. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz H-J: A

Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to

platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res,

61:8654–8658, 2001.


USC Department of Medicine 6 of 173

43. Pullarkat ST, Xiong Y-P, Ghaderi V, Stoehlmacher J, Ingles SA, Sherrod A, Warren R,

Tsao-Wei D, Groshen S, Lenz H-J: Thymidylate synthase gene polymorphism

determines thymidylate synthase mRNA levels and outcome of metastatic colorectal

carcinoma treated with 5-fluorouracil. Pharmacogenomics, 1:65–70, 2001.

44. Shirota Y, Stoehlmacher J, Brabender J, Xiong Y-P, Danenberg KD, Groshen S, Tsao-

Wei DD, Danenberg PV, Lenz H-J: ERCC1 mRNA levels and thymidylate synthase

(TS) mRNA levels predict survival in colorectal cancer patients receiving combination

oxaliplatin and fluorouracil chemotherapy. J Clin Oncol, 19:4298–4304, 2001.

45. Stoehlmacher J, Ghaderi V, Iqbal S, Groshen S, Tsao-Wei D, Park D, Lenz H-J: A

polymorphism of the XRCC1 gene predicts for response to platinum based treatment in

advanced colorectal cancer. Anticancer Res, 21:3075–3080, 2001.

46. Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata

S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz H-J, Gandara D, Doroshow JH:

Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced

malignancies. Clin Cancer Res, 7:1569–1576, 2001.

47. Lenz H-J, Anderson WF, Hall FL, Gordon EM: Clinical protocol. Tumor site specific

phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted

retroviral vector bearing a dominant negative cyclin G1 construct as intervention for

colorectal carcinoma metastatic to liver. Hum Gene The,r 13:1515–1537, 2002.

48. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz H-J: Thymidylate

synthase gene polymorphism predicts response to capecitabine in advanced colorectal

cancer. Int J Colorectal Dis, 17:46–49, 2002.

49. Stoehlmacher J, Ingles SA, Park DJ, Zhang W, Lenz H-J: The -9Ala/-9Val

polymorphism in the mitochondrial targeting sequence of the manganese superoxide

dismutase gene (MnSOD) is associated with age among Hispanics with colorectal

carcinoma. Oncology Reports, 9:235–238, 2002.

50. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz H-J:

Association between glutathione s-transferase P1, T1, and M1 genetic polymorphism

and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 94:936–

942, 2002.

51. Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G,

Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D,

Dorosho JH: Phase I pharmacodynamic study of time and sequence dependency of

hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.

Cancer Chemotherapy & Pharmacology, 50(5):353-359, 2002.

52. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz H-J,

Ladner R: A novel SNP within the 5’tandem repeat polymorphism of the thymidylate

synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res,

63(11):2898–2904, 2003.

53. Stoehlmacher J, Lenz HJ: Implications of genetic testing in the management of

colorectal cancer. Am J Pharmacogenomics, 3(2):73–88, 2003.

54. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E,

Mallik N, Lenz H-J: ERCC1 gene polymorphism as a predictor for clinical outcome in

advanced colorectal cancer patients treated with platinum-based chemotherapy. Clinical

Advances in Hematology and Oncology, 1(3):162–166, 2003.

55. Hecht JR, Blanke CD, Benson AB 3rd, Lenz H-J: Irinotecan and paclitaxel in



metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology (Huntington),

17(9):13–15, 2003.

56. Ramanathan RK, Clark J, Kemeny N, Lenz H-J, Gococo K, Haller D, Mitchell E,

Kardinal C: Safety and toxicity analysis of oxaliplatin (Eloxatin™) combined with 5-

fluorouracil or as a single agent in more than 5000 patients with previously treated

advanced colorectal cancer. J Clin Oncol, 21(15):2904–2911, 2003.

57. Juhasz A, Frankel P, Cheng C, Rivera H, Vishwanath R, Chiu A, Gargolin K, Yen Y,

Newman EM, Synold T, Wilczynski S, Lenz H-J, Gandara D, Albain KS, Longmate J,

Doroshow JH: Quantification of chemotherapeutic target gene mRNA expression in

human breast cancer biopsies: Comparison of real-time reverse transcription-PCR v

Relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of

PCR products. J Clin Lab Anal, 17(5):184–194, 2003.

58. Zhang W, Lu B, Gil J, Yang D, Groshen S, Lenz H-J: Interleukin-8 (IL-8) promoter

region gene polymorphism predicts pelvic recurrence after chemo-radiation in patients

with rectal cancer. Int J Radiat Oncol Riol Phys, 57(2):S382, 2003.

59. Lara PN Jr., Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J,

Doroshow JH, Lenz H-J, Lau DH, Gandara DR: Tirapazamine plus carboplatin and

paclitaxel in advanced malignant solid tumors: a California Cancer Consortium phase I

and molecular correlative study. Clin Cancer Res, 9(12):4356–4362, 2003.

60. Lara PN Jr., Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC,

Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH,

Lenz H-J, Doroshow JH, Gandara DR: California Cancer Consortium. SU5416 plus

interferon alpha in advanced renal cell carcinoma: a phase II California Cancer

Consortium Study with biological and imaging correlates of angiogenesis inhibition.

Clin Cancer Res, 9(13):4772–4781, 2003.

61. Garcia AA, Leichman L, Baranda L, Pandit L, Lenz HJ, Leichman CG. Phase II

clinical trail of 5-flourouracil, trimetrexate, and leucovorin (NFL) in patients with

advanced pancreatic cancer. Int J Gastrointestinal Cancer, 34(2-3): 79-86, 2003.

62. Stoehlmacher J, Lenz H-J: Cyclooxygenase-2 inhibitors in colorectal cancer. Semin

Oncol. 30(3 Suppl 6):10–16, 2003.

63. Stoehlmacher J, Goekkurt E, Lenz HJ. Pharmacogenetic ascpects in treatment of

colorectal cancer- an update. Pharmacogenomics, 4(6):767-77, Nov 2003.

64. Whitehead RP, Benedetti JK, Abbruzzese JL, ardalan B, Goodwin JW, Balcerzak SP,

Samlowski WE, Lenz H-J, Macdonald JS: A phase II study of high-dose 24 hour

continuous infusion 5-FU and leucovorin and low-dose PALA for patients with

advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study.

Investigational New Drugs, 22(3):335–341, 2004.

65. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ: A

multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-

FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer,

91:344–354, 2004.

66. Lenz HJ. Angiogenesis as a target in colorectal cancer therapy. (Introduction). Sem

Oncol, 31(6 Suppl 17):1-2, 2004

67. Iqbal S, Lenz H-J: Integration of novel agents in the treatment of colorectal cancer.

Cancer Chemotherapy and Pharmacology, 54(1): S32-S39, 2004.



68. Iqbal S, Lenz H-J: Capecitabine: the new generation of flouropyrimidines in colorectal

cancer. Expert Rev Anticancer Ther, 4(6):947-955, 2004.

69. Kimura T, Holland WS, Kawaguchi T, Williamson SK, Chansky K, Crowley JJ,

Doroshow JH, Lenz H-J, Dandara DR, Gumerlock PH. Mutant DNA in plasma of lung

cancer patients: Potential for monitoring response to therapy. Ann. N.Y. Acad. Sci,

1022:55-60, 2004.

70. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ,

Ladner RD. A 6 bp Polymorphism in the Thymidylate Synthase Gene Causes Message

Instability and is Associated with Decreased Intratumoral TS mRNA Levels.

Pharmacogenetics, 14(5):319-327, 2004. [PMID: 15115918]

71. Lara PN, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi

T, Gumerlock PH, Doroshow JH, Gandara DR. Intermittent dosing of the farnesyl

transferase inhibitor tipifarnib (R115777) in advanced mailgnant solid tumors: a phase I

California Cancer Consortium Trial. Anti-Cancer Drugs, 16(3):317-21, March 2005.

72. Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh

N. Gynecologic Oncology Group. Phase II clinical trial of capecitabine of ovarian

carcinoma recurrent 6-12 months after completion of primary chemotherapy, with

exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.

Gynecologic Oncology, 96(3):810-7, March 2005.

73. Zhang W, Park DJ, Lu B, Yang DY, Gordon M, Groshen S, Yun J, Press OA,

Vallboehmer D, Rhodes K, Lenz HJ. Epidermal growth factor receptor gene

polymorphisms predict pelvic recurrence in patients with rectal cancer treated with

chemoradiation. Clinical Cancer Research, 11(2 pt 1): 600-5, Jan 15, 2005.

74. Vallboehmer D, Lenz HJ. EGFR as a Target for Chemotherapy. Clin Colorectal

Cancer 5(1): S19-S27, 2005.

75. Vallboehmer, D, Zhang W. Gordon M, Yang DY, Yun J, Press OA, Rhodes KE,

Sherrod AE, Iqbal S, Danenberg K, Groshen S, Lenz HJ. Molecular Determinants of

Cetuxiamb Efficacy of Cetuxmab therapy. J Clin Oncology, 23(15): 3536-3544, 2005.

76. Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, Beringer P, Louie S. Phase I clinical

and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly

schedule. Cancer Chemotherapy and Pharmacology, 56(1):75-82, July 2005.

77. Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J. Tsao-Wei DD, Yun J,

Gordon M, Press OA, Rhodes K, Groshen S, Lenz HJ. Gene polymorphisms of

epidermal growth factor receptor and its downstream effector, interleukin-8, predict

oxaliplatin efficacy in patients with advanced colorectal cancer. Clinical Colorectal

Cancer, 5(2):124-31, July 2005.

78. Leichman CG, Benedetti JK, Zalupski MM, Hochster H, Shields AF, Lenz HJ, Wade

Iii JL, Bearden Iii JD, Macdonald JS. Assessment of infusional 5-Fluorouracil schedule

and dose intensity: a southwest oncology group and eastern cooperative oncology group

study.Clinical Colorectal Cancer, 5(2):119-23, July 2005.

79. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the

dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY

43-9006, in patients with advanced, refractory solid tumors. Clinical Cancer Research,

11(15):5472-5480, Aug 1, 2005.

80. Venook AP. Blanke CD. Niedzwiecki D. Lenz HJ. Taylor JR. Hollis DR. Sutherland

S. Goldberg RM. Cancer and Leukemia Group B/Southwest Oncology Group trial



80405: a phase III trial of chemotherapy and biologics for patients with untreated

advanced colorectal adenocarcinoma. Clinical Colorectal Cancer, 5(4):292-4, 2005

Nov.

81. Ajani J, Lee FC, Singh D, Haller DG, Lenz H-J, Benson AB, Yanagihara R, Phan AT,

Yao JC, Strumberg D. A Multicenter Phase II Trial of S-1 Plus Cisplatin in Patients

with Untreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. J

Clin Oncol, 21(24)4:1-5, 2006.

82. Kemeney NE, Niedzwiecki D, Hollis DR, Lenz H-J, Warren RS, Naughton MJ, Weeks

JC, Sigurdson ER, Herndon JE, Zhang C, Mayer RJ, Zhang W, Park DJ. Hepatic

Arterial Infusion Versus Systemic Therapy for Hepatic Metastatses from Colorectal

Cancer: A Randomized Trail of Efficacy, Quality of Life, and Molecular Markers

(CALGB 9481). J Clin Oncol, 24(9)1395-1403, March 2006.

83. McCoy S, Macdonald J, Rivkin S, Dakhil S, Lenz H-J, Abbruzzese J, Tanaka M,

Whitehead R. Phase II trial of R115777 in patients with advanced colorectal cancer: A

Southwest Oncology Group study. Invest New Drugs, 23(5):485-487, Oct. 2005,

[PMID: 16133800]

84. Garcia AA, Iqbal S, Quinn D, Edwards E, Lenz H-J, Weber J. Phase I Clinical Trial of

Weekly Docetaxel and Exisulind, A Novel Inducer of Apoptosis. Invest New Drugs,

24(1):79-83, 2006. [PMID: 16379039].

85. Lara P, Gandara D, Stadler W, Quinn D, Vanloan M, Gumerlock P, Vokes E, Lenz H-

J, Doroshow J, Longmate J, Vogelza N, Wexler J. A Randomized Phase II Trial of the

Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone Refractory Prostate

Cancer Patients with Bone Metastases. Clin Cancer Res, 12(5):1556-1563, March 1,

2006.

86. El-Khoueiry A, Lenz H-J. Pharmacogenomics and Molecular Biology in

Gastrointestinal Cancers. Atlas in GI Cancers, 2006.

87. Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S,

Press OA, Rhodes K, Lenz H-J. Genomic profiling associated with receurrence in

patients with rectal cancer treated with chemoradiation. Pharmacogenomics, 7:67-88,

Jan 2006.

88. Ajani J, Safran H, Bokemeyer C, Shah M, Lenz H-J, Van Cutsem E, Burris H,

Lebwohl D, Mullaney B. A multi-center phase II study of BMS-247550 (Ixabepilone)

by two schedules in patients with metastatic gastric adenocarcinoma previsouly treated

with a taxane. Invest New Drugs, 5:441-6. Mar 2006.

89. Whitehead R, McCoy S, Macdonald J, Rivkin S, Neubauer MA, Dakhil S, Lenz H-J,

Abbruzzese J, Tanaka M. Phase II trial of R115777 in patients with advanced colorectal

cancer: A Southwest Oncology Group study. Invest New Drugs, 24(4):335-41, July

2006.

90. Lenz H-J. Anti-EGFR Mechanism of Action: Antitumor Effect and Underlying Cause

of Adverse Events. Oncology, (20) 5:5-14, April 2006.

91. Vallbohmer D, Lenz H-J. Predictive and prognostic factors in the

neoadjuvant/adjuvant therapy of gastrointestinal tumors: wishful thinking or reality?

[German] Zentralblatt fur Chururgie, 131:148-156, May 2006.

92. Zhang W, Gordon M, Press OA, Rhodes K, Vallbohmer D, Yang DY, Park D, Fazzone

W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Cyclin D1 and Epidermal

Growth Factor Polymorphisms Associated with Survival in Patients with Advanced



Colorectal Cancer Treated with Cetuximab. Pharmacogenet Genomics, 16(7):475-483,

July 2006, [PMID: 16788380].

93. Schneider S, Park D, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal

S, Danenberg K, Lenz HJ. Gene expression in tumor-adjacent normal tissue is

associated with recurrence in patients with rectal cancer treated with adjuvant

chemoradiation. Pharmacogenetics & Genomics, 16(8):555-563, Aug 2006.

94. Azuma M, Danenberg K, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W,

Saigenji K, Danenberg P, Lenz H-J. Epidermal growth factor receptor and epidermal

growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin

Colorectal Cancer 6(3):214-218; Sep 2006.

95. El-Khoueiry AB, Lenz H-J. Second line strategies on the treatment of advanced

colorectal cancer. Curr Clin Onc: Colorectal Cancer, 119-130. October 2006.

96. Lenz H-J, Van Cutsem E, Khambata-Ford S, Mayer R, Gold P, Stella P, Mirtsching B,

Cohn A, Pippas A, Azarnia N, Tsuchihasi, Mauro D, Rowinsky E. Multicenter phase II

and translational study of cetuximab in metastatic colorectal carcinoma refractory to

irinotecan, oxaliplatin and flouropyrimidines. J Clin Onc, 24(30):4914-1921, October

2006.

97. Vallboehmer D, Iqbal S, Yang DY, Rhodes K, Zhang W, Gordon M, Fazzone W,

Schultheis A, Sherrod A, Danenberg K, Lenz H-J. Molecular Determinants of

Irinotecan Efficacy. International Journal of Cancer, 119(10):2435-42. Nov 15, 2006.

98. Yang D, Schneider S, Mizutomo A, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D,

Danenberg K, Danenberg P, Ladner R, Lenz H-J. Gene expression levels of epidermal

growth factor receptor, survivin, and vascular endothelial growth factor as molecular

markers of lymph node involvement in patients with locally advanced rectal cancer.

Clin Col Cancer, 6(4): 305-11, Nov 2006.

99. Lara PN, Longmate J, Koczywas M, Lenz HJ, Quinn DI, Davies AM, Lau DHM,

Gumerlock PH, Doroshow JH, Schenkein D, Kashala O, Gandara DR. Phase I Study of

Bortezomib plus Docetaxel in Advanced Non-Small-Cell Lung Cancer and Other Solid

Tumors. J Thorac Oncol, 1:126-134, 2006.

100. Park DJ, Lenz HJ. Determinants of chemosensitivity in gastric cancer. Curr Op

Pharmacol, 4: 337-344, 2006.

101. Vallbohmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, Fazzone W,

Schultheis AM, Sherrod AE, Danenberg KD, Lenz HJ. Molecular determinants of

irinotecan efficacy. Int J Cancer, 10: 2435-42, 2006.

102. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB,

Grothey A, Lenz H-J, Meropol NJ, Ramanathan RK, Becerra C, Wickham R,

Armostrong D, Viele C. The Continuum of Care: A Paradigm for the Management of

Metastatic Colorectal Cancer. The Oncologist, 1:38-50, 2007.

103. Synold T, Takimoto C, Doroshow J, Gandara D, Mani S, Remick S, Mulkerin D,

Hamilton A, Sharma S, Ramanathan R, Lenz H-J, Graham M, Longmate J, Kaufman

B, Ivy P. Dose-escalating and pharmacological study of oxaliplatin in adult cancer

patients with impaired hepatic function: A National Cancer Institute organ dysfunction

working group study. Clin Cancer Res, 15;13(12):3660-6, Jun 2007.

104. Chen H, Xia M, Lin M, Yang H, Kulhenkamp J, Li T, Sodir N, Chen Y, Lenz HJ,

Laird P, Clarke S, Mato J, Lu S. Role of methionine adenosyltranferase 2A and s-



Adenosylmethionine in mitogen-induced growth of human colon cancer cells.

Gastroenterology, 133(1):207-218, July 2007.

105. Garcia AA, Blessing JA, Darcy KM, Lenz HJ, Zhang W, Hannigan E, Moore DH.

Phase II clinical trial of capecitabine in the treatment of advanced, persistent or

recurrent squamous cell carcinoma of the cervix with translational research: A

gynecologic oncology group study. Gynecol Oncol, 3: 572-9, 2007.

106. Shibata S, Chow W, Frankel P, Juhasz A, Leong L, Lim D, Margolin K, Morgan R,

Newman E, Somlo G, Yen Y, Synold T, Gandara D, Lenz HJ, Doroshow J. A phase I

study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome

with gene expression. J Clin Oncol, 30: 4914-21, 2007.

107. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara R, Yao

JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in

patients with untreated, advanced gastric carcinoma in a multicenter phase II study.

Cancer, Jan 1;(109): 33-40, 2007.

108. Lenz H-J. Mangement and preparedness for infusion and hypersensitivity reactions.

Oncologist, 12(5): 601-9 May 2007.

109. O’Dwyer P, Eckhardt SG, Haller D, Tepper J, Ahnen D, Hamilton S, Benson AB,

Rothenberg M, Petrelli N, Lenz HJ, Diasio R, DuBois R, Sargent D, Sloan J, Johnson

CD, Comis R, O’Connell M. Priorities in Colorectal Cancer Research:

Recommendations from the Gastrointestinal Scientific Leadership Council of the

Coalition of Cancer Cooperative Groups. J Clin Oncol, 1;25(16):2313-2321, June 2007.

110. Zhang W, Gordon M, Schultheis AM, Nagashima F, Azuma M, Chang HM, Borucka

E, Yang DY, Sherrod AE, Lurje G, Iqbal S, Groshen S, Lenz H-J. FCGR2A and

FCGR3A polymorphisms associated with clinical outcome of EGFR-expressing

metastatic colorectal cancer patients treated with single-agent Cetuximab. J Clin Onc,

25(24) 3712-3718, Aug 2007.

111. Zhang W, Press OA, Haiman C, Yang D, Gordon MA, Fazzone W, El-Khoueiry A,

Iqbal S, Sherrod A, Lurje G, Lenz H-J. Association of Methylenetetrahydrofolate

Reductase Gene Polymorphisms and gender-specific survival in Patients with

Metastatic Colon Cancer. J Clin Onc, 25(24):2726-31, Aug 2007.

112. Press M, Lenz H-J. EGFR, HER2 and VEGF Pathways validated targets for cancer

treatment. Drugs, 67(14); 2045-2075, 2007.

113. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE,

Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX. Randomized phase II

trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and

bevacizumab alone in irinotecan-refractory colorectal cancer: The Bond-2 Study. J Clin

Onc, 25(29), 4557-4561, Oct 2007.

114. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder

JP, Lenz HJ, Schwartz B. Safety, pharmacokinetics, and preliminary antitumor activity

of sarafenib a review of four phase I trials in patients with advanced refractory solid

tumors. Onc, 12(4): 426-437, April 2007.

115. Azuma M, Shi M, Danenberg K, Gardner H, Barrett C, Jacques C, Sherod A, Iqbal S,

El-Khoueiry A, Yang D, Zhang W, Danenberg P, Lenz H-J. Serum lactate

dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and

VEGFR expression in metastatic CRC patients. Pharmacogenomics 8(12): 1705-1713,

2007.



116. Wilson PM, Ladner RD, Lenz H-J. Exploring alternative individualized treatment

strategies in colorectal cancer. Clin Colorectal Ca, 7(1): S28-S36, 2007.

117. Venook AP, Blanke CD, Niedzwiecki D, Lenz H-J, Taylor JR, Hollis DR, Sutherland

S, Goldberg RM. Revisiting the cancer leukemia group B/Southwest Oncology Group

80405 trial: a phase III trial of chemotherapy and biologic agents for patients with

untreated advanced colorectal adenocarcinoma. Clin Colorectal Ca 6(7): 536-8, May

2007.

118. Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz H-J, Egorin M.

Concentrations of the DNA methyltransferase inibitor 5-fluoro-2’-deoxycytidine

(FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and

tetrahydrouridine (THU). Cancer Chemotherapy and Pharmacology, 62(2): 363-368,

July 2007.

119. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK,

Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E,

E. Chao RC, Lenz HJ. Phase II trial of sunitinib in patients with metastatic colorectal

cancer after failure of standard therapy. J Clin Onc, 25(30): 4793-9, Oct 2007.

120. Lurje G, Zhang W, Lenz H-J. Molecuar prognostic markers in locally advanced colon

cancer. Clin Col Cancer, 6(10): 683-90, Nov 2007.

121. Garcia A, Hirte H, Fleming G, Yang D, Tsao-Wei D, Roman L, Groshen S, Swenson S,

Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz H-J, Oza A. Phase II

clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in

recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret

Hospital Phase II Consortia. J Clin Onc, 26(1):76-82, 2008.

122. Wilson PM, Ladner RD, Lenz H-J. Predictive and prognostic markers in colorectal

cancer. GastroIntestinal Ca Res, 1(6):237-246, 2008.

123. Gibbons J, Egorin M, Ramanathan R, Fu P, Mulkerin D, Shibabta S, Takimoto C, Mani

S, LoRusso P, Grem J, Pavlick A, Lenz H-J, Flick S, Reynolds S, Lagattuta T, Parise

R, Wang Y, Murgo A, Ivy P, Remick S. Phase I and pharmacokinetic study of imatinib

mesylate in patients with advanced malignancies and varying degrees of renal

dysfunction: A study by the National Cancer Institute organ dysfunction working

group. J Clin Onc, 26(4):570-576, 2008.

124. Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ,

Schenkein DP, Gandara DR. The proteasome inhibitor bortezomib in combination with

gemcitabine and carboplatin in advanced non-small cell lung cancer: a California

Cancer Consortium Phase I study. J Thoracic Onc, 3(1):68-74, Jan 2008.

125. Lurje G, Zhang W, Yang D, Groshen S, Hendifar A, Husain H, Nagashima F, Chang

FM, Fazzone W, Ladner R, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz H-J.

Thymidylate synthase haplotype is associated with tumor recurrence in stage II and

stage III colon cancer. Pharmacogenetics & Genomics, 18(2):161-8, Feb 2008.

126. Pohl A, Lurje M, Kahn M, Lenz H-J. Stem Cells in Colon Cancer. Comprehensive

Review. Clinical Colorectal Cancer, 7(2):92-98, March 2008.

127. Press OA, Zhang W, Gordon M, Yang D, Lurje G, Iqbal S, El-Khoueiry A, Lenz H-J.

Gender-related survival differences Associated with EGFR polymorphisms in

metastatic colon cancer. Cancer Res, 68(8): 3037-42, April 2008.

128. Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Kuramochi

H, Lenz H-J, Danenberg K, Danenberg P. Messenger RNA expression of vascular



endothelial growth factor and its receptors in primary colorectal cancer and

corresponding liver metastasis. Ann Surg Onc, 15(4):1232-8, 2008.

129. Pohl A, Zhang W, Ning Y, Manegold PC, Lurje G, Lenz HJ. Targeting Metastatic

Colorectal Cancer in 2008: A Long Way From 5-FU. Oncology 22(4):456-462, April

2008. [PMID: 18472617].

130. Kozuch, PS, Rocha-Lima CM, Dragovich T, Hochster H, O’Neil BH, Atiq OT, Pipas

M, Ryan DP, Lenz H-J. Bortezomib with or without Irinotecan in relapsed or

refractory colorectal cancer: Results from a randomized phase II study. J Clin Onc,

26(14):2320-2326, May 2008.

131. Sobrero A, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr Y, Lutz M, Vega-

Villegas ME, Eng C, Steinhauer S, Prausova J, Lenz H-J, Borg C, Middleton G,

Kroening H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris H. EPIC: Phase III

trial of cetuximab plus irinotecan after flouropyrimidine and oxaliplatin failure in

patients with metastatic colorectal cancer. J Clin Onc, 26(14):2311-2319, May 2008.

132. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K,

Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with

advanced neuroendocrine tumors. J Clin Onc, 26(20):3403-3410, July 2008.

133. Pohl A, Lenz HJ. Individualization of Therapy for Colorectal Cancer Based on Clinical

and Molecular Parameters. Gastrointest Cancer Res, 2(4 Suppl):S38-41, July 2008.

[PMID: 19343148].

134. Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, Wagman SD, Marx H,

Chu PG, Longmate JA, Lenz H-J, Ramanathan RK, Belani CP, Gandara DR. Phase II

Study of Oxaliplatin in Patients with Unresectable Metastatic, or Recurrent

Hepatocellular Cancer. A California Cancer Consortium Trial. Amer J Clin Onc,

31(4):317-322, August 2008, [PM ID: 18845988].

135. Kaufman H, Lenz H-J, Marshall J, Singh D, Garett C, Cripps C, Moore M, Von

Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB, Yu M, Caterini J,

Kim-Schulze S, DeBenedette M, Salha D, Vogel T, Elias I, Berinstein NL.

Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic

colorectal cancer. Clinical Cancer Research, 14(15):4843-4849, August 1, 2008.

136. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H,

Gordon MA, Nagashima F, Chang HM, Lenz HJ. Polymorphisms in VEGF and IL-8

predict tumor recurrence in stage III colon cancer. Annals of Oncology, 19(10):1734-

1741, Oct 2008.

137. Allen WL, Coyle VM, Jithesh PV, Proutski I, Stevenson L, Fenning C, Longley DB,

Wilson RH, Gordon M, Lenz HJ, Johnston PG. Clinical determinants of response to

irinotecan-based therapy derived from cell line models. Clinical Cancer Research,

14(20):6647-55, Oct 2008.

138. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R,

Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, and Lenz H-J.

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with

Cyclophosphamide and Bevacizumab. Clinical Cancer Research, 14(22):7554-63, Nov

2008, [PM ID: 19010874; PMC2586993].

139. Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S,

Azuma M, Mori R, Omori A, Lenz H-J, Danenberg KD, Danenberg PV. Messenger



RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.

International Journal of Oncology, 33(6): 1257-1262, Dec 2008.

140. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A,

Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz H-J.

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are

Associated with Progression-Free Survival Independent of K-ras in Metastatic

Colorectal Cancer Patients Treated with Single-Agent Cetuximab. Clinical Cancer

Research, 14(23): 7884-7895, Dec 1, 2008.

141. Lenz H-J, Future Research Directions for the Treatment of Metastatic Colorectal

Cancer. Clinical Advances in Hematology & Oncology, 6(12) Suppl 21:9-11, Dec 2008.

142. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz H-J. Thymidylate synthase

gene variation: predictive and prognostic markers. Mol Cancer Ther, 8(5):1000-1007,

May 2009.

143. Wilson PM, Fazzone W, LaBonte M, Lenz H-J, Ladner RD. Regulation human

dUTPase gene expression and p53-mediated transcriptional repression in response to

oxaliplation-induced DNA damage. Nucleic Acids Research, 37(1):78-95, Jan 2009.

144. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold P, Ning

Y, Zhang W, Lenz H-J. Polymorphisms in Interleukin 1 beta and interleukin 1 receptor

antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenetics

& Genomics, 19(2):95-102, Feb 2009.

145. Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD. Histone deacetylase in

hibitors suppress thymidylate synthase gene expression and synergize with the

fluoropyrimidines in colon cancer cells. International Journal of Cancer, 125(2):463-

473, Feb 2009.

146. Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Lenz

H-J, Danenberg K, Danenberg PV. Messenger RNA expression of COX-2 and

angiogenic factors in primary colorectal cancer and corresponding liver metastasis.

International Journal of Oncology, 34(4):1147-1153, April 2009.

147. Lara PN Jr., Natale R, Crowley J, Lenz H-J, Redman MW, Carleton JE, Jett J, Langer

CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of

irinotecan/ciplatin compared with etoposide/cisplatin in extensive stage small-cell lung

cancer: clinical and pharmacogenomic results from Southwest Oncology Group Trial

S0124. J Clin Oncol, 27(15):2530-5, May 2009.

148. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz H-J, Gordon M,

Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef

ML, Gandara DR, Albain KS. Phase II studies of gemcitabine and cisplatin in heavily

and minimally pretreated metastatic breast cancer. J Clin Oncol, 27(13):2163-9, May

2009.

149. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S,

Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN,

Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. Japanese-US Common-

Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung

Cancer: A Model for Assessing Population-Related Pharmacogenomics. J Clin Oncol,

27(21):3540-3456, July 20, 2009.

150. Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, verzi MP, Doddapaneni H, Beckwith

CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz H-J, Haiman CA, Yan C,



Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM,

Manak JR, Shivdasani R, Coetzee GA, Freedman ML. The 8q24 cancer risk variant

rs6983267 demonstrates long-range interaction with MYC in colorectal cancer. Nature

Genetics, 41(8):882-4, Aug 2009.

151. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL,

Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR.

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular

cancer. Cancer Chemother Pharmacol, 64(4):777-83, Sep 2009, [PMID: 19169683].

152. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ.

Gender Disparties in metastatic colorectal cancer survival. Clinical Cancer Research,

15(20):6391-7, Oct 2009.

153. Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara DR, Lenz HJ,

Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM.

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced

metastatic solid tumors: a California Cancer Consortium Study. Cancer Cancer

Chemother Pharmacol, 64(6):1149-55, Nov 2009, [PM ID: 19322566].

154. LaBonte M, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, Ladner RD.

The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric

cancer cells to the irinotecan active metabolite SN-38. International Journal of Cancer,

125(12):2957-69, Dec 2009, [PM ID: 19536776]

155. Lurje G, Husain H, Power DG, Power D, Yang D, Groshen S, Pohl A, Zhang W, Ning

Y, Manegold PC, El-Khoueiry A, Iqbal S, Tang LH, Shah MA, Lenz H-J. Genetic

variations in angiogenesis pathway genes associated with clinical outcome in localized

gastric adenocarcinoma. Annals of Oncology, 21:78-86, Jan 2010, [PM ID: 19622587;

PMC2795613].

156. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N.

Colorectal Cancer. The Lancet, 375(9719):1030-47, Mar 2010, [PM ID: 20304247].

157. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D,

Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ.A phase I/II trial of

vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal

cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother

Pharmacol, 65(5):979-88, April 2010, [PM ID: 20062993].

158. Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Ayazi S, Winder T, Ning Y, Yang

D, Klipfel NE, Chandrasoma P, Hagen JA, DeMeester SR, DeMeester TR, Lenz HJ.

Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized

adenocarcinoma of the esophagus. Annals of Surgery, 251(5):857-64, May 2010, [PM

ID:20101173].

159. Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A,

Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, Gruenberger

T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A,

Pavlidis N, Rougier P, Schmiegel W, Van de Velde C, Schmoll HJ, Sobrero A,

Tabernero J. Molecular markers and biological targeted therapies in metastatic

colorectal cancer: expert opinion and recommendations derived from the 11th

ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Annals of Oncol,

Suppl 6:vi1-10, Jun 2010, [PM ID:20534623].



160. Press OA, Zhang W, Gordon MA, Yang D, Haiman CA, Azuma M, Iqbal S, Lenz HJ.

Gender-related survival differences associated with polymorphic variants of estrogen

receptor-beta (ERbeta) in patients with metastatic colon cancer. Pharmacogenomics J,

Jun 2010, [PM ID: 20548329].

161. Wilson PM, Lenz HJ. Integrating biomarkers into clinical decision making for

colorectal cancer. Clin Colorectal Cancer, (9) Suppl 1:S16-S27, Jun 2010, [PM ID:

20630847].

162. Wilson PM, Bohanes P, Lenz HJ. Using The Colon Cancer Multigene Recurrence

Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction? Curr

Colorectal Cancr, 6(4):183-192, July 2010.

163. Winder, T, Lenz HJ. Beyond KRAS: a new approach in metastatic colorectal cancer.

The Lancet, 11(8):706-707, August 2010, [PM ID: 20619738].

164. Gold PJ, Goldman B, Iqbal S, Leichman LP, Lenz H-J, Blanke CD. Cetuximab as

second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest

Oncology Group study (S0415). J Thorac Onc, 5(9):1472-6, July 2010, [PM ID:

20631636].

165. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D,

LaBonte MJ, Wilson PM, Ladner RD, Lenz H-J. Interleukin-8 is associated with

proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon

cancer cell line models. International Journal of Cancer, 24;126-27, Sept. 2010, [PM

ID: 20648559] [NIHMS: 236038].

166. Zhang W, Azuma M, Lurje G, Gordon M, Yang D, Pohl A, Ning Y, Bohanes P, Gerger

a, Winder T, Hollywood E, Danenberg KD, Saltz L, Lenz HJ. Molecular Predictors of

combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory

colrectal Cancer (BOND-2 study). Anticancer Research, 30(10):4209-17, Oct 2010,

[PM ID: 21036743].

167. Winder T, Zhang W, Yang D, Ning Y, Bohanes P, gerger A, Wilson PM, Pohl A,

Mauro DJ, Langer C, Rowinsky EK, Lenz H-J. Germline Polymorphisms in Genes

Involved in the IGH1 Pathway Predist Efficacy of Cetuximab in Wild-type KRAS

mCRC Patients. Clin Cancer Res, 16(22):5591-5602, Nov. 15, 2010, [PM ID:

20935157; PMC2982939].

168. Zhang W, Winder T, Ning Y, Pohl A, Kahn M, Lurje G, LaBonte MJ, Wilson PM,

Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky K, Lenz H-J. A let-7

microRNA-binding site polymorphism in 3’ –untranslated region of KRAS gene

predicts response in wild-type KRAS patients with metatatic colorectal cancer treated

with cetuximab monotherapy. Annals of Oncology, 22(1):104-9, Jan 2011, [PM ID:

20603437].

169. Gordon MA, Zhang W, Yang D, Iqbal S, El-Khoueiry A, Nagashima F, Lurje G,

Labonte M, Wilson P, Sherrod A, Ladner RD, Lenz HJ. Gender-specific genomic

profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and

oxaliplatin. Pharmacogenomics, 12(1):27-39, Jan 2011, [PM ID: 21174620].

170. Zhang W, LaBonte MJ, Lenz, H-J. KRAS let-7 LCS6 SNP predicts cetuximab efficacy

in KRASwt metastatic colorectal cancer patients: Does treatment combination partner

matter? Annals of Oncology, 22(2):484-485, Feb 2011, [PM ID: 21278223].

171. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz H-J, El-

Khoueiry A, Pinski J, Garcia AA. Phase I Clinical Trial of Pegylated Liposomal



Doxorubicin and Docetaxel in Patients With Advanced Solid Tumors. Am J Clin Oncol,

34(1):27-31, Feb 2011, [PM ID: 20142723].

172. El-Khoueiry A, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara

D, Lenz HJ. A randomised phase II of gemcitabine and sorafenib versus sorafenib

alone in patients withmetastatic pancreatic cancer. Invest new Drugs, 30(3):1175-83,

Mar 2011, [PM ID: 21424698].

173. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA,

Wang WS, Etienne-Grimaldi MC, Wei Q. ERCC1 and ERCC2 Polymorphisms Predict

Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal

Cancer: A Systemic Review and Meta-analysis. Clinical Cancer Res, 17(6):1632-1640,

Mar 2011, [PM ID: 21278243].

174. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y,

Groshen S, Lenz H-J. Survival of metastatic gastric cancer: Significance of age, sex

and race/ethnicity. J Gastrointest Oncol, 2(2):77-84, Mar 2011, [PMID: 22811834].

175. Gerger A, LaBonte M, Lenz HJ. Molecular Predictors of Response to

Antiangiogenesis Therapies. The Cancer Journal, 17(2):134-141, Apr 2011, [PM ID:

21427557].

176. Pohl A, Azuma M, Zhang W, Yang D, Ning Y, Winder T, Danenberg K, Lenz HJ.

Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in

metastatic colorecal cancer. Pharmacogenomics, 11(2):93-9, April 2011, [PM ID:

20368716].

177. Grimminger PP, Danenberg P, Dellas K, Arnold D, Rodel C, Machiels JP, Haustermans

K, Debucquoy A, Velenik V, Sempoux C, Bracko M, Holscher AH, Semrau R, Yang

D, Danenberg K, Lenz H-J,Vallbohmer D. Biomarkers for Cetuximab-Based

Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer. Clinical Cancer

Res, 17(10):3469-3477, May 2011, [PM ID: 21558395].

178. Labonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ,

Ladner RD. The dual EGFR/HER 2 inhibitor lapatinib synergistically enhances the

antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer

models. Cancer Research, 71(10):3635-48, May 2011, [PM ID: 21464044].

179. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA,

Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis IO, Ali S,

Lenz HJ, Stebbing J. Kinome screening for regulators of the estrogen receptor

identifies LMTK3 as a new therapeutic target in breat cancer. Nature Med, 17(6):715-9,

May 2011, [PM ID: 21602804].

180. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD,

Shibata SI, Blanke, CD. Southwest Oncology Group study S0413: a phase II trial

lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic

gastric cancer. Annal Oncology, 22(12):2610-5, May 2011, [PMID: 21415234].

181. Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ,

Holcombe RF, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients

with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest

Oncology Group study S0202. Cancer Chemother Pharmacol, 68(6):1595-602, May

2011, [PM ID: 21556747].

182. Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T,

Ballal S, Rawinsky EK. A phase II randomized study of cetuximab and bevacizumab



alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic

adenocarcinoma. Invest New Drugs, 30(4):1597-606. June 2011, [PM ID: 21629990].

183. Stebbing J, Filipovic A, Ellis IO, Green AR, D’Silva TR, Lenz HJ, Coombes RC,

Wang T, Lee SC, Giamas G. LMTK3 expression in beast cancer: association with

tumor phenotype and clinical outcome. Breast Cancer Res Treat, 132(2):537-44, June

2011, [PM ID: 21671015].

184. Grimminger PP, Shi M, Barrett C, Lebwohl D, Danenberg KD, Brabender J, Vigen CL,

Danenberg PV, Winder T, Lenz HJ. TS and ERCC-1 mRNA expressions and clinical

outcome in patients with metastatic colon cancer in CONFIRM-1 and-2 clinical trials.

Pharmacogenomics Journal, doi: 10.1038/tpj.2011.29, July 2011, [PM ID: 21788964].

185. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD,

Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of sorafenib in

patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.

Invest New Drugs, 30(4):1646-51, July 2011, [PM ID: 21748296].

186. Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, LaBonte MJ, Grimminger

P, Holscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K,

Machiels JH, Sempoux C, Rodel C, Bracko M, Velenik V, Lenz H-J. EGF61

polymorphism predicts complete pathologic response to cetuximab-based

chemoradiation independent of KRAS status in locally advanced rectal cancer patients.

Clinical Cancer Res, 17(15):5161-5169, Aug 2011, [PMID: 21673069].

187. Bohanes P, Labonte MJ, Winder T, Lenz HJ. Predictive molecular classifiers in

colorectal cancer. Semin Oncology, 38(4):576-87, Aug 2011, [PM ID: 21810517].

188. Winder T, Ning Y, Yang D, Zhang W, Power DG, Bohanes P, Gerger A, Wilson PM,

Lurge G, Tang LH, Shah M, Lenz HJ. Germline polymorphisms in genes involved in

the CD44 signaling pathway are associated with clinical outcome in localized gastric

adenocarcioma (GA). International Journal Cancer, 129(5):1096-104, Sep 2011, [PM

ID: 21105049; PMC3139396].

189. Bohanes P, LaBonte MJ, Lenz H-J. A Review of Excision Repair Cross-

complementation Group 1 in Colorectal Cancer. Clinical Colorectal Cancer, 10(3):157-

164, Sep 2011, [PM ID: 21855036].

190. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T,

LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz H-J.

Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-

based chemotherapy in patients with metastatic colorectal cancer. Clinical Cancer

Research, 17(17):5783-92, Sep 2011, [PM ID: 21791631; PMC3174848].

191. Press OA, Zhang W, Gordon MA, Yang D, Haiman CA, Azuma M, Iqbal S, Lenz HJ.

Gender-related survival differnces associated with polymorphic variants of estrogen

receptor- (ER) in patients with metastatic colon cancer. Pharmacogenomics J,

11(5):375-82, Oct 2011, [PM ID:20548329; PMC2941547].

192. Labonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes

PO, Benhaim L, El-Khoueiry R, El-Khoueiry A, Lenz HJ. The Cyclin D1 (CCND1)

A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER-

2-positive metastatic breast cancer. Ann Oncl, 23(6):1455-64, Oct 2011, [PMID:

21989330].

193. Gerger A, Zhang W, Dr. Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson

PM, Benhaim L, Paez D, El-khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. Common



cancer stem cell gene variants predict colon cancer recurrence. Clinical Cancer

Research, 17(21):6934-43, Nov 2011, [PM ID:21918173].

194. Winder T, Bohanes P, Zhang W, Yang D, Power DG, Ning Y, Gerger A, Wilson PM,

Tang LH, Shah M, Lee AS, Lenz HJ. GRP78 promoter polymorphism rs391957 as

potential predictor for clinical outcome in gastric and colorectal cancer patients. Annals

of Oncology, 22(11):2431-9, Nov 2011, [PM ID: 21382870; PMC3200220].

195. Leichman LP, Goldman BH, Bohanes PO, Lenz HJ, Thomas CR, Billingsley KG,

Corless CL, Iqbal S, Gold PJ, Benedetti JK, Danenberg KD, Blanke CD. S0356: a

phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and

exteranl-beam radiation therapy before surgery for patients with esophageal

adenocarcinoma. J Clin Oncol, 29(34):4555-60, Dec 2011, [PM ID: 22025151;

PMC3236655].

196. Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton

A, Lorusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy

SP, Neuwirth R, Von Moltke L, Venkatakrishnan K, Mulkerin D. Dose-escalating and

pharmacological study of bortezomib in adult cancer patients with impaired renal

function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer

Chemotherapy Pharmacol, 68(6):1437-47, Dec 2011, [PM ID: 21479634].

197. Benhaim L, Labonte MJ, Lenz HJ. Pharmacogenomics and metastatic colorectal

cancer: current knowlegde and prespectives. Scand J Gastroenterol, 47(3):325-39, Dec

2011, [PM ID: 22182673].

198. Wilson PM, Labonte MJ, Lenz HJ, Mack PC, Ladner RD. Inhibition of dUTPase

Induces Synthetic Lethality with Thymidylate Synthase-Targeted Therapies in Non-

Small Cell Lung Cancer. Mol Cancer Ther, 1(3):616-28, Dec 2011, [PM ID:

22172489].

199. Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G, Gordon MA,

Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG. A systems biology

approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38

drug resistance in colorectal cancer. Mol Cancer Ther, 11(1):119-31, Jan 2012, [PM

ID: 22027693].

200. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven

S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ.

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and

progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC),

treated with bevacizumab-based chemotherapy. 13(2):173-80, doi: 10.1038/tpj.2011.61,

Jan 2012, [PM ID: 22231565; PMC3326190].

201. Paez D, Labonte MJ, Bohanes P, Zhang W, Benhaim L, Ning Y, Wakatsuki T,

Laupakis F, Lenz HJ. Cancer dormancy: a model of early disseminationand late cancer

recurrence. Clin Cancer Res, 18(3):645-53, Feb 2012, [PM ID: 22156560; PMC

3272421].

202. Bohanes P, Loupakis F, Labonte MJ, Wakatsuki T, Lenz HJ. “HER majesty’s a pretty

nice girl but she changes from day to day”. J Clin Oncol, 30(4):465-6, Feb 2012, [PM

ID: 22203763].

203. Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S,

Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH,

Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. A phase I and



pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbozone

(3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California

Cancer Consortium Study. Cancer Chemother Pharmacol, 69(3):835-43, Mar 2012,

[PM ID: 22105720; PMC3288125].

204. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D,

Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders

RJ, Parchment RE, Tomaszewski JE, Doroshow JH. A Phase I Study of Veliparib in

Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid

Tumors and Lymphomas. Clin Cancer Res,18(6):1726-1734, Mar 2012, [PM ID:

22307137].

205. Paez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel

chemotherapeutics). Gastroenterol Clin North Am, 41(1):189-209, Mar 2012, [PM ID:

22341258].

206. Ning Y, Labonte MJ, Zhang W, Bohanes P, Gerger A, Yang D, Benhaim L, Paez D,

Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ.

The CXCR2 antagonist, SCH-52123, demonstrates antitumor activity and sensitizes

cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther, 11(6):1353-

64, Mar 2012, [PM ID: 22391039].

207. Tomblyn MB, Goldman BH, Thomas CR Jr., Benedetti JK, Lenz HJ, Mehta V, Beeker

T, Gold PJ, Abbruzzese JL, Blanke CD. Cetuximab Plus Cisplatin, Irinotecan,

Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced,

Unresectable Espohageal Cancer: A Phase-II Study of The SWOG (S0414). J Thorac

Oncol, April 2012, 7(5):906-12, [PM ID: 22481235].

208. Ning Y, Lenz HJ. Targeting IL-8 in colorectal cancer. Expert Opin Ther Targets,

16(5):491-7, April 2012, [PM ID: 22494524]

209. Winder T, Wilson PM, Yang D, Zhang W, Ning Y, Power DG, Bohanes P, Gerger A,

Tang LH, Shah M, Lenz HJ. An individual coding polymorphism and the haplotype of

the SPARC gene predict gastric cancer recurrence. Pharmacogenomics J. 13(4):342-8,

doi: 10.1038/tpj.2012.11, April 2012, [PM ID: 22491017].

210. Morgan RJ, Leong L, Chow W, Gandara D, Grankel P, Garcia A, Lenz HJ, Doroshow

JH. Phase II trial of bryostatin-1 in combination with cisplatin inpatients with recurrent

or persistent epithelial ovarian cancer: a California cancer consortium study. Invest New

Drugs, 30(2):723-8, April 2012, [PM ID: 20936324].

211. Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim

L, Paez D, Wakatsuki T, Loupakis F, El-Khoueiry R, Zhang W, Lenz HJ. Influence of

sex on the survival of patients with esophageal cancer. J Clin Oncol, 30(18):2265-72,

May 2012, [PM ID: 22585694].

212. Grothey A, Lenz HJ. Explaining the Unexplainable: EGFR Antibodies in Colorectal

Cancer. J Clin Oncol, 30(15):1735-7, May 2012, [PM ID: 22473160].

213. Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Yang D, Chung HK, Choi D,

Labonte MJ, Lander RD, Nogulapalli Venkata KC, Rosenberg DO, Petasis NA, Lenz

HJ, Hong YK. Interleukim-8 and its receptor CXCR2 in the tumour microenvironment

promote colon cancer growth, progression and metastasis. J Clin Oncol, 106(11):1833-

41, June 2012, [PM ID: 22617157; PMC3364111].

214. Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, Lebwohl D, Sherrod A,

Ladner RD, Zhang W, Danenberg PV, Trarbach T, Folprecht G, Meinhardt G, Lenz



HJ. Intratumoral expression profiling of genes involved inangiogenesis in colorectal

ancer patients treated with chemotherapy plus the VEGFR inhibitor

PTK787/ZK222584 (vatalanib). Pharmacogenomics J, 13(5):410-6. doi:

10.1038/tpj.2012.23. June 2012, [PM ID: 22664478].

215. Stevenson L, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart GE, Lenz HJ,

Van Schaeybroeck S, Longley DB, Johnston PG. Identification of galanin and its

receptor GalR1 as novel determinants of resistance to chemotherapy and potential

biomarkers in colorectal cancer. Clin Cancer Res, 18(19):5412-26, Aug 2012, [PM ID:

22859720].

216. Barzi A, Lenz HJ. Angiogenesis-related agents in esophageal cancer. Expert opin Biol

Ther, 21(10):1335-45, Aug 2012, [PM ID: 22860627].

217. Choi I, Lee YS, Chung HK, Choi D, Ecoiffier T, Lee HN, Kim KE, Lee S, Park EK,

Maeng YS, Kim NY, Ladner RD, Petasis NA, Koh CJ, Chen L, Lenz HJ, Hong YK.

Interleukin-8 reduce post-surgical lymphedema formation by promoting lymphatic

vessel regeneration. Angiogenesis,16(1):29-44, Sep 2012, [PM ID: 22945845].

218. Benhaim L, Loupakis F, Labonte MJ, Lenz HJ. Selecting the best targeted agent in

first-line treatment of unresectable liver metastases from colorectalcancer: does the

bench have the answers? J Hepatobiliary Pancreat Sci, 19(5):528-35, Sep 2012, [PM

ID: 22735932].

219. Wilson PM, Labonte MJ, Lenz HJ. Assessing the in vivo efficacy of biologic

antiangiogenic therapies. Cancer Chemother Pharmacol, 71(1):1-12, Oct 2012, [PM

ID: 23053262].

220. Zwicker Jl, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha

S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg

D, Furie B. Prediction and prevention of thromboembolic events with enoxaparin in

cancer patients with elevated tissue factor-bearing microparticles: a randomized-

controlled phase II trial (the Microtec study). BR J Heamatol, 160(4):530-7, doi:

10.1111/;bjh.12163, Dec 2012, [PM ID: 23240761].

221. Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-

Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L

immunotherpy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J

Gastrointest Surg, 17(1):94-100, Jan 2013, [PM ID: 23229886].

222. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y,

Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ,

Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib

monotherapy for previously treated metastatic colorectal cancer (CORRECT): an

international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet,

381(9863):303-12, Jan 2013, [PM ID: 23177514].

223. Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner

RD. Sustained inhibition of deacetylases is required for the antitumor activity of the

histone deactylase inhimbitors panobinostat and vorinostat in models of colorectal

cancer. Invest New Drugs, 31(4);845-57, Jan 2013, [PM ID: 23299388].

224. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic

cytotoxic and biological therapies of colorectal liver metastases: expert consensus

statement. HPB Oxford. 15(2):106-15, Feb 2013, [PM ID:23297721].



225. Winder T, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, Ning Y, Gerger A,

Stebbing J, Lenz HJ. Insulin-like growth factor receptor polymorphism defines clinical

outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen.

Pharmacogenomics J. 14(1):28-34, Mar 2013, [PM ID: 23459444].

226. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of Response for

the Antiangiogenic Agent Bevacizumab. J Clin Oncol, 31(9):1219-30, Feb 2013, [PM

ID: 23401453].

227. Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ,

Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF. Assessment of HER2

gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in

the INT-0116/SWOG9008 clnical trial. Ann Oncol, 24(7):1754-61, July 2013, [PM ID:

23524864; PMC3690906].

228. Absenger G, Benhaim L, Szkandera J, Zhang W, Yang D, Labonte MJ, Pichler M,

Stotz M, Samonigg H, Renner W, Gerger A, Lenz HJ. The cyclin D1 (CCND1) rs9344

G>A polymorphism predicts clinical outcome in colon cancer patients treated with

adjuvant 5-FU-based chemotherapy. Pharmacogenomics J, 14(2):130-4, Apr 2013,

[PM ID: 23567490].

229. Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan

JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K.

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a

phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest

New Drugs, 32(1):113-22. Apr 2013, [PM ID: 23568716; PMC3775976].

230. Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, Wilson SS,

Benson M, Lerner SP, Tangen CM, Thompson IM. SWOG S0353: Phase II Trial of

Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer who had

Recurrence after at Least 2 Prior Courses of Intravesical Bacillus Calmette-Guérin. J

Urol, 190(4):1200-4, Apr 2013, [PM ID: 23597452;PMC4113593].

231. Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y,

El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P, Lenz HJ. Gender-specific

profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III

colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. Pharmacogenomics

J. Jun 2013. doi: 10.1038/tpj.2013.21. [PM ID: 23752739].

232. Stintzing S, Lenz HJ. MicroRNA-21 in Colorectal Cancer: "Just Another Brick in the

Wall"? J Natl Cancer Inst, 105(12):840-1. doi: 10.1093/jnci/djt128, Jun 2013, [PM ID:

23704279].

233. Iqbal S, Lenz HJ, Gandara DR, Shibata SI, Groshen S, Synold TW, Newman EM. A

phase I trial of oxaliplatin in combination with docetaxel in patients with advanced

solid tumors. Cancer Chemother Pharmacol, 72(1):85-91, Jun 2013, [PM ID:

23712328; PMC3779138].

234. Kwak EL, Shapiro GI, Cohen SM, Becerra CR, Lenz HJ, Cheng WF, Su WC, Robohn

M, Maulf FL, Lobmeyer MT, Chand VK, Iafrate AJ. Phase 2 trial of afatinib, an ErbB

family blocker, in solid tumors genetically screened for target activation. Cancer.

119(16):3043-51, Jun 2013, [PM ID: 23775486].

235. Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ,

Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, Lorusso P, Rudek

MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.

http://www.ncbi.nlm.nih.gov/pubmed?term=Zhang%20W%5BAuthor%5D&cauthor=true&cauthor_uid=23752739

http://www.ncbi.nlm.nih.gov/pubmed/23752739


http://www.ncbi.nlm.nih.gov/pubmed?term=Suttle%20AB%5BAuthor%5D&cauthor=true&cauthor_uid=23653147

http://www.ncbi.nlm.nih.gov/pubmed?term=Ottesen%20LH%5BAuthor%5D&cauthor=true&cauthor_uid=23653147

http://www.ncbi.nlm.nih.gov/pubmed?term=Lenz%20HJ%5BAuthor%5D&cauthor=true&cauthor_uid=23653147

http://www.ncbi.nlm.nih.gov/pubmed?term=Kummar%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23653147

http://www.ncbi.nlm.nih.gov/pubmed?term=Harvey%20RD%5BAuthor%5D&cauthor=true&cauthor_uid=23653147

http://www.ncbi.nlm.nih.gov/pubmed?term=Hamilton%20AL%5BAuthor%5D&cauthor=true&cauthor_uid=23653147



Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic

Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.

Clin Cancer Res, 19(13):3631-3639, July 2013, [PM ID: 23653147; PMC3700623].

236. Páez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhaim L, Kahn M, Lenz F, Lenz

C, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ. Association of common gene variants

in the WNT/β-catenin pathway with colon cancer recurrence. Pharmacogenomics J,

14(2):142-50, July 2013, [PM ID: 23817222].

237. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P,

Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A,

Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ. Prospective

Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal

Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. PloS One,

4;8(7):e66774. doi: 10.1371/journal.pone.0066774. July 2013, [PM ID: 23861747;

PMC3701556].

238. Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A,

NingY, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W,

Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ. Prognostic role of lemur

tyrosine kinase-3germline polymorphisms in adjuvant gastric cancer in Japan and the

Unted States. Mol Cancer Ther, 12(10): 2261-72, Aug 2013, [PM ID: 23918832;

PMC3810398].

239. Stintzing S, Lenz HJ. Protein kinase inhibitors in metastatic colorectal cancer. Let’s pic

patients, tumors and kinase inhibitors to piece the puzle together! Expert Opin

Pharmacother, 14(16):2203-20, Aug 2013, [PM ID: 23941461].

240. Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: Estrogen pathway in

colorectal cancer. Clin Cancer Res, 19(21):5842-8, Aug 2013, [PM ID: 23965904;

PMC3836673].

241. Louie SG, Ely B, Lenz HJ, Albain KS, Gotay C, Coleman D, Raghavan D, Shields AF,

Gold PJ, Blanke CD. Higher capecitabine AUC in elderly patients with advanced

colorectal cancer (SWOG S0030). Br J Cancer, 109(7):1744-9, Sept 2013, [PM ID:

24022189; PMC3790171].

242. Kimball BC, James KM, Yost KJ, Fernandez CA, Kumbamu A, Leppin AL, Robinson

ME, Geller G, Roter DL, Larson SM, Lenz HJ, Garcia AA, Baddocklii CH, Jatori A,

de Nuncio ML, Montori VM, Koening BA, Tilburt JC. Listening in on difficult

conversations: an observational, multi-center investigation of real-time conversations in

medical oncology. BMS cancer, 13(1):455, Oct 2013, [PM ID: 24093624;

PMC3850997].

243. Sunakawa Y, Lenz HJ, Ichikawa W. RAS mutations in colorectal cancer. N Engl J

Med, 369(22):2159, Nov 2013, [PM ID: 24283233].

244. LaBonte MJ, Lenz HJ. Role of cyclin polymorphisms in predicting outcome of 5-

fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle.

Pharmacogenomics, 14(14):1671-4, Nov 2013, [PM ID: 24192114].

245. Stintzing S, Lenz HJ. A small cog in a big wheel: PIK3CA mutations in colorectal

cancer. J Natl Cancer Inst. 105(23):1775-6, Dec 2013, [PM ID: 24231451].

246. Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A.

Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a



http://www.ncbi.nlm.nih.gov/pubmed?term=Loupakis%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Cremolini%20C%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Yang%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Salvatore%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Bohanes%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Schirripa%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Benhaim%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Lonardi%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Antoniotti%20C%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Graziano%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Lucchesi%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Ronzoni%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=De%20Vita%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23861747

http://www.ncbi.nlm.nih.gov/pubmed?term=Falcone%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23861747



measure of quality of care. Clin Colorectal Cancer, 12(4):275-9, Dec 2013, [PM ID:

24188686].

247. Lee YS, Choi D, Kim NY, Yang S, Jung E, Hong M, Yang D, Lenz HJ, Hong YK.

CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer

development. Int J Cancer, 135(1):232-7, doi: 10.1002/ijc.28668. Dec 2013, [PM ID

24338666].

248. Lenz HJ. Testing for RAS Mutations in Patients with Metastatic Colorectal Cancer.

Colorectal Cancer in Focus. Clinical Advances in Hematology & Oncology. 12(1):48-

49, Jan 2014, [PM ID: 25000315].

249. Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, Wakatsuki T, Labonte

MJ, Sintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ. Plastin

Polymorphisms Predict Genter-and Stage-Specific Colon Cancer Recurrence after

Adjuvant Chemotherapy. Mol Cancer Ther, 13(2):1-12, Jan 2014, [PM ID: 24170770].

250. El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR,

Lenz HJ, Blanke CD. S0941: a phase 2 SWOG study of sorafenib and erlotinib in

patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer, Jan

2014, 110(4):882-7, [PM ID 24423918].

251. Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, Hsiang J,

Brabender J, Friedrich M, Alakus H, Holscher AH, Lara P, Danenberg KD, Lenz HJ,

Gandara DR. KRAS mutations in non-small-cell lung cancer and colorectal cancer:

Implications for EGFR-targeted therapies. Lung Cancer, 83(2): 163-7, Feb 2014, [PM

ID: 24331409].

252. Robinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan

JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab, T, Chen HX Fuchs CS, Ng K.

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a

phase I study of pertuzumab plus cetuximab in cetuximab-refactory patients.

Investigational New Drugs, 32(1):113-22, doi: 10.1007/s10637-013-9956-5, Feb 2014,

[PM ID: 23568716].

253. Loupakis F, Antoniotti C, Cremolini C, Zhang W, Yang D, Wakatsuki T, Bohanes P,

Schirripa M, Salvatore L, Masi G, Ricci V, Graziano F, Ruzzo A, Benhaim L,

Marmorino F, Ning Y, El-Khoueiry R, Falcone A, Lenz HJ. Prospective study of

EGFR intron 1 (CA) repeats variants as predictors of benefit from cetuximab and

irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.

Pharmacogenomics J, 14(4):322-7, doi: 10.1038/tpj.2014.1. Feb 2014, [PM ID:

24513691].

254. Sebio A, Stintzing S, Stremitzer S, Zhang W, Lenz HJ. Panitumumab : leading to

better overall survival in metastatic colorectal cancer? Expert Opin Biol Ther,

14(4):535-48, doi: 10.1517/14712598.2014.894502, Apr 2014, [PM ID: 24593265].

255. Bendell JC, Lenz HJ, Ryan T, El-Rayes BF, Marshall JL, Modiano MR, Hart LL,

Kingsley CD, George TJ, Nakashima D, Berlin JD. Phase ½ study of KRN330, a fully

human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for

patients with metastatic colorectal cancer. Invest New Drugs, 32(4):682-90.doi:

10.1007/s10637-014-0088-3, Aug 2014, [PM ID: 24691674].

256. Sebio A, Kahn M, Lenz HJ. The potential of targeting Wnt/B-catenin in colon cancer.

Expert Opin Ther Targets,18(6):611-5, June 2014, [PM ID: 24702624].



257. Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. Standing the test of

time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol,

11(5):282-98, May 2014, [PM ID: 24732946].

258. Stintzing S, Lenz HJ. Molecular Pathways: Turning Proteasomal Protein Degradation

into a Unique Treatment Approach. Clin Cancer Res, Apr 2014, 20:3064-3070, [PM

ID: 24756373].

259. Stremitzer S, Sebio A, Stintzing S, Lenz HJ. Panitumumab safety for trating colorectal

cancer. Expert Opin Drug Saf, 13(6):843-51. doi: 10.1517/14740338.2014.915024,

June 2014, [PM ID: 24766434].

260. Lin EH, Lenz HJ, Saleh MN, Mackenzie MJ, Knost JA, Pathiraja K, Langdon RB, Yao

SL, Lu BD. A randomized, phase II study of the anti-insulin-like growth factor receptor

type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with

advanced colorectal cancer. Cancer Med, 3(4):988-97., Aug 2014, [PM ID: 24905030].

261. Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, Lombardo Y,

Frampton AE, Green AR, Ellis IO, Ali S, Lenz HJ, Thanou M, Stebbing J, Giamas G.

The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated

Induction of Integrin B1. Sci Signal, 17:7(330):ra58, June 2014, [PM ID: 24939894].

262. Van Schaeybroeck S,Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV,

Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ,

Lawler M, Longley DB, Johnston PG. ADAM17-Dependent c-MET-STAT3 Signaling

Mediates Resistance To MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Rep,

7(6):1940-55, June 2014, [PM ID: 24931611].

263. Lenz HJ, Kahn M. Safely Targeting Cancer Stem Cells Via Selective Catenin

Coactivator Antagonism. Cancer Sci, 105(9):1087-92, Sept 2014, [PM ID: 24975284]

264. Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy

M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz HJ, Giamas G. KSR1 Regulates

BRCA1 degradation and inhibits breast cancer growth. Oncogene, 34(16):2103-14,

June 2014, [PM ID: 24909178].

265. Geva R, Vecchione L, Kalogeras KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D,

Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G,

Johansen JS, Hogdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D,

vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello

F, Piessevauz H, Tejpar S. FCGR polymorphisms and cetuximab efficacy in

chemorefractory metastatic colorectal cancer: an international consortium study. Gut,

64(6):921-8, July 2014, [PM ID: 25011934].

266. Ulrich CM, Rankin C, Toriola AT, Makar KW, Altug-Teber O, Benedetti JK, Holmes

RS, Smalley SR, Blanke CD, Lenz HJ. Polymorphisms in folate-metabolizing enzymes

and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-

0144; SWOG 9304). Cancer, 120(21):3329-37, July 2014, [PM ID: 25041994].

267. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, Setiawan VW, El-

Khoueiry A. Impact of sex on the survival of patients with hepatocellular carcinoma: A

Surveillance, Epidemiology, and End Results analysis. Cancer, 120(23):3707-16, July

2014, [PM ID: 25081299].

268. Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li

JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ. Genes

involved in pericyte-driven tumor maturation predict treatment benefit of first-line



FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.

Pharmacogenomics J, 15(1):69-76. doi: 10.1038/tpj.2014.40, July 2014, [PM ID:

25069475].

269. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim Ej, Gong IY, Tanaka M, Bechett L,

Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN Jr. Pharmacodynamic

separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic

cancer: therapeutic and biomarker results. Int J Clin Oncol, 20(3):518-24, Aug 2014,

[PM ID: 25091263; PMC4318776].

270. Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock

W, Salzman DW, Zhang W, Yang D, Pilati C, Bouche O, Piessevaux H, Tejpar S. A

let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in

Patients with Metastatic colorectal Cancer reated with Salvage

Cetuximab/Panitumumab Monotherapy. Clin Cancer Res, 20(17):4499-510, Sept 2014,

[PM ID: 25183481].

271. Wakatsuki T, Stintzing S, Zhang W, Yang D, Azuma N, Ning Y, Yamauchi S,

Matsusaka S, Volz NB, Sunakawa Y, Koizumi W, Watanabe M, Barzi A, El-Khoueiry

AB, Shah MA, Lenz HJ. Single nucleotide polymorphisms in AREG and EREG are

porgnostic biomarkers in locally advanced gastric cancer patients after surgery with

curative intent. Pharmacogenet Genomics, 24(11):539-47, Nov 2014, [PM ID:

25203737; PMC ID: 4190124].

272. Sunakawa Y, Wakatsuki T, Yang D, Zhang W, NingY, Stintzing S, Stremitzer S,

Yamauchi S, Sebio A, El-Khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M,

Watanabe M, Koizumi W, Lenz HJ. Prognostic impact of the c-MET polymorphism on

the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics,

24(12):588-96, Dec 2014, [PM ID: 25203738; PMC ID: 4218879].

273. Lenz HJ, Stintzing S.So much effort, so little progress. J Natl Cancer Inst, 106(10),

Sept 2014, [PM ID: 25246612].

274. Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP,

Wakatsuki T, Iqbal S, Gaur R, Benedetti JK, Blake CD. Dual blockade of epidermal

growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic

pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and

cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer,120(19):2980-

5, Oct 2014, [PM ID: 25041791].

275. Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paes D, Loupakis

F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G,

Stebbing J, Lenz HJ. Genetic variants of kinase suppressors of Ras (KSR1) to predict

survival in patients with ERα-positive advanced breast cancer. Clin Cancer Res,

15(3):235-40, Oct 2014, [PM ID: 25287073].

276. Hobday TJ, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler

HL, Lenz HJ, Chen H, Erichman C. Multicenter Phase II Trial of Temsirolimus and

Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol, 33(14):1551-6, Dec

2014, [PM ID: 25488966; PMC4417726].

277. Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F,

Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ. Integrin

genetic variants and stage-specific tumor recurrence in patients with stage II and II

colon cancer. Pharmacogenomics J, 15(3)226-34, Dec 2014, [PM ID: 25487679].



278. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB,

Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel,

C, Carroll MI, Newman EM. Phase I study of the halichondrin B analogue eribulin

mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer,

111(12):2268-74, Dec 2014, [PM ID: 25349975; PMC4264453].

279. Maus MK, Hanna DL, Stephens CL, Astrow SH, Yang D, Grimminger PP, Loupakis F,

Hsiang JH, Zeger G, Wakatsuki T, Barzi A, Lenz HJ. Distinct gene expression profiles

of proximal and distal colorectal cancer: implications for cytotoxic and targeted

therapy. Pharmacogenomics J, 15(4):354-62, Dec 2014, [PM ID: 25532759;

PMC4478287]

280. Sebio A, Gerger A, Matsusaka S, Yang D, Zhang W, Stremitzer S, Stintzing S,

Sunakawa Y, Yamauchi S, Ning Y, Fujimoto Y, Ueno M, Lenz HJ. Genetic variants

within obesity-related genes are associated with tumor recurrence in patients with

stages II/III colon cancer. Pharmacogenet Genomics, 25(1):30-7, Jan 2015, [PM ID:

25379721; PMC4260998].

281. Hochster HC, Uboha N, Messersmith W, Gold PJ, ONeil BH, cohen D, Denlinger C,

Cohen S, Leichman CG, Leichman L, Lenz HJ. Erratum to: Phase II study of

selumetinib (AZD6244, ARRY-142866) plus irinotecan as second-line therapy in

pateints with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol,

75(1):17-23, doi: 10.1007/s00280-014-2625-3, Jan 2015, [PM ID: 25322874].

282. Newman EM, Morgan RJ, Kummar S, Beumer JH, Blachard MS, Ruel C, El-Khoueiry

AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eisman JL, Doroshow JH. A phase I,

pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase

inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer

Chemother Pharmacol, 75(3):537-46, Jan 2015, [PM ID: 25567350; PMC4344391].

283. Bohanes P, Rankin C, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA,

Martenson JA, Benson AB 3rd, Mayer RJ, Cripps CM, Danenberg KD, Makar KW,

Zhang W, Benedetti JK, Lenz HJ. Pharmacogenetic analysis of INT 0144 trial:

association of polymorphisms with survival and toxicity in rectal cancer patients treated

with 5-FU and radiation. Clin Cancer Res, 21(7):1583-90, Jan 2015, [PM ID:

25589620; PMC4566931].

284. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Teipar S, Melezinek I, Beier F,

Stroh C, Rougier P, Van Krieken JH, Ciardiello F. Fluorouracil, Leucovorin, and

Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. J Clin

Oncol, 33(7):692-700, Jan 2015, [PM ID: 25605843].

285. Stintzing S, Stremitzer S, Sebio A, Lenz HJ. Predictive and prognostic markers in the

treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.

Hematol Oncol Clin North Am, 29(1):43-60, Feb 2015, [PM ID: 25475572].

286. Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi

S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M,

Watanabe M, Koizumi W, Lenz HJ. Association of variants in genes encoding for

macrophage-related functions with clinical outcome in patients with locoregional

gastric cancer. Ann Oncol, 26(2):332-9, Feb 2015, [PM ID: 25411415; PMC4304380].

287. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi

S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. Genetic

variations in angiopoietin and pericyte pathways and clinical outcome in patients with



resected colorectal liver metastases. Cancer, 121(11):1898-905, Feb 2015, [PM ID:

25690670; PMC4260998].

288. Szkandera J, Herzog S, Pichler M, Stiegelbauer V, Stotz M, Schaberi-Moser R,

Samonigg H, Asslaber M, Lax S, Leitner G, Renner W, Lenz HJ, Berghold A, Gerger

A. LGR5 rs17109924 is predictive genetic biomarker for time to recurrence in patients

with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.

Pharmacogenomics J, 15(5):391-6, Feb 2015, [PM ID: 25665511].

289. Loupakis F, Yand D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C,

Langer C, Scherer SJ, Muller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ. Primary

tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst,

107(3), Mar 2015, [PM ID: 25713148; PMC4565528].

290. Barzi A, Lenz HJ. Cost-effectiveness of genomic testing for colorectal cancer: are we

there yet? Oncology (Williston Park), 29(3):183-4, Mar 2015, [PM ID: 25783978].

291. Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ,

Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV.Circulation

cytokines and monocyte subpopulations as biomarkers of outcome and biological

activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br J

Cancer, 112(7):1199-205, Mar 2015, [PM ID: 25756398; PMC4385961].

292. Stremitzer S, Sunakawa Y, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Yamauchi

S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. Variations in

genes involved in immune response checkpoints and association with outcomes in

patients with resected colorectal liver metastases. Pharmacogenomics J, 15(6):521-9,

Mar 2015, [PM ID: 25752522].

293. Matsusaka S, Lenz HJ. Pharmacogenomics of fluorouracil -based chemotherapy

toxicity. Expert Opin Drug Metab Toxicol, 11(5):811-21, Mar 2015, [PM ID:

25800061].

294. Sunakawa Y, Lenz HJ. Molecular classification of gastric adenocarcinoma: translating

new insights from the cancer genome atlas research network. Curr Treat Options

Oncol, 16(4):17, Apr 2015, [PM ID: 25813036].

295. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, Lanza

DG, Berger NA, Markowitz SD, Lenz HJ, Nadeau JH, Pizarro TT, Heaney JD. IL-33

activates tumor stroma to promote intestinal polyposis. Natl Acad Sci U S A,

112(19):E2487-96, May 2015, [PM ID: 25918379; PMC4434739].

296. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N,

Yamazaki N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher

E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H,

Benedetti F, Mizuquchi H, Makris L, Ito M, Ohtsu A. Randomized trial of TAS-102 for

refractory metastatic colorectal cancer. N Engl J Med, 372(20):1909-19, May 2015,

[PM ID: 25970050].

297. Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Kinkhardt U, Beier F,

Duecker K, VanKrieken JH, Tejpar S. FOLFOX4 plus cetuximab treatment and RAS

mutations in colorectal cancer. Eur J Cancer, 51(10):1243-52. doi:

10.1016/j.ejca.2015.04.007, May 2015, [PM ID: 25937522].

298. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi

S, Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stift J, Wrba F, Gruenberger T,

Lenz HJ. Variations in genes involved in dormancy associated with outcome inpatients



with resected colorectal liver metastases. Ann Oncol, 26(8): 1728-1733, doi:

10.1093/annonc/mdv224, May 2015, [PM ID: 25957329; PMC4511220].

299. Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: A review of the

mechanism of action. Cancer Treat Rev, 41(9):777-783, June 2015, [PM ID: 26428513;

PMC4624296].

300. Lee NS, Evgrafov OV, Souaiaia T, Bonyad A, Herstein J, Lee JY, Kim J, Ning Y, Sixto

M, Weitz AC, Lenz HJ, Wang K, Knowles JA, Press MF, Salvaterra PM, Shung KK,

Chow RH. Non-coding RNAs derived from an alternatively spliced REST transcript

(REST-003) regulate breast cancer invasiveness. Sci Rep, 5:11207. doi:

10.1038/srep11207, June 2015, [PM ID: 26053433; PMC4459148].

301. Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S,

Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ.

Cyokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in

Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR

Approach. Mol Cancer Ther, 14(10):2401-2408, July 2015, [PM ID: 26227487].

302. Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A,

Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S,

Yamauchi S, Loupakis F, Cremolini C, Falcome A, Lenz HJ. Polymorphisms in Genes

Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal

Cancer. Mol Cancer Ther, 14(10): 2374-2381, July 2015, [PM ID: 26206335].

303. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouche

O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A,

Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating

DNA and Protein biomarkers to predict the clinical activity of regorafenib and assess

prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory

analysis of the CORRECT trial. Lancet Oncol, 16(8):937-48, July 2015, [PM ID:

26184520].

304. Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ, Kornek G,

Scheithauer W, Zielinski CC, Pabinger I, Ay C, Prager GW. Integrin beta-3 genetic

variants and risk of venous thromboembolism in colorectal cancer patients.Thrombosis

Research, 136:865-869, Aug 2015, [PM ID: 26440977].

305. Cremolini C, Loupakis F, Lenz HJ. Response. J Natl Cancer Inst, 107(10). pii: djv205.

doi: 10.1093/jnci/djv205, Sep 2015, [PM ID: 26389154].

306. Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B,

Lewis MD, Colevas AD, Doroshow J, Newman EM. Pharmacodynamics (PD) and

pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial

in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer

Chemother Pharmacol, 76(5):897-907, Sep 2015, [PM ID: 26362045].

307. Sebio A, Matsusaka S, Zhang W, Yang D, Ning Y, Stremitzer S, Sunakawa Y,

Yamauchi S, Fujimoto Y, Ueno M, Lenz HJ. Germline polymorphisms in genes

involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.

Pharmacogenomics J, doi: 10.1038/tpj.2015.64, Sep 2015, [PM ID: 26370619] [Epub

ahead of print].

308. Sebio A, Lenz HJ, Molecular Pathways: Hippo Signaling, a Critical Tumor

Suppressor. Clin Cancer Res, 21(22):5502-7, Sep 2015, [PM ID: 26384319].



309. Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D,

Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S,

Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ. Variations in

genes regulating tumor-associated macrophages (TAMs) to predict outcomes of

bevacizumab-based tretment in patients with metastatic colorectal cancer: Results from

TRIBE and FIRE3 trials. Ann Oncol, 26(12):2450-6, Sep 2015, [PM ID: 26416897;

PMC4658546].

310. Renfro LA, Loupakis F, Adams RA, Seymour MT, Schmoll HJ, Douillard JY, Hurwitz

H, Fuchs CF, Diaz-Rubio E, Porchen R, Tournigand C, Chibaudel B, Falcone A,

Tebbutt NC, Punt CJA, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz

LB, de Gramont A, Sargent DJ, Lenz HJ. Body Mass Index Is Prognostic in

Metastatic Colorectal Cancer: Pooled Analysis of Patients from First-Line Clinical

Trials in the ARCAD Database. Journal of Clin Onc, 34(2):144-50, Oct 2015, [PM ID:

26503203].

311. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R,

Wallace J, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P,

Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL.

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a

Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin

Oncol, 33(36):4284-92, Nov 2015, [PM ID: 2652777].

312. Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y,

Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A,

Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ. Genetic

variants associated with colorectal brain metastases susceptibility and survival.

Pharmacogenomics J, doi: 10.1038/tpj.2015.86, Dec 2015, [PM ID: 26689941][Epub

ahead of print].

313. Miyamoto Y, Lenz HJ, Baba H. A novel antimetabolite: TAS-102 for metastatic

colorectal cancer. Expert Rev Clin Pharmacol, 9(3):355-65, Jan 2016, [PM ID:

26677869].

314. Leichman L, Groshen S, O’Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG,

Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Carson RC,

Hamilton SR, Hochster HS. Phase II Study of Olaparib (AZD-2281) After Standard

Systemic Therapies for Disseminated Colorectal Cancer. Oncologist, 21(2):172-7, Jan

2016, [PM ID: 26786262].

315. Sunakawa Y, Schirripa M, Lenz HJ. Understanding the FOLFOXIRI-regimen to

optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol, 100:117-

26. doi: 10.1016/j.critrevonc.2016.01.020, Jan 2016, [PM ID: 26850575].

316. Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, NingY, Sunakawa Y, Okazaki S,

Berger MD, Miyamoto Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. Prognostic

Impact of IL-6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated

with Bevacizumab-Based Chemotherapy. Clin Cancer Res, 22(13): doi: 10.1158/1078-

0432.CCR-15-2422, Feb 2016, [PM ID: 26839145].

317. Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A,

Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD,

Vokes EE, Cohen EE. Phase II trial of dasatinib for recurrent or metastatic c-KIT

expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary



tumors. Ann Oncol, 27(2):318-23. doi: 10.1093/annonc/mdv537, Feb 2016, [PM ID:

26598548].

318. Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang

D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W,Mizunuma N, Lenz HJ.

TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer

Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Mol Cancer

Ther, 15(6):1405-11, Mar 2016, [PM ID:26983880].

319. Schirripa M, Lenz HJ. Colorectal cancer: Overcoming resistance to anti-EGFR therapy

– where do we stand? Nat Rev Gastroenterol Hepatol, 13(5):258-9, Mar 2016, [PM ID:

27006256].

320. Hana DL, Lenz HJ. Novel therapeutics in metastatic colorectal cancer: molecular

insights and pharmacogenomic implications. Expert Rev Clin Pharmacol, 14:1-18, Apr

2016, [PM ID: 27031164].

321. Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao

S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa

Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ. Combined

assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-

containing chemotherapy for metastatic colorectal cancer. Cancer Biol Ther, 17(7):751-

9. doi: 10.1080/15384047.2016.1178426, April 2016, [PM ID: 27104867;

PMC4970538].

322. Schmit SL, Schumacher FR, Edlund CK, Conti DV, Ihenacho U, Wan P, Van Den Berg

D, Casey G, Fortini BK, Lenz HJ, Tusié-Luna T, Aguilar-Salinas CA, Moreno-Macías

H, Huerta-Chagoya A, Ordóñez-Sánchez ML, Rodríguez-Guillén R, Cruz-Bautista I,

Rodríguez-Torres M, Muñóz-Hernández LL, Arellano-Campos O, Gómez D, Alvirde

U, González-Villalpando C, González-Villalpando ME, Le Marchand L, Haiman CA,

Figueiredo JC. Genome-wide association study of colorectal cancer in Hispanics.

Carcinogenesis, Apr 2016, 37(6):547-56, [PM ID: 27207650].

323. Berger MD, Lenz HJ. The safety of monoclonal antibodies for treatment of colorectal

cancer. Expert Opin Drug Saf., 15(6):799-808, Apr 2016, [PM ID: 26982510].

324. Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y,

Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M,

Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ. Clinical

Significance of TLR1 I602S Polymorphism for Patients with Metastic Colorectal

Cancer Treated with FOLFIRI plus Bevaciumab. Mol Cancer Ther, 15(7):1740-5. doi:

10.1158/1535-7163.MCT-15-0931, May 2016, [PM ID: 27196764].

325. Sunakawa Y, Cao S, Volz NB, Berger MD, Yang D, Parekh A, Zhang W, Matsusaka S,

Ning Y, Stremitzer S, Stintzing S, Sebio A, Okazaki S, Wakatsuki T, Azuma M,

Watanabe M, Koizumi W, Wu AH, Lenz HJ. Genetic variations in immunomodulatory

pathways to predict survival in patients survival in patients with locoregional gastric

cancer. Pharmacogenomics J, doi: 10.1038/tpj.2016.46, May 2016, [PM ID: 27241062]

[Epub ahead of print].

326. Schirripa M, Loupakis F, Lenz HJ. CDX2 as a Prognostic Biomarker in Colon Cancer.

N Engl J Med, 2;374(22):2183, June 2016, [PM ID: 27248629].

327. Labonte MJ, Yang D, Zhang W, Wilson PM, Nagarwala YM, Koch KM, Briner C,

Kaneko T, Rha SY, Gladkov O, Urba SG, Sakaeva D, Pishvaian MJ, Hsieh RK, Lee

WP, Lenz HJ. A phase II biomarker-embedded study of lapatinib plus capecitabine as



first-line thearpy in patients with advanced or metastic gastric cancer. Mol Cancer

Ther, (9):2251-8. doi: 10.1158/1535-7163.MCT-15-0908, June 2016, [PM ID:

27325685].

328. Miyamoto Y, Hanna DL, Zhang W, Baba H, Lenz HJ. Molecular Pathways: Cachexia

Signaling-A Targeted Approach to Cancer Treatment. Clin Cancer Res, 22(16):3999-

4004. doi: 10.1158/1078-0432.CCR-16-049, June 2016, [PM ID: 27340276; PMC

4987228].

329. Schirripa M, Lenz HJ. Biomarker in Colorectal Cancer. Cancer J, 22(3):156-64. doi:

10.1097/PPO.0000000000000190, June 2016, [PM ID: 27341592].

330. Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S,

Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC,

Hanna DL, Lenz HJ. Impact of sex, age and ethnicity/race on the survival of patients

with rectal cancer in the United States from 1988 to 2012. Oncotarget, 7(33):53668-

53678. doi: 10.18632/oncotarget.10696, July 2016, [PM ID: 27449091].

331. Ning Y, Zhang W, Hanna DL, Yang D, Okazaki S, Berger MD, Miyamoto Y, Suenaga

M, Schirripa M, El-Khoueiry A, Lenz HJ. Clinical relevance of EMT and stem-like

gene expression in circulation tumor cells of metastatic colorectal cancer patients.

Pharmacogenomics J, doi: 10.1038/tpj.2016.62, Aug 2016, [PM ID: 27503579][Epub

ahead of print].

332. Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang

D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S,

Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ. CXCR4

polymorphism predicts progression-free survival in metasttic colorectal cancer patients

treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics J, doi:

10.1038/tpj.2016.59, Aug 2016, [PM ID: 27503580][Epub ahead of print].

333. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz

JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working

Group. ESMO/ASCO Recommendations for a Global Curriculum (GC) in Medical

Oncology-Edition 2016. Ann Oncol, 27(8):1378-81, doi: 10.1093/annonc/mdw239,

Aug 2016,[PM ID: 27457308; PMC4959930].

334. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP,

Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J,

Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S,

De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff

M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A,

Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz

U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T,

Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG,

Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K,

Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski

P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper

L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan

R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS,

Wildiers H, Yarden Y. ESMO/ASCO Recommendations for a Global Curriculum in

Medical Oncology Edition 2016. ESMO Open, 1(5):e000097. Review, Sep 2016, [PM

ID: 27843641].



335. Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A,

Takahashi T, Parekh A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S,

Barzi A, Berger MD, Lenz HJ. A genetic variant in Rassf1a predicts outcome in

mCRC patients treated with cetuximab plus chemothearpy : results from FIRE-3 and

JACCRO 05 and 06 trials. Pharmacogenomics J, doi: 10.1038/tpj.2016.69, Oct 2016,

[PM ID: 27698403][Epub ahead of print].

336. Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz

HJ, Heinemann V. Prognostic and Predictive Relevance of Primary Tumor Location in

Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of

CRYSTAL and FIRE-3 Trials. Jama Oncol, doi: 10.1001/jamaoncol.2016.3797, Oct

2016, [PM ID: 27722750][Epub ahead of print].

337. Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SR, Tang S,

Grebennik D, Kauh JS, Lenz HJ, Flaherty KT, Hodi FS, Lawrence DP, Wolchok, JD.

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody

IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res,

22(21):5204-5210, Oct 2016, [PM ID: 27797971; PMC5117650].

338. Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A,

Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Stift J, Wrba F,

Gruenberger T, Lenz HJ. Expression of Genes Involved in Vascular Morphogenesis

and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients

Undergoing Liver Resection. Mol Cancer Ther, 15(11):2814-2821, Nov 2016, [PM ID:

27535973].

339. Morgen EK, Lenz HJ, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis

CS, Dobrovic A, O’ Callaghan CJ, Liu G. Germline Polymorphisms as biomarkers of

tumor response in colorectal cancer patients treated with anti-EGFR monoclonal

antibodies: a systematic review and meta-analysis. Pharmacogenomics J, doi:

10.1038/tpj.2016.56, Nov 2016, [PM ID: 27897268][Epub ahead of print].

340. Shabihkhani M, Yu SS, Yang D, Lin S, Hamilton AS, Lenz HJ, Barzi A. Metastatic

Colorectal Cancer in Hispanics: Treatment Outcome in Treated Population. Clin

Colorectal Cancer,5(4):e221-e227, doi: 10.1016/j.clcc.2016.03.001, Dec 2016, [PM

ID: 27553907].

341. Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS,

Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS,

Bertagnolli MM. A Study of Thymidylate Synthase Expression as a Biomarker for

Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.

Oncologist 22: 107-114, Jan 2017, [PMID: 27821793][PMC5313270]

342. van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T,

Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R,

Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T,

Schellens JHM. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with

or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov, 7:

610-619, June 2017 [PM ID: 28363909]

343. Trosko JE, Lenz HJ. What roles do colon stem cells and gap junctions play in the left

and right location of orgin colorectal cancers? J Cell Commun Signal, 11(1):79-87. doi:

10.1007/s12079-017-0381-y, Mar 2017, [PM ID: 28220297; PMC5362582].



344. Black DS, Peng C, Sleight AG, Nguyen N, Lenz HJ, Figueiredo JC. Mindfulness

practice reduces cortisol blunting during chemotherapy: A randomized controlled study

of colorectal cancer patients. Cancer. doi: 10.1002/cncr.30698, Apr 2017, [PM ID:

28387949] [Epub ahead of print].

345. Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing

S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A,

Miyamoto Y, Mizunuma N, Lenz HJ. Prognostic impact of FOXF1 polymorphisms in

gastric cancer patients. Pharmacogenomics J: April 2017, [PMID: 28398355]

346. Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van

Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F. Prognostic and predictive

value of primary tumour side in patients with RAS wild-type metastatic colorectal

cancer treated with chemotherapy and EGFR directed antibodies in six randomised

trials. Ann Oncol: April 2017, [PMID: 28407110]

347. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino

F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A,

Yamaguchi T, Loupakis F, Lenz HJ. Genetic variants of DNA repair-related genes

predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.

Ann Oncol 28: 1015-1022, May 2017, [PMID: 28453695]

348. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. Comparative effectiveness of screening

strategies for colorectal cancer. Cancer. 123(9):1516-1527. doi: 10.1002/cncr.30518,

May 2017, [PM ID: 28117881].

349. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S,

Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi

S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ.

Autophagy-related polymorphisms predict hypertension in patients with metastatic

colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and

FIRE-3 trials. Eur J Cancer, 77:13-20. doi: 10.1016/j.ejca.2017.02.02, May 2017, [PM

ID: 28347919].

350. Schirripa M, Loupakis F, Lenz, HJ. CDX2 as a prognostic biomarker inColon Cancer.

N Engl J Med., 374(22):2183. doi: 10.1056/NEJMc1602584#SA2, June 2017, [PM ID:

27248629].

351. Puccini A, Berger MD, Zhang W, Lenz HJ. What We Know About Stage II and III

Colon Cancer: It's Still Not Enough. Target Oncol 12: 265-275, June 2017, [PMID:

28504299]

352. Puccini A, Lenz HJ. New perspectives for colorectal cancer. Oncotarget 8: 41782-

41783, June 2017, [PMID: 28620138]

353. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D,

Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM,

Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB,

Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With

Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type

Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 317:

2392-2401, June 2017, [PMID: 28632865]

354. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger

MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A,

Falcone A, Stintzing S, Lenz HJ. Single nucleotide polymorphisms in the IGF-IRS



pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int

J Cancer. 141: 383-392, July 2017, [PMID: 28369940] [PMC5510747]

[NIHMS863866]

355. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp D, Piha-Paul S ,

Subbiah V, Tsimberidou AM, Huang H, Veronese S, DiNicolantonio F, Pingle SC,

Vibat CR, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Koptz S,

Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-

Generation Sequencing for quantitative Detection of KRAS Mutations in Urine Cell-

Free DNA from Patients with Advanced Cancers. Clin Cancer Res, 23: 3657-3666, July

2017, [PMID: 28096270] [PMC5511562] [NIHMS844652]

356. Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S,

Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T,

Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ. Predictive value of TLR7

polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal

cancer. Int J Cancer 141: 1222-1230, Sept. 2017, [PMID: 28569041] [PMC5528002]

[NIHMS881823]

357. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill

A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz

S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or

microsatellite instability-high colorectal cancer (CheckMate 142): an open-label,

multicentre, phase 2 study. Lancet Oncol 18: 1182-1191, Sept. 2017, [PMID:

28734759]

358. Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of

primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer

84: 69-80, Oct. 2017, [PMID: 28787661]

359. Ricker CN, Hanna DL, Peng C, Nguyen NT, Stern MC, Schmit SL, Idos GE, Patel R,

Tsai S, Ramirez V, Lin S, Shamasunadara V, Barzi A, Lenz HJ, Figueiredo J. CDNA

mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal

cancer. Cancer 123: 3732-3743, Oct. 2017, [PMID: 28640387] [PMC5610604]

[NIHMS872444]

360. Weisenberger DJ, Liang G, Lenz HJ. DNA methylation aberrancies delineate clinically

distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.

Oncogene 37: 566-577 (02/2018). [PMID: 28991233]

361. Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA,

Shields AF, Lenz HJ, Marshall. Comparative molecular analyses of left-sided colon,

right-sided colon, and rectal cancers. Oncotarget 8: 86356-86368, Oct. 2017, [PMID:

29156800] [PMC5689690]

362. Barzi A, Yang D, Mostofizadeh S, Lenz HJ. Trends in colorectal cancer mortality in

hispanics: a SEER analysis. Oncotarget. 2017 Oct 19;8(65):108771-108777. doi:

10.18632/oncotarget.21938. eCollection 2017 Dec 12. [PMID: 29312566]

[PMC5752479]

363. Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD,

Miyamoto Y, Suenaga M, Iqbal S, Barzi A, Cremolini C, Falcone A, Battaglin F,

Salvatore L, Borelli B, Helentjaris TG, Lenz HJ. Tandem repeat variation near the

HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based



chemotherapy in patients with metastatic colorectal cancer. Cancer 123: 4506-4514,

Nov. 2017, [PMID: 28708932] [PMC5673544] [NIHMS889623]

364. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli

B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A,

Yamaguchi T, Loupakis F, Lenz HJ. Potential role of polymorphisms in the transporter

genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients

with refractory metastatic colorectal cancer. Eur J Cancer 86: 197-206, Nov. 2017,

[PMID: 28992563]

365. Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y,

Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W,

Falcone A, Loupakis F, Lenz HJ. Impact of genetic variations in the MAPK signaling

pathway on outcome in metastatic colorectal cancer patients treated with first-line

FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Ann Oncol 28: 2780-

2785, Nov. 2017, [PMID: 29045529] 366. Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ,

Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW. Determination of an

optimal response cut-off able to predict progression-free survival in patients with well-

differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an

alternative to the current RECIST-defined response. Br J Cancer: 2018 Jan;118(2):181-

188. doi: 10.1038/bjc.2017.402. Epub 2017 Nov 21. [PMID: 29161241][PMC5785750]

367. Puccini A, Lenz HJ. Colorectal cancer in 2017: Practice-changing updates in the

adjuvant and metastatic setting. Nat Rev Clin Oncol: 2018 Feb;15(2):77-78.

doi:10.1038/nrclinonc.2017.185. Epub 2017 Nov 28. [PMID: 29182161]

368. Lenz HJ, Philip P, Saunders M, Kolevska T, Mukherjee K, Samuel L, Bondarde S,

Dobbs T, Tagliaferri M, Hoch U, Hannah AL, Berkowitz M. Randomized study of

etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal

cancer. Cancer Chemother Pharmacol 80: 1161-1169, Dec. 2017, [PMID: 29043412]

369. Puccini A, Berger MD, Naseem M, Tokunaga R, Battaglin F, Cao S, Hanna DL,

McSkane M, Soni S, Zhang W, Lenz HJ. Colorectal cancer: epigenetic alterations and

their clinical implications. Biochim Biophys Acta 1868: 439-448, Dec. 2017, [PMID:

28939182] [PMCID: PMC5757873]

370. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane J, Baba

H, Lenz HJ. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target

for novel cancer therapy. Cancer Treatment Reviews. doi:10.1016/j.ctrv.2017.11.007,

Dec. 2017, [PMID: 29207310] [PMC5801162]

371. Suenaga M, Schirripa M, Cao S, Zhang W,Yang D, Cremolini C, Lonardi S, Bergamo

F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez Jr. R, Barzi A,

Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ. Potential

role of PIN1 genotypes in predicting benefit from oxaliplatin-and irinotecan-based

treatment in patients with metastatic colorectal cancer. The Pharmacogenomics J. 2018

Sep;18(5): 623-632. [PMID: 29925895] [PMCID: PMC6151284]

372. Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi

R, Gonzalez R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D,

Lenz HJ, Uetake H, Danenberg PV, Danenberg K. Frequencies and expression levels

of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various



cancer types. Biochem Biophys Res Commun. 2018 June; 500(3): 621-625. [PMID:

29679564]

373. Hanna DL, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger

MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G,

Astrow SH, Falcone A, Lenz HJ. Prognostic Value of ACVRL1 Expression in

Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With

Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin

Colorectal Cancer. 2018 Sep;17(3): e471-e488. [PMID: 29636300] [PMCID:

PMC6110978]

374. Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, Battaglin

F, Soni S, McSkane M, Zhang W, Lenz HJ. Outlooks on Epstein-Barr virus associated

gastric cancer. Cancer Treat Rev. 2018 May; 66: 15-22. 66:15-22. doi:

10.1016/j.ctrv.2018.03.006. Review. [PMID: 29631196] [PMC5964025]

[NIHMS958090]

375. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti

C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr., Barzi A,

Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ. Gene Polymorphisms in

the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin

Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin

Colorectal Cancer. 2018 June; 17: e395-e414. pii: S1533-0028(17)30522-4. doi:

10.1016/j.clcc.2018.02.010. [PMID: 29606345]

376. Manegold P, Lai KKY, Wu Y, Teo JL, Lenz HJ, Genyk YS, Pandol SJ, Wu K, Lin DP,

Chen Y, Nguyen C, Zhao Y, Kahn M. Differentiation Therapy Targeting the β-

Catenin/CBP Interaction in Pancreatic Cancer. Cancers (Basel). 2018 Mar 29;10(4).

pii: E95. doi: 10.3390/cancers10040095. [PMID: 29596326] [PMC5923350]

377. Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK,

Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP,

Hurwitz H, Lenz HJ. A phase 1 dose-escalation study of veliparib with bimonthly

FOLFIRI in patients with advanced solid tumours. Br J Cancer. 2018 Apr;118(7): 938-

946. doi: 10.1038/s41416-018-0003-3. Epub 2018 Mar 12. [PMID: 29527010]

378. Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM,

Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ. Landscape of

Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large

Patient Cohort of Gastrointestinal Cancers. Mol Cancer Res. 2018 Mar 9; 16:805-812.

pii:molcanres.0735.2017. doi: 10.1158/1541-7786.MCR-17-0735 [PMID: 29523759]

379. Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y,

Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F,

Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. NOS2

polymorphisms in prediction of benefit from first-line chemotherapy in metastatic

colorectal cancer patients. PLoS One. 2018 Mar 9;13(3): e0193640. doi:

10.1371/journal.pone.0193640. eCollection 2018. [PMID: 29522543] [PMC5844536]

380. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y,

Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. A phase I trial of escalating doses of

cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular

carcinoma. Cancer Chemother Pharmacol. 2018 May;81(5):957-963. doi:

10.1007/s00280-018-3553-4. Epub 2018 Mar 8. [PMID: 29520435]



381. Keedy VL, Lenz HJ, Saltz L, Whisenant JG, Berlin JD, Camacho LH. First-in-human

phase I dose escalation study of MK-8033 in patients with advanced solid tumors.

Invest New Drugs. 2018 Jan 29. 2018 Oct;36(5):860-868. [PMID: 29376210]

382. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA,

Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M,

Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. Durable Clinical

Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-

Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol.

2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

[PMID: 29355075]

383. Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, Lonardi S, Zagonel

V, Lenz HJ, Loupakis F. The role of tumor angiogenesis as a therapeutic target in

colorectal cancer. Expert Rev Anticancer Ther. 2018 Mar;18(3):251-266. doi:

10.1080/14737140.2018.1428092. Epub 2018 Jan 19. [PMID: 29338550]

384. Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, Longo-

Munoz F, Portales F, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y,

Makris L, Loehrer P, Lenz HJ, Ohtsu A; RECOURSE Study Group. The subgroups of

the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with

best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018

Feb; 90:63-72. doi: 10.1016/j.ejca.2017.10.009. Epub 2017 Dec 21. [PMID: 29274618]

385. Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA,

Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Cetuximab Combined

With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant

Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clin Colorectal

Cancer. 2018 Mar; 17(1): e121-e125. doi: 10.1016/j.clcc.2017.10.008. Epub 2017 Oct

24. [PMID: 29233486]

386. Ferris RL, Lenz HJ, Trotta AM, García-Foncillas J, Schulten J, Audhuy F, Merlano M,

Milano G. Rationale for combination of therapeutic antibodies targeting tumor cells and

immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1

isotype immune effector stimulation. Cancer Treat Rev. 2018 Feb; 63:48-60. doi:

10.1016/j.ctrv.2017.11.008. Epub 2017 Dec 2. Review. [PMID: 29223828]

387. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S,

Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini

A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ. A Polymorphism within

the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer

Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clin Cancer

Res. 2018 Feb 15;24(4):784-793. doi: 10.1158/1078-0432.CCR-17-1663. Epub 2017

Dec 5. [PMID: 29208668]

388. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba

H, Lenz HJ. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A

target for novel cancer therapy. Cancer Treat Rev. 2018 Feb; 63:40-47. doi:

10.1016/j.ctrv.2017.11.007. Epub 2017 Nov 26. Review. [PMID: 29207310]

[PMC5801162] [NIHMS925571]

389. Miyamoto Y, Zhang W, Lenz HJ. Molecular Landscape and Treatment Options for

Patients with Metastatic Colorectal Cancer. Indian J Surg Oncol. 2017 Dec; 8(4):580-



590. doi: 10.1007/s13193-016-0543-z. Epub 2016 Jul 27. Review. [PMID: 29203992]

[PMC5705494]

390. Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML, Saunders M,

Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F,

Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G. Nintedanib for the

treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a

phase III, international, randomized, placebo-controlled study. Ann Oncol. 2018 Sep

1;29(9):1955-1963. [PMID: 30010751]

391. Moehler M, Göpfert K, Lenz HJ. Outlook: Immunotherapy in Gastrointestinal

Carcinoma - Innovative Strategies. Oncol Res Treat 41:313-315 (04/2018). [PMID:

29705792]

392. Shah MA, Starodub AN, Sharma S, Berlin J, Patel MR, Wainberg ZA, Chaves J,

Gordon MS, Windsor K, Brachmann CB, Huang X, Vosganian G, Maltzman JD, Smith

V, Silverman JA, Lenz HJ, Bendell JC. Andecaliximab/GS-5745 Alone and Combined

with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction

Adenocarcinoma: Results from a Phase I Study. Clin Cancer Res: 2018 Aug 15;

24(16):3829-3837. [PMID: 29691300]

393. McSkane M, Stintzing S, Heinemann V, Puccini A, Naseem M, Cao S, Lenz HJ, Jelas

I. Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer

Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3

Study. Clin Colorectal Cancer. 2018 Sep;17(3):215-222.e3. doi:

10.1016/j.clcc.2018.05.003. Epub 2018 May 10. [PMID: 29880436]

394. Chen EY, Blanke CD, Haller DG, Benson AB, Dragovich T, Lenz HJ, Robles C, Li H,

Mori M, Mattek N, Sanborn RE, Lopez CD. A Phase II Study of Celecoxib With

Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated

Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol, 41(12):1193-1198

(12/2018). [PMID: 29782360] [PMCID: PMC6240505]

395. Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, Qu C,

Melas M, Van Den Berg DJ, Wang H, Tring S, Plummer SJ, Albanes D, Alonso MH,

Amos CI, Anton K, Aragaki AK, Arndt V, Barry EL, Berndt SI, Bezieau S, Bien S,

Bloomer A, Boehm J, Boutron-Ruault MC, Brenner H, Brezina S, Buchanan DD,

Butterbach K, Caan BJ, Campbell PT, Carlson CS, Castelao JE, Chan AT, Chang-

Claude J, Chanock SJ, Cheng I, Cheng YW, Chin LS, Church JM, Church T, Coetzee

GA, Cotterchio M, Cruz Correa M, Curtis KR, Duggan D, Easton DF, English D,

Feskens EJM, Fischer R, FitzGerald LM, Fortini BK, Fritsche LG, Fuchs CS, Gago-

Dominguez M, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Giovannucci EL,

Gogarten SM, Gonzalez-Villalpando C, Gonzalez-Villalpando EM, Grady WM,

Greenson JK, Gsur A, Gunter M, Haiman CA, Hampe J, Harlid S, Harju JF, Hayes

RB, Hofer P, Hoffmeister M, Hopper JL, Huang SC, Huerta JM, Hudson TJ, Hunter

DJ, Idos GE, Iwasaki M, Jackson RD, Jacobs EJ, Jee SH, Jenkins MA, Jia WH, Jiao S,

Joshi AD, Kolonel LN, Kono S, Kooperberg C, Krogh V, Kuehn T, Küry S, Lacroix A,

Laurie CA, Lejbkowicz F, Lemire M, Lenz HJ, Levine D, Li CI, Li L, Lieb W, Lin Y,

Lindor NM, Liu YR, Loupakis F, Lu Y, Luh F, Ma J, Mancao C, Manion FJ,

Markowitz SD, Martin V, Matsuda K, Matsuo K, McDonnell KJ, McNeil CE, Milne

R, Molina AJ, Mukherjee B, Murphy N, Newcomb PA, Offit K, Omichessan H, Palli

D, Cotoré JPP, Pérez-Mayoral J, Pharoah PD, Potter JD, Qu C, Raskin L, Rennert G,

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30010751&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=9ooHWzp3ILsA-F4WFjgdyaEVwilOeNh9T26wiR2mPr8&e=



https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_29880436&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=DWiQ6CN-9NHOH57vrcjdSI9ZQ7UbzwWOhOlQUrAA5ok&e=





Rennert HS, Riggs BM, Schafmayer C, Schoen RE, Sellers TA, Seminara D, Severi G,

Shi W, Shibata D, Shu XO, Siegel EM, Slattery ML, Southey M, Stadler ZK, Stern

MC, Stintzing S, Taverna D, Thibodeau SN, Thomas DC, Trichopoulou A, Tsugane S,

Ulrich CM, van Duijnhoven FJB, van Guelpan B, Vijai J, Virtamo J, Weinstein SJ,

White E, Win AK, Wolk A, Woods M, Wu AH, Wu K, Xiang YB, Yen Y, Zanke BW,

Zeng YX, Zhang B, Zubair N, Kweon SS, Figueiredo JC, Zheng W, Marchand LL,

Lindblom A, Moreno V, Peters U, Casey G, Hsu L, Conti DV, Gruber SB. Novel

Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst:

(06/2018). [PMID: 29917119]

396. Li M, Mulkey F, Jiang C, O'Neill BH, Schneider BP, Shen F, Friedman PN,

Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS,

Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook A, Owzar K,

Kroetz D. Identification of a Genomic Region Between SLC29A1 and HSP90AB1

Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405

(Alliance). Clin Cancer Res, E-publication ahead of print: (06/2018). 2018 Oct

1;24(19):4734-4744. [PMID: 29871907]

397. Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA,

Marshall JL, Goldberg RM. Comparative Molecular Analyses of Esophageal Squamous

Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.

Oncologist. 2018 Nov;23(11):1319-1327. [PMID: 29866946]

398. Battaglin F, Puccini A, Naseem M, Schirripa M, Berger MD, Tokunaga R, McSkane

M, Khoukaz T, Soni S, Zhang W, Lenz H-J. Pharmacogenomics in colorectal cancer:

current role in clinical practice and future perspectives. J Cancer Metastasis Treat

2018; 4:12. DOI: 10.20517/2394-4722.2018.04

399. Battaglin F, Naseem M, Puccini A, Lenz HJ. Molecular biomarkers in gastro-

esophageal cancer: recent developments, current trends and future directions. Cancer

Cell Int. 18: 99 (07/2018). Review. [PMID: 30008616] [PMCID: PMC6042434]

400. Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML, Saunders M,

Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F,

Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G. Nintedanib for the

treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a

phase III, international, randomized, placebo-controlled study. Ann Oncol. 29(9): 1955-

1963 (09/2018). [PMID: 30010751] [PMCID: PMC6158765]

401. Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA,

Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME. Impact of

Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist.

(07/2018). [PMID: 30018131]

402. Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C,

Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S, Yamaguchi T, Eto T,

Fujii M, Ichikawa W, Lenz HJ. Immune-related Genes to Dominate Neutrophil-

lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in

Metastatic Colorectal Cancer. Clin Colorectal Cancer. 17(4):e741-e749 (12/2018).

[PMID: 30219280] [PMCID: PMC6249067]

403. Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, Bosanac I, Choong N,

Scappaticci F, Mancao C, Lenz HJ. MAVERICC, a Randomized, Biomarker-stratified,

Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-



line Chemotherapy in Metastatic Colorectal Cancer. Clin Cancer Res. (09/2018).

[PMID: 30224341]

404. Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T,

Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y,

Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W. Tumor Sidedness

and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in

Metastatic Colorectal Cancer. Mol Cancer Ther. 17(12):2788-2795 (12/2018). [PMID:

30275242]

405. Tokunaga R, Cao S, Naseem M, Lo JH, Battaglin F, Puccini A, Berger MD, Soni S,

Millstein J, Zhang W, Stintzing S, Loupakis F, Cremolini C, Heinemann V, Falcone A,

Lenz HJ. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic

Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. Clin Colorectal

Cancer. 2019 Mar;18(1):e8-e19. doi: 10.1016/j.clcc.2018.09.003. Epub 2018 Sep 13.

[PMID: 30293873]

406. Puccini A, Battaglin F, Lenz HJ. Management of Advanced Small Bowel Cancer. Curr

Treat Options Oncol. 19(12): 69, (11/2018). Review. [PMID: 30397729]

407. Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y,

Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ. Genetic variants in CCL5 and

CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic

colorectal cancer patients. Int J Cancer. (11/2018). [PMID: 30411783]

408. Cheng Q, Shi X, Han M, Smbatyan G, Lenz HJ, Zhang Y. Reprogramming Exosomes

as Nanoscale Controllers of Cellular Immunity. J Am Chem Soc. (11/2018). [PMID:

30452238]

409. Loupakis F, Hurwitz HI, Saltz L, Arnold D, Grothey A, Nguyen QL, Osborne S, Talbot

J, Srock S, Lenz HJ. Impact of primary tumour location on efficacy of bevacizumab

plus chemotherapy in metastatic colorectal cancer. Br J Cancer. 119(12): 1451-1455.

(11/2018). [PMID: 30487637]

410. Battaglin F, Naseem M, Lenz HJ, Salem ME. Microsatellite instability in colorectal

cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol

Oncol. 16(11): 735-745 (11/2018). [PMID: 30543589]

411. Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S,

Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M,

Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE,

Varki A, Zippelius A, Läubli H. Self-associated molecular patterns mediate cancer

immune evasion by engaging Siglecs on T cells. J Clin Invest. (11/2018). 128(11):

4912-4923. [PMID: 30130255].

412. Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W,

Baba H, Lenz HJ. B cell and B cell-related pathways for novel cancer treatments.

Cancer Treat Rev. 73: 10-19 (12/2018). Review. [PMID: 30551036]

413. Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS,

Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J. Phase II

Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus

FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist.

(12/2018). [PMID: 30552157]

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30130255&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=ZkH35EbCtuhjN49IBEkCU1sNDM-qLRFfb_R_wlcu-uA&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30130255&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=ZkH35EbCtuhjN49IBEkCU1sNDM-qLRFfb_R_wlcu-uA&e=



414. Cheng Q, Shi X, Han M, Smbatyan G, Lenz HJ, Zhang Y. Reprogramming Exosomes

as Nanoscale Controllers of Cellular Immunity. J Am Chem Soc.(12/2018).

140(48):16413-16417. [PMID: 30452238]

415. Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD,

Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ. Role of CCL5

and CCR5 gene polymorphisms in epidermal growth factor receptor signalling

blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. Eur J Cancer.

(01/2019). 107:100-114. [PMID: 30554073]

416. Battaglin F, Lenz HJ. What Should We Do Better? Lessons from Negative Results of a

Biomarker Validation Study. J Natl Cancer Inst. (01/2019). doi: 10.1093/jnci/djy217.

[Epub ahead of print]. [PMID: 30649462]

417. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K,

Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe

JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC,

Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB,

Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI,

Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla

MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan

DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell

PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan

AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F,

Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C,

Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL,

Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV,

Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O,

Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J,

García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE,

Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H,

Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ,

Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E,

Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G,

Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson

M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T,

Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA,

Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam

S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, et al.

Shared heritability and functional enrichment across six solid cancers. Nat Commun.

(01/2019). 25;10(1):431. [PMID: 30683880]

418. Puccini A, Marín-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz HJ, Loupakis

F, Battaglin F. Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Saf.

(02/2019). 42(2):211-233. [PMID: 30649748]

419. Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W,

Baba H, Lenz HJ. B cell and B cell-related pathways for novel cancer treatments.

Cancer Treat Rev. (02/2019). 73:10-19. [PMID: 30551036]

420. Hopper JL, Huang SC, Huerta JM, Hudson TJ, Hunter DJ, Idos GE, Iwasaki M,

Jackson RD, Jacobs EJ, Jee SH, Jenkins MA, Jia WH, Jiao S, Joshi AD, Kolonel LN,

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30452238&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=G888CTDAtW9J4etXDHTCNuO5-dCscGC_S37V57Hsu8Q&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30452238&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=G888CTDAtW9J4etXDHTCNuO5-dCscGC_S37V57Hsu8Q&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30649462&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=PX9dhHMzhT8eweE25rJD7KsDICiI5lNgS_NKl5_W92s&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30649462&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=PX9dhHMzhT8eweE25rJD7KsDICiI5lNgS_NKl5_W92s&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30683880&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=GVnu0cDnRM1ux6LZO67dFWwtQSUk8jTpKc65FBMfsZM&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30649748&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=Th_Prou1J1AHIIy4Aj8ypIFlLXkuTa3iHfsVbSGLP-c&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30551036&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=GPqsVV_i9JdUkZ0t8SqghJPhprbUohdkcV1UBFyofsc&e=



Kono S, Kooperberg C, Krogh V, Kuehn T, Küry S, LaCroix A, Laurie CA,

Lejbkowicz F, Lemire M, Lenz HJ, et al. Novel Common Genetic Susceptibility Loci

for Colorectal Cancer. J Natl Cancer Inst. (02/2019). 111(2):146-157. doi:

10.1093/jnci/djy099. [PMID: 29917119]

421. Chan BM, Hochster HS, Lenz HJ. The safety and efficacy of trifluridine-tipiracil for

metastatic colorectal cancer: A pharmacy perspective. Am J Health Syst Pharm.

(02/2019). 76(6):339-348. doi: 10.1093/ajhp/zxy006. [PMID: 31361848]

422. Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA,

Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME. Impact of

Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist.

(03/2019). 24(3):319-326. [PMID: 30018131]

423. Tokunaga R, Cao S, Naseem M, Battaglin F, Lo JH, Arai H, Loupakis F, Stintzing S,

Puccini A, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM,

Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz

HJ. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic

colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. Int J

Cancer. (03/2019). doi: 10.1002/ijc.32261. Epub ahead of print. [PMID: 30856283]

424. Puccini A, Loupakis F, Stintzing S, Cao S, Battaglin F, Togunaka R, Naseem M,

Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger

DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. Impact of

polymorphisms within genes involved in regulating DNA methylation in patients with

metastatic colorectal cancer enrolled in three independent, randomised, open-label

clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. Eur J Cancer.

(04/2019). 111:138-147. [PMID: 30852420]

425. Weekes C, Lockhart AC, Lee JJ, Sturm I, Cleton A, Huang F, Lenz HJ. A phase 1b

study evaluating the safety and pharmacokinetics of regorafenib in combination with

cetuximab in patients with advanced solid tumors. Int J Cancer. (04/2019). doi:

10.1002/ijc.32317. Epub ahead of print. [PMID: 30958892]

426. Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ,

Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F,

Kabbarah O. Impact of Consensus Molecular Subtype on Survival in Patients With

Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). J Clin

Oncol. (05/2019). JCO1802258. doi: 10.1200/JCO.18.02258. [Epub ahead of print].

[PMID: 31042420]

427. Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg

RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ,

Kabbarah O. Mutational Analysis of Patients With Colorectal Cancer in

CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor

Mutational Burden for Patient Outcome. J Clin Oncol. (05/2019). 37(14):1217-1227.

[PMID: 30865548]

428. Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, Qu C,

Melas M, Van Den Berg DJ, Wang H, Tring S, Plummer SJ, Albanes D, Alonso MH,

Amos CI, Anton K, Aragaki AK, Arndt V, Barry EL, Berndt SI, Bezieau S, Bien S,

Bloomer A, Boehm J, Boutron-Ruault MC, Brenner H, Brezina S, Buchanan DD,

Butterbach K, Caan BJ, Campbell PT, Carlson CS, Castelao JE, Chan AT, Chang-

Claude J, Chanock SJ, Cheng I, Cheng YW, Chin LS, Church JM, Church T, Coetzee

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_29917119&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=p_8qbTb4V7npt8hu-LZrUnlGJ4XPJsN7WSbM7OcoIls&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_29917119&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=p_8qbTb4V7npt8hu-LZrUnlGJ4XPJsN7WSbM7OcoIls&e=

https://www.ncbi.nlm.nih.gov/pubmed/31361848


https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30018131&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=1-fCqkGOZTc2VMNKuiE4hVatMEc0Eg4afhKrj-epCNk&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30018131&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=1-fCqkGOZTc2VMNKuiE4hVatMEc0Eg4afhKrj-epCNk&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30856283&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=MhaeSHxS5q3dhOkDIuHWQQGdis3gHz08uhZV83dk5mY&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30856283&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=MhaeSHxS5q3dhOkDIuHWQQGdis3gHz08uhZV83dk5mY&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30852420&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=UTgaK9Chha3cdC218XYY3sfV3CUvdvnAt2vu9BwjbUc&e=




https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30958892&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=kssKekuPn0UAarI2TYEX6PR2opjXSFMlkfajdaysN-0&e=



https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31042420&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=3C0m0JtsOISRv1QwVNXcRmiPEN0ndR82EHpKxOjM2pc&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31042420&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=3C0m0JtsOISRv1QwVNXcRmiPEN0ndR82EHpKxOjM2pc&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30865548&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=jjFgZqlkPB86kNRICejWm-e5pb6BCGXgpmCbG3fn-oQ&e=





GA, Cotterchio M, Cruz Correa M, Curtis KR, Duggan D, Easton DF, English D,

Feskens EJM, Fischer R, FitzGerald LM, Fortini BK, Fritsche LG, Fuchs CS, Gago-

Dominguez M, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Giovannucci EL,

Gogarten SM, Gonzalez-Villalpando C, Gonzalez-Villalpando EM, Grady WM,

Greenson JK, Gsur A, Gunter M, Haiman CA, Hampe J, Harlid S, Harju JF, Hayes RB,

Hofer P, Hoffmeister M, Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S,

Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ.

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy

of bevacizumab in metastatic colorectal cancer patients. Int J Cancer. (05/2019).

144(10):2567-2577. [PMID: 30411783]

429. Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo

JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, Shields

AF, Marshall JL, Baba H, Korn WM, Lenz HJ. Molecular Profiling of Appendiceal

Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.

Clin Cancer Res. (05/2019). 25(10):3096-3103. [PMID: 30692096]

430. Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, Bosanac I, Choong N,

Scappaticci F, Mancao C, Lenz HJ. MAVERICC, a Randomized, Biomarker-stratified,

Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-

line Chemotherapy in Metastatic Colorectal Cancer. Clin Cancer Res. (05/2019).

25(10):2988-2995. [PMID: 30224341]

431. Tilburt J, Yost KJ, Lenz HJ, Zúñiga ML, O'Byrne T, Branda ME, Leppin AL, Kimball

B, Fernandez C, Jatoi A, Barwise A, Kumbamu A, Montori V, Koenig BA, Geller G,

Larson S, Roter DL. A Multicenter Comparison of Complementary and Alternative

Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-

Centeredness, and Practice Context. Oncologist. (05/2019). pii: theoncologist.2019-

0093. doi: 10.1634/theoncologist.2019-0093. Epub ahead of print. [PMID: 31101701]

432. Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A,

Shangguan T, Zhao H, El-Rayes B. Safety of Nivolumab plus Low-Dose Ipilimumab in

Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient

Metastatic Colorectal Cancer. Oncologist. (05/2019). pii: theoncologist.2019-0129. doi:

10.1634/theoncologist.2019-0129. Epub ahead of print. [PMID: 31147488]

433. Warsame R, Kennedy CC, Kumbamu A, Branda M, Fernandez C, Kimball B, Leppin

AL, O'Byrne T, Jatoi A, Lenz HJ, Tilburt JC. Conversations About Financial Issues in

Routine Oncology Practices: A Multicenter Study. J Oncol Pract. (06/2019).

JOP1800618. doi: 10.1200/JOP.18.00618. Epub ahead of print. [PMID: 31162996]

434. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ,

Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K,

Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib

dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a

randomised, multicentre, open-label, phase 2 study. Lancet Oncol. (06/2019). pii:

S1470-2045(19)30272-4. doi: 10.1016/S1470-2045(19)30272-4. Epub ahead of print.

[PMID: 31262657]

435. Battaglin F, Puccini A, Ahcene Djaballah S, Lenz HJ. The impact of panitumumab

treatment on survival and quality of life in patients with RAS wild-type metastatic

colorectal cancer. Cancer Manag Res. (06/2019). 11:5911-5924. doi:

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30411783&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=S1ObwMpNwqvJ4h7T6P9m-G_0oqhT1eTwZ7nofipBfWM&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30411783&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=S1ObwMpNwqvJ4h7T6P9m-G_0oqhT1eTwZ7nofipBfWM&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30692096&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=pLpkmiD3nW10vyzdA9vSS_WMlN4_vTlU9tFIDQ0HK1E&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30692096&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=pLpkmiD3nW10vyzdA9vSS_WMlN4_vTlU9tFIDQ0HK1E&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30224341&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=BoJUTomx6X1Q9quMWx-0YXUX8RQi55cQNnxejshupKc&e=



https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31101701&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=ZCqDPMj4uq27QYeNx_Tn9J59I3G7a7M1kljOL4A3pPU&e=



https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31147488&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=YPniUjk-2prCXcxYbufXjhZTFnFTSsSoOd8IukPa1Lc&e=



https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31162996&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=8tT324dj_JQktm71yuU3T8Kb_6UXJkxWFKwl3VTtx9I&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31162996&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=8tT324dj_JQktm71yuU3T8Kb_6UXJkxWFKwl3VTtx9I&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31262657&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=Vm0veyuybws6fnRp0go_IT4lM_L1GVJgovewNlywuww&e=








10.2147/CMAR.S186042. eCollection 2019. [PMID: 31388315][PMCID:

PMC6607986]

436. Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Scott Shaffer J, Suarez CJ, Berghoff AS,

Cremolini C, Falcone A, Loupakis F, Birner P, Preusser M, Lenz HJ, Curtis C.

Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet.

(07/2019). 51(7):1113-1122. [PMID: 31209394]

437. El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J,

Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. The current

state of molecular testing in the treatment of patients with solid tumors, 2019. CA

Cancer J Clin. (07/2019). 69(4):305-343. [PMID: 31116423]

438. Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS,

Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J. Phase II

Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus

FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist.

(07/2019). 24(7):921-932. [PMID: 30552157]

439. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK,

Lin MH, Toriguchi K, Antonia RJ, Warren RS. High thymidylate synthase gene

expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS

One. (07/2019). 14(7):e0219469. doi: 10.1371/journal.pone.0219469. eCollection 2019.

[PMID: 3129133].

440. Barzi A, Hershman DL, Till C, Barlow WE, Ramsey S, Lenz HJ, Hochster HS, Unger

JM. Osteoporosis in colorectal cancer survivors: analysis of the linkage between

SWOG trial enrollees and Medicare claims. Arch Osteoporos. (07/2019). 14(1):83. doi:

10.1007/s11657-019-0629-7. [PMID: 31352608]

441. Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg

RJ, Berlin J, Messersmith WA, Cohen SJ. A phase 1b dose escalation study of Wnt

pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in

patients with previously untreated metastatic pancreatic cancer. Invest New Drugs.

(07/2019). doi: 10.1007/s10637-019-00824-1. Epub ahead of print. [PMID: 31338636]

442. Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, Betge J, Härtel

N, Kather JN, Weis CA, Gaiser T, Marx A, Weiss C, Hofheinz R, Miller IS, Loupakis

F, Lenz HJ, Byrne AT, Ebert MP. Aryl hydrocarbon receptor nuclear translocator-like

(ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via

regulation of vascular endothelial growth factor A. EBioMedicine. (07/2019). 45:139-

154. doi: 10.1016/j.ebiom.2019.07.004. Epub 2019 Jul 9. [PMID: 31300350]

443. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK,

Lin MH, Toriguchi K, Antonia RJ, Warren RS. High thymidylate synthase gene

expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS

One. (07/2019). 14(7):e0219469. doi: 10.1371/journal.pone.0219469. eCollection 2019.

[PMID: 31291332]

444. Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz

R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF,

Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N,

Doroshow JH, Chen AP.A Phase I Pharmacokinetic Study of Belinostat in Patients with

Advanced Cancers and Varying Degrees of Liver Dysfunction. Br J Clin Pharmacol.

(07/2019). doi: 10.1111/bcp.14054. Epub ahead of print. [PMID: 31271459]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607986/

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31209394&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=j9-apAnZlh1V6b1fs-bPyqMh1U4zhhoNY_xMyRxd1GE&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31116423&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=4enmyM8nzB3-_bwQsgRDQBtXC3N8MYD4ivLDdUCjyQ8&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31116423&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=4enmyM8nzB3-_bwQsgRDQBtXC3N8MYD4ivLDdUCjyQ8&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_30552157&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=f8d_Sk0n1TXi7yVMzlo9zS_DoOXCdMqBuj17jqZnnPw&e=



https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31291332&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=iyekpXYkmCpeY197fI5JECg4OLtGpnK9-2QVtSZabWM&e=

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_31291332&d=DwMGaQ&c=clK7kQUTWtAVEOVIgvi0NU5BOUHhpN0H8p7CSfnc_gI&r=NVNkAX3QM37MRZKgqDiL5g&m=dnKNDGJn5I-BrNiihHzUANMMmSQMiMJxbcLs_c8n31Y&s=iyekpXYkmCpeY197fI5JECg4OLtGpnK9-2QVtSZabWM&e=















445. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F,

O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K,

Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA.

Associations of Physical Activity With Survival and Progression in Metastatic

Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG

80405. J Clin Oncol. (08/2019). JCO1901019. doi: 10.1200/JCO.19.01019. [Epub

ahead of print]. [PMID: 31408415]

446. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ,

Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K,

Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib

dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a

randomised, multicentre, open-label, phase 2 study. Lancet Oncol. (08/2019).

20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28. [PMID:

31262657]

447. Innocenti F, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM,

Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ,

Kabbarah O. Reply to S. Sorscher. J Clin Oncol. (09/2019). 37(25):2291-2293. [PMID:

31268798]

Non Peer Reviewed (Invited papers, reviews and editorials)

1. Lenz H-J, Raghavan D, Doroshow J, Gandara DR: Phase I study of bryostatin-1 in

combination with cisplatin in treating patients with metastatic or unresectable solid

tumors including non-small-cell lung cancer. Clin Lung Cancer 1:151–152, 1999.

2. Lenz H-J, Beart RW: Molecular staging of cancer-commentary. Cancer Case

Presentations: The Tumor Board. Publication by the Commission on Cancer of the

American College of Surgeons. 60–72, 2000.

3. Iqbal S, Lenz H-J: Current data with irinotecan and cetuximab in colorectal cancer.

Advances in Colon Cancer 5:6–8, 2001.

4. Iqbal S, Lenz H-J: Determinants of prognosis and response to therapy in colorectal

cancer. Curr Oncol Rep 3:102–108, 2001.

5. Lenz H-J: Gene markers and prediction of response to oxaliplatin and fluorouracil in

current management of gastrointestinal malignancies. Selected Presentations from

ASCO, 2002.

6. Stoehlmacher J, Lenz H-J: The predictive value of thymidylate synthase (TS) and

excision repair cross-complementing (ERCC) gene in first- and second-line

chemotherapy of patients with colorectal cancer. Amer J Oncol Rev 1:29–32, 2002.

7. Iqbal S, Lenz HJ: Targeted therapy and pharmacogenomic programs. Cancer

97(8):2076–2082, 2003.

8. Lenz H-J: Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev

29(1):41–48, 2003.

9. Iqbal S, Lenz H-J: Molecular predictors of treatment and outcome in colorectal cancer.

Curr Gastroenterol Rep 5(5):399–405, 2003.

10. Doroshow JH, Synold TW, Gandara DR, Mani S, Remick SC, Mulkerin D, Hamilton

A, Sharma S, Ramanathan RK, Lenz H-J, Graham M, Longmate J, Takimoto CH, Ivy

P: Pharmacology of Oxaliplatin in Solid Tumor Patients with Hepatic Dysfunction: A










Preliminary Report of the National Cancer Institute Organ Dysfunction Working

Group. Semin Oncol 30(4):14–19, 2003.

11. Lenz H-J: Pharmacogenomics in Colorectal Cancer. Semin Oncol 30(4):47–53, 2003.

12. Doroshow JH, Synold TW, Gandara D, Mani S, Remick S, Mulkerin D, Hamilton A,

Sharma S, Ramanathan R, Lenz H-J, Graham M, Longmate J, Takimoto C, Ivy P:

Pharmacology of Oxaliplatin in Solid Tumor Patients with Hepatic Dysfunction: A

Preliminary Report of the National Cancer Institute Organ Dysfunction Working

Group. Semin Oncol 30(4):14–19, 2003.

13. Park DJ, Stoehlmacher J, Lenz H-J: Tailoring chemotherapy in advanced colorectal

cancer. Curr Opin Pharmacol 3(4):378–385, 2003.

14. Lenz, H-J: (Editorial) The use and development of germline polymorphisms in clinical

oncology. J Clin Oncol 22(13): 2519–2521, 2004.

15. Lenz H-J: (Editorial) Molecular markers in gastrointestinal cancer: targeted therapy

and tailored chemotherapy. Onkologie 27(1):12–14, 2004.

16. Lenz H-J: Single-agent Cetuximab active in refractory colon cancer. Oncology News

International 13:10, 2004.

17. Lenz H-J: Biomarkers and Pharmacogenomics. Amer J Onc Rev 3(10) 7:44-55, 2004.

18. Park DJ, Lenz H-J. The role of proteasome inhibitors in solid tumors. Annals of

Medicine. 36(4):296-303, 2004.

19. Iqbal S, Lenz H-J. Angiogenesis inhibitors in the treatment of colorectal cancer.

(Review) Sem Oncol 31(6 Suppl 17):10-16, 2004.

20. Iqbal S, Stoehlmacher J, Lenz HJ. Tailored Chemotherapy for Colorectal Cancer: A

New Approach to Therapy. Cancer Invest 22(5):762-773, 2004. [PMID: 15581057;

PMC Journal – In Process.]

21. Lenz H-J, Lynch PM. Epidemiology, pharmacogenomics, and hereditary cancer of the

colon and rectum. Curr Colorectal Cancer Rep 1(2), Nov 2005.

22. Iqbal S, Lenz H-J. Individualized Chemotherapy Based on Genetic and Genomic

Profiling. Curr Colorectal Cancer Rep 1(2): 91-102, Nov 2005.

23. El-Khoueiry A, Lenz H-J. Should continous infusion 5-flourouracil (5-FU) become the

standard of care in the USA as it is in Europe? Cancer Investigation 24:1-6, Feb 2006.

24. El-Khoueiry A, Lenz H-J. The role of pharmacogenetics in making treatment decisions

in colorectal cancer. Curr Colorectal Cancer Rep 2(3) July 2006.

25. Zhang W, Gordon M, Lenz HJ. Novel approaches to treatment of advanced colorectal

cancer with anti-EGFR monoclonal antibodies. Annals of Medicine 38(8); 545-551,

2006.

26. Lenz HJ. Treatment of colorectal cancer since the introduction of irinotecan. A

Supplement to Community Oncology, pg 3-7. May 2007.

27. Lenz HJ. Mangement and Preparedeness for Infusion and Hypersensitivity Reactions.

The Oncologist 12:601-609, 2007.

28. Manegold P, Lenz HJ. Molecular Markers. New Treatment Strategies for Metastatic

Colorectal Cancer.85-108, 2008.

29. Lenz H-J, Johnston J. Accomplishments in 2007 in Biologic Markers for

Gastrointestinal Cancers. Gastrointestinal Cancer Research 2(suppl 1):S51-S56,

May/June 2008

30. Lenz HJ. Colon Cancer Stem Cells: A New Target In the War Against Cancer.

Gastrointestinal Cancer Research. 203-204, 2(4) July/August 2008



31. Lurje G, Pohl A, Manegold P, Lenz H-J. Individualization of Therapy Based on

Clinical and Molecular Parameters. Curr Colorectal Cancer Rep 4:193-200, October

2008.

32. Lenz H-J. First-line combination treatment of colorectal cancer with hepatic

metastases: Choosing a targeted agent. Cancer treatment Reviews. 34 Suppl 2:S3-7,

2008.

33. Lenz H-J. Basics of Signal Transduction and Targeting EGFR Pathways. 6th Latin

American Workshop in Molecular Targeted Therapy of Cancer. pg 12-13, Buenos

Aires, Argentina. Nov 21, 2008.

34. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncologist. 77(6):400-10, Feb

2009.

35. Pohl A, Lurje G, Manegold PC, Lenz HJ. Pharmacogenomics and –genetics in

colorectal cancer. Advanced Drug Delivery Reviews. 61(5):375-380, May 2009.

36. Kohne C-H, Lenz H-J. Chemotherapy with Targeted Agents for Treatment of

Metastatic Colorectal Cancer. The Oncologist, 14(5):478-488, May 2009.

37. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz H-J, Ladner RD. DNA

microarray profiling of genes differentially regulated by the histone deacetylase

inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Medical Genomics,

30;2:67, Nov 2009.

38. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer.

Cancer Treat Rev. 36:550-556, Apr 2010, [PM ID: 20363564]. 39. Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic

colorectal cancer. Cancer J, 16(3);262-72, May 2010 [PM ID: 20526105].

40. Winder T, Lenz HJ. Vascular endothelial growth factor and epidermal growth factor

signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology,

138(6):2163-76, Jun 2010 [PM ID: 20420953].

41. Winder T, Lenz HJ. Mucinous adenocarcinomas with intra-abdominal dissemination: a

review of current therapy. Oncologist, 15(8):836-44, July 2010 [PMID: 20656916].

42. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R,

Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H,

Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A.

Prognostic and predictive biomarkers in resected colon cancer: current status and future

perspectives for integrating gemonics into biomarker discovery. Oncologist, 15(4):390-

404, 2010 [PM ID: 20350999].

43. Allen WL, Jithesh PV, Oliver GR, Proutski I, Longley DB, Lenz H-J, Proutski V,

Harkin PD, Johnston PG. The Colorectal cancer disease-specific transcriptome

facilitates the discovery of more biologically and clinically relevant information. BMC

Cancer, 10(1):687, Dec 2010 [PM ID: 21172019].

44. Lurje G, Lenz HJ. Molecular response prediction in multimodality treatment for

adenocarcinoma of the esophagus and esophagogastric juction. Recent Results Cancer

Research. 182:179-91, 2010 [PM ID: 20676881].

45. Stintzing S, Lenz HJ. Targeted therapies: Cetuximab dosing by rash-is the scaling of

EVEREST meaningful? Nat Rev Clin Oncol, 14;9(10);554-6. doi:10.1038/nrclinonc,

Aug 2012, [PM ID: 22889974].

46. Lenz H-J: (Editorial) Primary Tumor Sidedness as Prognostic and Predictive

Biomarker in Metastatic Colorectal Cancer: Further Validation of a Potentially



Practice-Changing Variable. JAMA Oncol, PMID: 27722749 DOI:

10.1001/jamaoncol.2016.3777 Oct 10, 2016.

Abstracts

1. Lenz H-J, Fischer JT, Steinke B, Waller HD: Chronic thrombotic-thrombocytopenic

purpura: report of a case and review of the literature. Blut 53:182, 1986.

2. Lenz H-J, Steinke B, Waller HD: Recognition of relapse of patients with malignant

lymphoma: efficiency of different methods. Blut 53:226, 1986.

3. Lenz H-J, Roos UM, Steinke B, Waller HD: Central nervous involvement in breast

cancer: analysis of possible risk factors. Blut 57:245, 1988.

4. Lenz H-J, Schuler U, Hicking W, Dahmer W, Robinson C, Ehninger G: Phase I study

of clebopride IV, a new benzamide derivate. Blut 57:238, 1988.

5. Lenz H-J, Steinke B, Roos UM, Beidritzky M, Waller HD: Central nervous

involvement in breast cancer. J Cancer Res Clin Oncol 114:28, 1988.

6. Lenz H-J, Steinke B, Roos UM, Beidritzky M, Waller HD: Cerebrale manifestationen

bei patientinnen mit mammakarzinom. Klinische Wochenschrift 66(Suppl XIII):269,

1988.

7. Lenz H-J, Brunner T, Schlag H, Pawelec G, Ehninger G: Phase I study of continuous

IV n-IL-2. Blut 61:p. 165, A380, 1990.

8. Lenz H-J, Reichmann U, Waller HD: Autoimmune hemolytic anaemia in a patient

with polycythemia vera: first description. Blut 61:p. 196, A501, 1990.

9. Horikoshi T, Danenberg KD, Volkenandt M, Lenz H-J, Simoneau A, Jones PA,

Bertino JR, Danenberg PV: Characterization of p53, thymidine kinase, and

dihydrofolate reductase gene mutations by analysis of RNA conformational

polymorphisms. Proc AACR 33:2392, 1992.

10. Lenz H-J, Horikoshi R, Danenberg KS, Gustavsson B, Leichman LP, Danenberg PV:

A carcinoid tumor lacking thymidylate synthase (TS) activity expresses a truncated TS

mRNA. Proc AACR 33:A88, 1992.

11. Leichman LP, Danenberg PV, Leichman CG, Lenz H-J, Danenberg KD, Baranda J,

Kornmann M: Intratumoral thymidylate synthase expression and response to 5-

fluorouracil (5FU)-leucovorin (LV) in patients with colorectal cancer. Proc AACR

34:A2103, 1993.

12. Lenz H-J, Danenberg KD, Manno DJ, Danenberg PV: Inhibition of eukaryotic mRNA

splicing by 5-fluorouracil (FU)-substituted snRNA. Proc AACR 34:A2085, 1993.

13. Lenz H-J, Leichman CG, Danenberg P, Silberman H, Horikoshi T, Kiyabu M,

Danenberg K, Spears CP, Laine L, Fuerst M, Leichman LP: Thymidylate synthase gene

expression predicts response of primary gastric cancer to 5-fluorouracil (5FU)-

leucovorin-cisplatin (DDP). Proc ASCO 12:A585, 1993.

14. Lenz H-J, Schnieders B, Danenberg KD, Goker E, Shane B, Bertino JR, Danenberg

PV: A polymerase chain reaction assay for folylpolyglutamate synthetase (FPGS) gene

expression: marked variation in human leukemia blast samples. Proc AACR 34:A3004,

1993.

15. Schmittgen TD, Danenberg KD, Horikoshi T, Lenz H-J, Danenberg PV: Effect of 5-

fluoro-and 5-bromouracil-substituted mRNA on the translation of human thymidylate

synthase. Proc AACR 34:A2478, 1993.



16. Schmittgen TD, Ju JF, Danenberg KD, Lenz H-J, Danenberg PV: Cisplatin inhibits

pre-mRNA splicing in a mammalian nuclear extract. Proc AACR 34:A2400, 1993.

17. Johnston PG, Lenz H-J, Danenberg KD, Leichman LP, Leichman CG, Allegra CJ,

Danenberg PV: Thymidylate synthase protein and gene expression predicts for

response to 5-fluorouracil, leucovorin chemotherapy in patients with colorectal and

gastric cancer. Proc ASCO 13:A569, 1994.

18. Leichman CG, Lenz H-J, Leichman LP, Baranda J, Danenberg KD, Groshen S,

Boswell W, Silberman J, Garcia Y, Danenberg PV: Quantitation of intratumoral

thymidylate synthase expression predicts for disseminated colorectal cancer resistance

to protracted infusion 5-fluorouracil and weekly leucovorin. Proc ASCO 13:A592,

1994.

19. Lenz H-J, Danenberg KD, Schnieders B, Bertino JR, Danenberg PV: Improved RNA-

SSCP analysis of p53 mutations. Proc AACR 35:A3600, 1994.

20. Lenz H-J, Danenberg KD, Uziely B, Muggia FM, Danenberg PV: Co-regulation of

thymidylate synthase (TS) and MDR in patients with breast cancer? Proc ASCO

13:A298, 1994.

21. Manno DJ, Lenz H-J, Danenberg KD, Danenberg PV: Splicing behavior of 5-

fluorouracil (FU)-substituted precursor-mRNA. Proc AACR 35:A2675, 1994.

22. Uziely B, Delaflor-Weiss E, Lenz H-J, Groshen S, Jeffers S, Watkins K, Danenberg

KD, Russell C, Leichman CG, Muggia FM, Press M: Paclitaxel (Taxol) in refractory

breast cancer: response correlates with low levels of MDR1 gene expression. Proc

ASCO 13:A104, 1994.

23. Banerjee D, Lenz H-J, Schnieders B, Kheradpour A, Manno DJ, Danenberg KD,

Danenberg PV, Bertino JR: Transfection of wild type but not mutant p53 induces early

monocytic differentiation in HL60 cells. Proc AACR 36:A295, 1995.

24. Formenti SC, Uziely B, Dunnington G, Spicer DV, Krecker E, Lenz H-J, Groshen S,

Watkins K, Danenberg KD, Danenberg P, Leichman CG, Muggia FM: Continuous

infusion (CI) 5-fluorouracil (FU) with radiation in locally advanced breast cancer:

clinico-pathological and biological correlates. Proc ASCO 14:A358, 1995.

25. Lenz H-J, Danenberg KD, Leichman LP, Leichman CG, Danenberg PV: p53 Status

predicts for response to 5-fluorouracil/leucovorin in patients with advanced colon

cancer. Proc AACR 36:A3332, 1995.

26. Lenz H-J, Ju J-F, Danenberg KD, Banerjee D, Bertino JR, Danenberg PV: Effect of

p53 activity on the cytotoxicity of 5-fluoro-2'-deoxyuridine and its inhibition of

thymidylate synthase. Proc AACR 36:A121, 1995.

27. Lenz H-J, Ju J-F, Danenberg KD, Leichman LP, Leichman CG, Haag C, Danenberg

PV: TS levels and p53 function predicts for response to 5-fluorouracil/leucovorin in

patients with advanced colon cancer. Proc ASCO 14:A487, 1995.

28. Banerjee D, Lenz H-J, Hochhauser D, Danenberg K, Danenberg PV, Bertino JR: A

role of p53 in the G2/M checkpoint in HL60 cells following radiation damage. Proc

AACR 37:A4167, 1996.

29. Formenti SC, Lenz H-J, Dunnington G, Johnston P, Keren-Rosenberg S, Spicer DV,

Danenberg K, Danenberg P: Initial p53 status as potential predictor for pathological

response to the combination of 5FU and radiotherapy in locally advanced breast cancer.

Proc ASCO 15:174, 1996.



30. Hayashi K, Danenberg KD, Metzger R, Solonga D, Lenz H-J, Leichman CG,

Danenberg PV, Leichman LP: Differential thymidylate synthase (TS) gene expression

in squamous cell carcinoma and adenocarcinoma of the esophagus. Proc ASCO 15:499,

1996.

31. Hayashi K, Metzger R, Danenberg KD, Lenz H-J, Leichman LP, Danenberg PV:

Quantitative and qualitative analysis of p16 gene expression in esophageal tumors by

RT-PCR. Proc AACR 37:A43, 1996.

32. Ju J-F, Lenz H-J, Danenberg KD, Schonthal A, Banerjee D, Bertino JR, Danenberg

PV: The cell-cycle arresting agent mimosine is selectively cytotoxic to cells lacking

functional p53. Proc AACR 37:A14, 1996.

33. Lenz H-J, Danenberg KD, Danenberg PV, Johnston P, Florentine B, Leichman CG,

Hayashi K, Metzger R, Leichman LP: p53 Status and thymidylate synthase (TS)

expression are associated and predict for recurrence in patients with stage II colon

cancer (CC). Proc ASCO 15:A501, 1996.

34. Lenz H-J, Danenberg KD, Leichman CG, Hayashi K, Metzger R, Salonga D, Banerjee

D, Bertino JR, Leichman LP, Danenberg PV: p53 Point mutation thymidylate synthase

(TS) gene expression and clinical response in gastrointestinal cancer. Proc AACR

37:A1351, 1996.

35. Lenz H-J, Danenberg KD, Leichman CG, Hayashi K, Metzger R, Salonga D, Kortes

V, Banerjee D, Bertino JR, Groshen S, Leichman LP, Danenberg PV: p53 Status and

thymidylate synthase levels are predictors of chemotherapy efficacy in patients with

advanced colorectal cancer. Proc ASCO 15:A504, 1996.

36. Metzger R, Danenberg KD Danenberg PV, Hayashi K, Lenz H-J, Groshen S,

Leichman CG, Baranda J, Crookes P, Laine L, Leichman LP: Excision repair cross

complementing (ERCC)-1 gene in primary gastric cancer: A determinant of response to

cisplatin-based chemotherapy. Proc ASCO 15:A505, 1996.

37. Metzger R, Danenberg KD, Hayashi K, Lenz H-J, Groshen S, Leichman CG, Baranda

J, Crookes P, Laine L, Danenberg PV, Leichman LP: ERCC1 expression correlates

with response of primary gastric cancer to cisplatin-based chemotherapy. Proc AACR

37:A1350, 1996.

38. Danenberg PV, Metzger R, Hayashi K, Salonga D, Danenberg KD, Kelsen D, Schwartz

G, Fink U, Sendler A, Lenz H-J, Leichman LP: Lower TS expression in esophageal

squamous cell carcinoma (ESCC) than in esophageal adenocarcinoma (EAC) is

associated with different response rates to 5-fluorouracil-based protocols. Proc ASCO

16:A919, 1997.

39. Danenberg KD, Metzger R, Salonga D, Lenz H-J, Leichman LP, Leichman CG,

Baranda J, Schwartz EL, Wadler D, Danenberg PV: Thymidine phosphorylase

expression in colorectal tumors together with that of thymidylate synthase predict

tumor responses to 5-fluorouracil. Proc AACR 38:A4127, 1997.

40. Elwell A, Xiong Y-P, Chang M, Leichman CG, Johnston OG, Groshen S, Leichman

LP, Beart RW, Lenz H-J: p53, p21 and thymidylate synthase protein expression:

associations with recurrence in stage II and III rectal cancer. Proc ASCO 16:A915,

1997.

41. Farrugia DC, Danenberg KD, Cunningham D, Metzger R, Danenberg PV, Lenz H-J,

Aherne GW, MacVicar D, McCarthy K, Norman AR, Jackman AL: Predictors of



response and toxicity in patients with advanced colorectal cancer (CRC) treated with

tomudex. Proc ASCO 16:952, 1997.

42. Formenti SC, Dunnington G, Lenz H-J, Russell CR, Silberman H, Spicer DV, Groshen

S, Watkins K, Muggia FM, Press M, Danenberg PV: Original p53 status predicts for

pathological response to 5-fluorouracil and radiation in locally advanced breast cancer.

J Clin Oncol 16:A590, 1997.

43. Ju J-F, Kane SE, Lenz H-J, Danenberg KD, Danenberg PV: Sensitization of tumors to

fluoropyrimidines with antisense against thymidylate synthase. Proc AACR 38:A3196,

1997.

44. Lenz H-J, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S,

Danenberg PV, Leichman LP: P53 and TS expression in untreated stage II colon

cancer: association with recurrence, survival, and tumor site. Proc AACR 38:A4123,

1997.

45. Lenz H-J, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S,

Danenberg PV, Leichman LP: p53 and TS expression in untreated stage II colon

cancer: association with recurrence, survival and tumor site. Proc ASCO 16:A1997,

1997.

46. Xiong Y-P, Danenberg KD, Metzger R, Salonga D, Groshen S, Danenberg PV, Davies

MM, Allen-Merch TG, Lenz H-J: Thymidylate synthase (TS) mRNA levels predict for

survival and response to hepatic artery infusion (HAI) with FUDR in patients with

colorectal liver metastases. Proc ASCO 16:A918, 1997.

47. Lenz H-J, Xiong Y-P, Udalve A, Chang M, Leichman LP, Beart RW, Anton P, Kam

L: Thymidylate synthase (TS) and ERCC1 MRNA expression in patients with

inflammatory bowel disease (IBD). Proc ASCO 17:562a, 1998.

48. Perry S, McGregor JR, Morrel F, Lenz H-J: Transfection with wild-type p53 prevents

nitric oxide-induced cell cycle arrest and apoptosis of HL-60 leukemia cells. Nitric

Oxide 2:121, 1998.

49. Shibata S, Doroshow JH, Lin S, Chu D, Pezner R, Chow W, Leong L, Morgan R,

Margolin K, Raschko J, Somlo G, Tetef M, Yen Y, Wagman L, Longmate J, Toth L,

Danenberg KD, Danenberg PV, Lenz H-J, Carroll M: RT-PCR analysis of thymidylate

synthetase (TS), ribonucleotide reductase (RR), and ERCC-1 expression in patients

(PTS) with locally advanced gastrointestinal (GI) malignancies treated with surgery,

intraoperative radiation therapy (IORT) with concurrent 5-FU and external beam

radiation (EBRT) with prolonged 5-FU infusion. Proc ASCO 17:562a, 1998.

50. Xiong Y-P, Udalve A, Chang M, Leichman LP, Leichman CG, Beart RW, Kam L,

Anton P, Lenz H-J: Thymidylate synthase (TS), COX-1 and COX-2 gene expression

levels in active and inactive mucosae in patients with imflammatory bowel disease

(IBD). Proc AACR 39:488, 1998.

51. Garcia AA, Leichman L, Baranda J, Lenz H-J, Angeles A, DeJong L, Leichman CG:

Phase II study of trimetrexate (neutrexin), 5-fluorouracil, and leucovorin (NFL) in

Advanced Pancreatic. Proc ASCO 18:971, 1999.

52. Lenz H-J, Habashy M, Xiong Y-P, Lynch R, Cardonna S, Pullarkat S, Tsao-Wei D,

Ladner R: dUTPase expression in GI cancer: associations with response and survival.

Proc ASCO 18:970, 1999.

53. Reddy GR, Gandara DR, Edelman MJ, Doroshow JH, Lau D, Lenz H-J, Israel V,

Albain K, Jaslowski A, Lauder I, Conklin T, Maryon T: Gemcitabine (GEM) in



platinum (PLAT) treated non-smallcell lung cancer (NSCLC). Proc ASCO 18:2007,

1999.

54. Synold TW, Newman E, Lenz H-J, Gandara DR, Chow W, Leong L, Morgan Jr R,

Raschko J, Shibata S, Leichman CG, Carroll M, Longmate J, Doroshow JH:

Prospective evaluation of docetaxel (D) pharmacokinetics (PK) and toxicity in patients

with tumor-related hepatic dysfunction (HD). Proc ASCO 18:643, 1999.

55. Synold TW, Spicer DV, Muggia F, Tetef M, Gandara DR, Groshen S, Lenz H-J,

Newman EM, Johnson K, Doroshow JH: The pharmacokinetics of paclitaxel (P) are

unaffected by the multidrug resistance (MDR) reversing agent SDZ PSC 833 (PSC) in

patients (PTS) with metastatic breast cancer (BC) despite an improvement in overall

response rate. Proc AACR 40:344, 1999.

56. Tetef ML, Doroshow JH, Synold T, Leichman CG, Lenz H-J, Gandara DR, Longmate

J, Maryon T, Ter Veer A, Groshen S, Carrol M, Chow W, Leong L, Margolin K,

Morgan R, Raschko J, Shibata S, Somlo G, Yen Y: Phase I study of 96 hour (hr)

continuous infusion (CI) of dexrazoxane (DEX) followed by 72 hour CI of topotecan in

patients (PTS) with advanced malignancies. Proc ASCO 18:884, 1999.

57. Xiong Y-P, Bochner B, Lieskovsky G, Johnston P, Groshen S, Lenz H-J: p53 and

thymidylate synthase (TS): potential prognostic indicators of survival in patients with

localized prostate cancer. Proc ASCO 18:1216, 1999.

58. Doroshow JH, Tetef M, Margolin K, Somlo G, Frankel P, Longmate J, Synold T,

Gandara DR, Lenz H-J, Albain KS: Significant activity of gemcitabine (GEM) and

cisplatin (DDP) in both heavily (H) and minimally (M)-pretreated metastatic breast

cancer (MBC) patients (PTS): a California Cancer Consortium/Loyola University

Chicago trial. Proc ASCO 19:609H, 2000.

59. Ladner RD, Stoehlmacher J, Lynch FJ, Wei D, Xiong Y-P, Sherrod A, Caradonna SJ,

Lenz H-J: DUTPase isoform expression in normal and neoplastic tissues: association

with survival and response to 5-FU in colon and gastric cancer. Proc AACR 41:4056,

2000.

60. Lara Jr P, Gandara DR, Lau DH, Edelman MJ, Mack PC, Gumerlock PH, Lenz H-J,

Israel V, Raschko J, Longmate J, Frankel P, Doroshow JH: Activity of high dose

toremifene (TOR) plus cisplatin (CDDP) in advanced non-small-cell lung cancer

(NSCLC): a phase II California Cancer Consortium trial. Proc ASCO 19:1983, 2000.

61. Law L, Lara Jr PN, Reddy GP, Edelman MJ, Doroshow JH, Lau DH, Lenz H-J, Israel

V, Albain K, Longmate J, Frankel P, Gandara DR: Salvage gemcitabine (GEM) in

platinum-treated non-small-cell lung cancer (NSCLC): a phase II California Cancer

Consortium trial. Proc ASCO 19:2095, 2000.

62. Lenz H-J, Bupta M, Xiong Y-P, Synold T, Tsao-Wei D, Groshen S, Gandara DR,

Koda RT, Doroshow JH: Phase I study of bryostatin-1 and cisplatin (CDDP). Proc

ASCO 19:795, 2000.

63. Pullarkat ST, Ghaderi V, Ingles SA, Xiong Y-P, Chen P, Stoehlmacher J, Gupta M,

Tsao-Wei D, Groshen S, Lenz H-J: Human thymidylate synthase gene polymorphism

determines response to 5-FU chemotherapy. Proc ASCO 19:942, 2000.

64. Pullarkat ST, Xiong Y-P, Ingles SA, Sherrod A, Ghaderi V, Tsao-Wei D, Groshen S,

Lenz H-J: Human thymidylate synthase gene polymorphism determines intratumoral

thymidylate synthase mRNA level: implications for fluoropyrimidine chemotherapy.

Proc AACR 41:4583, 2000.



65. Xiong Y-P, Yen CF, Warren R, Stoehlmacher J, Pullarkat ST, Tsao-Wei D, Lenz H-J,

Zandi E: Elevated expressions of IkB kinases and thymidylate synthase in liver

metastasized colon carcinomas: a possible mechanism for drug resistance. Proc ASCO

19:2557, 2000.

66. Danenberg KD, Hollywood E, Shirota Y, Brabender J, Xiong Y-P, Park J, Baylor L,

Stoehlmacher J, Lew A, Danenberg PV, Lenz H-J, Delsen D, Saltz LB: Thymidylate

synthase gene expression levels in primary colorectal tumors correlate with those in

matched metastases. Proc ASCO 20:1722, 2001.

67. Gandara DR, Lara Jr PN, Lau DH, Raschko J, Lenz H-J, Doroshow JH: Tirapazamine

(TPZ) plus taxol/carboplatin (carbo): California Cancer Consortium phase I trial and

implications for SWOG 0003. Proc ASCO 20:1332, 2001.

68. Gray CR, Lara PN, Gandara DR, Kauderer C, Tichauer G, Lenz H-J, Doroshow JH,

Meyers FJ: HER-2/neu screening in hormone refractory prostate cancer (HRPC): a

California Cancer Consortium trial of trastuzumab and docetaxel. Proc ASCO 20:723,

2001.

69. Laptalo L, Lara Jr PN, Lay DH, Lauderer C, Tichauer G, Lenz H-J, Raschko J,

Doroshow JH, Gandara DR: HER-2/neu screening in advanced non-small-cell lung

cancer (NSCLC): a California Consortium trial of trastuzumab & docetaxel. Proc

ASCO 20:1338, 2001.

70. Park DJ, Stoehlmacher J, Zhang W, Groshen S, Lenz H-J: Human thymidylate

synthase gene polymorphism determines response to capecitabine chemotherapy in

advanced colorectal cancer. Proc ASCO 20:514, 2001.

71. Ramanathan R, Lenz H-J, Gococo K, Kardinal C: Safety profile of oxaliplatin (single

agent or with 5-FU) from the large North American compassionate use experience in

advanced colorectal cancer. Proc ASCO 20:551, 2001.

72. Shibata S, Chow W, Frankel R, Leong L, Lim D, Longmate JA, Margolin K,

McNamara M, Morgan R, Raschko J, Somlo G, Synold T, Tetef M, Twardowski P,

Yen Y, Doroshow J, Lenz H-J, Gandara DR: A phase I trial of oxaliplatin (OX) in

combination with gemcitabine (G): a California Cancer Consortium trial. Proc ASCO

20:381, 2001.

73. Shirota Y, Brabender J, Stoehlmacher J, Xiong Y-P, Danenberg KD, Danenberg PV,

Lenz H-J: ERCC1 and TS expression levels predict survival in patients with advanced

colorectal carcinoma under 5-FU/oxaliplatin treatment. Proc ASCO 20:513, 2001.

74. Stoehlmacher J, Brabender J, Shirota Y, Park DJ, Danenberg KD, Danenberg PV, Lenz

H-J: Association between mRNA expression level of epidermal growth factor receptor

(EGFR), immunohistochemistry (IHC), and response to the EGFR-inhibitor C225 in

advanced colorectal carcinoma. Proc ASCO 20:593, 2001.

75. Ajani JA, Shah MA, Bokemeyer C, Lenz H-J, Burris HA, Van Gutsem E, Usakewicz

J, Peeters O, Voi M, Lebwohl D, Safran H: Phase II study of the novel epothilone

BMS-247550 in patients (PTS) with metastatic gastric adenocarcinoma previously

treated with a taxane. Proc ASCO 21:619, 2002.

76. Blanke CD, Benson AB, Dragovich R, Lenz H-J, Haller D, Robles C, Buchbinder A:

A phase II trial of celecoxib (CX), irinotecan (I), 5-Fluorouracil (5FU), and leucovorin

(LCV) in patients (PTS) with unresectable or metastatic colorectal cancer (CRC). Proc

ASCO 21:505, 2002.



77. Galvin IV, Mack P, Lara PN, Lau DH, Lenz H-J, Doroshow JH, Gandara DR,

Gumerlock PH: Plasma levels of hypoxia-induced secreted proteins: potential markers

of response to a tirapazamine-containing regimen. Proc AACR 43:5400, 2002.

78. Gandara DR, Lara PN, Edelman MJ, Law L, Lau D, Israel V, Lenz H-J, Albain KS,

Gumerlock PH, Mack PC, Gandour-Edwards R, Longmate J, Frankel P, Doroshow JH:

p53 Status in platinum-refractory non-small-cell lung cancer (NSCLC) receiving

gemcitabine (GEM): a California Cancer Consortium trial. Proc ASCO 21:1247, 2002.

79. Iqbal S, Lenz H-J, Groshen S, Wei Y, Gandara DR, Lara PN, Gumerlock P, Doroshow

JH, Twardowski P, Synold T: Phase I study of PS-341 in combination with 5-FU/LV in

solid tumors. Proc ASCO 21:370, 2002.

80. Lenz H-J: Pharmacogenetic determinants of clinical outcome and toxicity in colon

cancer. Eur J Cancer 38(Suppl. 7):S68 #212, 2002.

81. Lenz H-J, Park DJ, Zhang W, Tsao-Wei D, Groshen S, Zahedy S, Mallik N, Gil J,

Stoehlmacher J: A multivariate analysis of genetic markers for clinical response to 5-

FU/oxaliplatin chemotherapy in advanced colorectal cancer. Proc ASCO 21:513, 2002.

82. Lenz H-J, Zhang W, Zahedy S, Gil J, Yu M, Stoehlmacher J: A 6 base-pair deletion in

the 3 UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in

colorectal tumors: a possible candidate gene for colorectal cancer risk. Proc AACR

43:3274, 2002.

83. Martel CL, Lara PN, Gumerlock PH, Mack PC, Galvin IV, Lau DHM, Turrell C,

Chambers AF, Wilson SM, Le Q, Lenz H-J, Doroshow JH, Gandara DR: Markers of

tumor-related hypoxia (TRH) in a phase I study of tirapazamine (TPZ) plus taxol &

carboplatin (carbo). Proc ASCO 21:68, 2002.

84. Newman EM, Longmate JA, Lenz H-J, Carroll MI, Stalter SK, Lim DW, Raschko JW,

Shibata SI, Somlo G, Doroshow JH: Phase I and pharmacokinetic evaluation of the

DNA methyltransferase inhibitor 5-fluoro-2’-deoxycytindine: a California Cancer

Consortium study. Proc ASCO 21:431, 2002.

85. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Gil J, Zahedy S, Lenz H-

J: XPD polymorphism is associated with clinical outcome in advanced colorectal

cancer patients treated with 5-FU/oxaliplatin chemotherapy. Proc ASCO 21:534, 2002.

86. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Zahedy S. Gil J, Mallik

N, Lenz H-J: ERCC1 polymorphism is associated with differential ERCC1 mRNA

levels. Proc AACR 43:1591, 2002.

87. Pegram M, Ku N, Shepard M, Speid L, Lenz H-J: Enzyme-catalyzed therapeutic

activation (ECTA) NB1011 (Thymectacin) selectively targets thymidylate synthase

(TS)overexpressing tumor cells: preclinical and phase I clinical results. Eur J Cancer

38(Supp. 7):S34, #99, 2002.

88. Rosen LS, Dragovich T, Lenz H-J, Lin E, Wiggins L, Brown GL, Maack C,

Macpherson J, Dombroski J, Henner WD: Phase II study of TLK286 (glutathione

analog activated by GST P1-1) in refractory colorectal cancer. Eur J Cancer 38 (Supp

7):S35, #101, 2002.

89. Stoehlmacher J, Brabender J, Groshen S, Park DJ, Danenberg KD, Tsao-Wei DD,

Zhang W, Sherrod A, Danenberg PV, Lenz H-J: Glutathione S-transferase P1

polymorphism: association with mRNA expression and survival of patients with

metastatic colorectal cancer. Proc AACR 43:832, A4130, 2002.



90. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Zahedy S, Mallik N, Lu

B, Gil J, Lenz H-J: Glutathione S-transferase polymorphisms predict survival of

patients with colorectal cancer. Proc ASCO 21:349, 2002.

91. Strumberg D, Hilger R, Scheulen ME, Awada A, Piccart M, Hirte H, Moore M, Clark J,

Lenz H-J, Voliotis D, Petrenciuc O, Martell R, Humphrey R, Coppieters S: Final

results of a phase I pharmacokinetic and pharmacodynamic study of the RAF kinase

inhibitor BAY 43-9006 in patients with solid tumors. Proc ASCO 21:121, 2002.

92. Zhang W, Stoehlmacher J, Park DJ, Groshen S, Tsao-Wei D, Zahedy S, Lu B, Gil J,

Mallik N, Lenz H-J: A polymorphic dinucleotide repeat in intron 1 of EGFR (epithelial

growth factor receptor) gene is associated with clinical response to platinum based

chemotherapy in patients with advanced colorectal disease. Proc ASCO 21:533, 2002.

93. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Gil J, Zahedy S, Lenz H-

J: XPD polymorphism is associated with clinical outcome in advanced colorectal

cancer patients treated with 5-FU/oxaliplatin chemotherapy. Proc ASCO 21:534, 2002.

94. Stoehlmacher J, Lenz H-J: Implications of genetic testing in the management of

colorectal cancer. American Journal Pharmacogenomics 3(2): 73–88, 2003.

95. Mandola M, Stoehlmacher J, Muller-Weeks S, Cesarone G, Groshen S, Tsao- Wei D,

Lenz H-J, Ladner R: A novel SNP within the tandem repeat polymorphism of the

thymidylate synthase gene abolishes USF-1 binding and predicts outcome of the

metastatic colorectal carcinoma treated with 5-flourouracil. Proc AACR 44:618, 2003.

96. Zhang W, Gil J, Stoehlmacher J, Groshen S, Tsao-Wei D, Sones E, Yun J, Mallik N,

Lenz H-J: Interleukin 10 gene promoter IL-10.G microsatellite polymorphism alone

may be associated with clinical outcome of advanced colorectal cancer patients with

platinum-based chemotherapy. Proc AACR 44:2511, 2003.

97. Stoehlmacher J, Mandola M, Yun J, Sones E, Zhang W, Gil J, Mallik N, Park D, Yu M,

Ladner R, Lenz H-J: Alterations of the thymidylate synthase (TS) pathway and

colorectal cancer risk- The impact of three TS polymorphisms. Proc AACR 44: 2614,

2003.

98. Lara P, Frankel P, Gumerlock PH, Mack PC, Law LY, Lenz H-J, Lau DH, Longmate

J, Doroshow JH, Gandara DR, Intermittent dosing of the farnesyl transferase inhibitor

R115777 in advanced malignant solid tumors: A Phase I California Cancer Consortium

Trial. Proc ASCO 22:878, 2003.

99. Strumberg D, Awada A, Piccart M, Hirte H, Moore M, Clark J, Lenz H-J, Lathia C,

Coppieters S, Humphrey R: Final report on the phase I clinical program of the novel

RAF kinase inhibitor BAY 43-9006 in patients with refractory solid tumors. Proc

ASCO 22:813, 2003.

100. Yun J, Zhang W, Stoehlmacher J, Park D, Groshen S, Tsao-Wei D, Sones E, Gil J,

Mallick N, Lenz H-J: Association of genetic polymorphisms of IL-8 and its receptor

CXCR1 and survival of patients with metastatic colorectal cancer treated with

5FU/oxaliplatin. Proc ASCO 22:847, 2003.

101. Twardowski PW, Gandara DR, Lara PN, Lenz H-J: Phase I trial of SU5416 in

combination with weekly paclitaxel in patients with advanced malignancies. Proc

ASCO 22:944, 2003.

102. Wong KK, Eder JP, Clark J, Lenz H-J, Smith J, Lee RJ, Lathia C, Humphrey R: Final

results of a phase I study to determine the safety, maximum tolerated dose,

pharmacokinetics and pharmacodynamics of BAY-43-9006 in repeated cycles of 1



week on/ 1 week off in patients with advanced refractory solid tumors. Proc ASCO

22:976, 2003.

103. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz H-J, Naughton MJ, Weeks JC,

Herndon JE, Zhang K, Mayer RJ: Hepatic arterial infusion (HAI) versus systemic

therapy for hepatic metastases from colorectal cancer; a CALGB randomized trial of

efficacy, quality of life (QOL), cost effectiveness, and molecular markers. Proc ASCO

22:1010, 2003.

104. Zhang W, Lu B, Schneider S, Danenberg K, Gil J, Stoehlmacher J, Ye W, Groshen S,

Sherrod A, Lenz H-J: Epidermal growth factor receptor (EGFR) gene expression

levels and genomic polymorphism predict pelvic recurrence in patients with rectal

cancer treated with chemoradiation. Proc ASCO 22:1028, 2003.

105. Gams RA, Ramanathan RK, Clark J, Kemeny N, Lenz H-J, Gococo KO, Haller DG,

Mitchell E, Mitchell E, Kardinal C: The oxaliplatin treatment access program:

Compassionate use experience of oxaliplatin as a single agent or in combination with 5-

fluorouracil in more than 7000 patients with previously treated advanced colorectal

cancer. Proc ASCO 22:1065, 2003.

106. Whitehead RP, McCoy S, MacDonald J, Rivkin SE, Neubauer M, Dakhil S, Lenz H-J,

Tanaka M, Abbruzzese JL: Phase II trial of R115777 (NSC #70818) in patients with

advanced colorectal cancer: A Southwest Oncology Group study. Proc ASCO 22:1092,

2003.

107. Gil JY, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Park D, Yun J, Mallik N,

Sones E, Lenz H-J: Functional polymorphisms of matrix metalloproteinases may

predict distant metastases in patients with advanced colorectal cancer. Proc ASCO

22:1100, 2003.

108. Singh DA, Kindler HL, Eng C, Skoog L, Lenz H-J, Taber D, Vokes EE: Phase II trial

of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer. Proc

ASCO 22:1127, 2003.

109. Lu B, Gil J, Stoehlmacher J, Zhang W, Ye W, Groshen S, Sherrod A, Yun J, Sones E,

Lenz H-J: GSTP1 ILE(105) Val polymorphism is associated with pelvic recurrence in

patients with rectal cancer treated with chemoradiation. Proc ASCO 22:1143, 2003.

110. Lenz H-J, Schneider S, Zhang W, Danenberg K, Gil J, Stoehlmacher J, Ye W, Groshen

S, Sharrod A, Danenberg PV: Gene expression profile in normal tissue predicts pelvic

recurrence in patients with rectal cancer treated with adjuvant chemoradiation therapy.

Proc ASCO 22:1185, 2003.

111. Park DJ, Gil J, Lu B, Zhang W, Ye W, Groshen S, Sherrod A, Yun J, Mallik N, Lenz

H-J: Genomic profiling is associated with pelvic recurrence in patients with rectal

cancer treated with chemoradiation. Proc ASCO 22:1458, 2003.

112. Iqbal S, Garber J, Yang D, Agafitei R, Groshen S, Lujan R, Garcia A, Kornowski A,

Lenz H-J: Pilot trial of 5-FU/oxaliplatin (CIFOX) as a compassionate use regimen in

patients with metastatic colorectal cancer: The USC experience. Proc ASCO 22:1510,

2003.

113. Padmanabhan A, Iqbal S, Stoehlmacher J, Yun J, Garcia A, Agafitei R, Yang D,

Groshen S, Karnowski A, Lenz H-J: Pilot trial of 5-FU/oxaliplatin (CIFOX) for

patients with metastatic colorectal cancer after progression with 5-FU/LV/CPT-11

(IFL). Proc ASCO 22:1511, 2003.



114. Garber J, Padmanabhan A, Iqbal S, Lenz HJ: Retrospective analysis of 5-FU/LV/CPT-

11 2 weeks on/1 week off (IFL2), a pilot study. Proc ASCO 22:1515, 2003.

115. Ru J, Byone S, Nelson T, Katz M, Garcia A, Lenz H-J, Daniels J, Iqbal S: Hepatic

intra-arterial infusion (HIA) of cisplatin and mitomycin-C for hepatocellular carcinoma

(HCC): The USC experience. Proc ASCO 22:1519, 2003.

116. Schneider S, Brabender J, Stoehlmacher J, Schneider PM, Uchida K, Yochim J, Yang

D, Danenberg K, Lenz H-J, Danenberg PV: Promoter variant in cyclooxigenase-2 is

associated with lymph node involvement in patients with locally advanced non-small

cell lung cancer. Proc ASCO 22:2621, 2003.

117. Johl J, Lara PN, Lau DH, Gandara DR, Raschko J, Lenz H-J, Longmate J, Doroshow

J: Chloroquinoxaline sulfonamide (CQS) in metastatic platinum-refractory small cell

lung cancer (SCLC): A California Cancer Consortium phase II trial. Proc ASCO

22:2782, 2003.

118. Kimura T, Synold T, Mahaffey CM, Labauve AE, Mack PC, Lenz H-J, Gandara DR,

Doroshow JH, Gumerlock PH: E7389, a novel antimicrotubule agent with potent p53-

independent induction of p27, Bcl2 phosphorylation and cytotoxicity in non-small cell

lung cancer (NSCLC). Proc ASCO 22:2804, 2003.

119. Leong LA, Frankel P, Juhasz A, Lawrence J, Lim D, Shibata S, Yen Y, Lenz H-J,

Gandara DR, Doroshow JH: Ribonucleotide reductase M1 and M2 (RR-M1, -M2),

cytidine deaminase (CDA), deoxycytidine deaminase (dCDA), deoxycytidine kinase

(dCK), and excision repair cross complementation – 1 (ERCC-1) expression in

advanced malignancies treated with combined oxaliplatin and gemcitabine. Proc ASCO

22:3456, 2003.

120. Stoehlmacher J, Zhang W, Gil J, Park D, Groshen S, Tsao-Wei D, Sones E, Yun J,

Mallik N, Lenz H-J: Angiogenic profiling predicts distant metastatic site in patients

with colorectal cancer. Proc ASCO 22:1136, 2003.

121. Lenz H-J: A Novel SNP within the tandem repeat polymorphism of the thymidylate

synthase gene abolishes USF-1 binding and predicts outcome of metastatic colorectal

carcinoma treated with 5-flourouracil. Presented at: AACR poster session, R618.

Washington, DC, 7/2/2003.

122. Lenz H-J: Interleukin 10 gene promoter IL-10.Gmicrosatellite polymorphism alone

may be associated with clinical outcome of advanced colorectal cancer patients with

platinum-based chemotherapy. Presented at: AACR poster session, 2511. Washington,

DC, 7/12/2003.

123. Lenz H-J: Alterations of the thymidylate synthase (TS) pathway and colorectal cancer

risk – The impact of three TS polymorphisms. Presented at: AACR poster session,

2614. Washington, DC, 7/13/2003.

124. Zhang W, Lu B, Gil J, Yang D, Groshen S, Lenz H-J: Interleukin-8 (IL-8) promoter

region gene polymorphism predicts pelvic recurrence after chemo-radiation in patients

with rectal cancer. Int J Radiat Oncol Biol Phys 57(2):S382, 2003.

125. Yun J, Zhang W, Stoehlmacher J, Park D, Groshen S, Tsao-Wei D, Sones E, Gil J,

Mallick N, Lenz H-J: Association of genetic polymorphisms of IL-8 and its receptor

CXCR1 and survival of patients with metastatic colorectal cancer treated with

5FU/Oxaliplatin. Onkologie 26(suppl 3):p15, A847, 2003.

126. Gams RA, Ramanathan RK, Clark J, Kemeney N, Lenz H-J, Gococo KO, Haller DG,

Mitchell E, Kardinal C: The oxaliplatin treatment access program: Compassionate use



experience of oxaliplatin as s single agent or in combination with 5-flourouracil in more

than 7000 patients with previously treated advanced colorectal cancer. Onkologie

26(3):p21, A1065, 2003.

127. Iqbal S, Garber J, Yang D, Agafitei R, Groshen S, Lujan R, Garcia A, Kornowski A,

Lenz H-J: Pilot trial of 5-FU/oxaliplatin (CIFOX) as a compassionate use regimen in

patients with metastatic colorectal cancer: The USC experience. Onkologie 26(3):p39,

A1510, 2003.

128. Padmanabhan A, Iqbal S, Stoehlmacher J, Yun J, Garcia A, Agafitei R, Yang D,

Groshen S, Karnowski A, Lenz H-J: Pilot trial of 5-FU/oxaliplatin (CIFOX) for

patients with metastatic colorectal cancer after progression with 5-FU/LV/CPT-11

(IFL). Onkologie 26(3):p39, A1511, 2003.

129. Leong LA, Frankel P, Juhasz A, Lawrence J, Lim D, Shibata S, Yen Y, Lenz H-J,

Gandara DR, Doroshow JH: Ribonucleotide reductase M1 and M2 (RR-M1, -M2),

cytidine deaminase (CDA), deoxycytidine deaminase (dCDA), deoxycytidine kinase

(dCK), and excision repair cross complementation – 1 (ERCC-1) expression in

advanced malignancies treated with combined oxaliplatin and gemcitabine. Onkologie

26(3):p46, A3456, 2003.

130. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ,

Ladner RD. A 6 bp polymorphism in the thymidylate synthase gene causes message

instability and is associated with decreased intratumoral TS mRNA levels.

Pharmacogenetics 14(5):319–327. May 2004.

131. Iqbal S, Cole S, Yang D, Lara PN, Gumerlock PH, Shibata S, Synold T, Doroshow JH,

Gandara D, Lenz HJ: Phase I study of PS-341 (bortezomib) with 5-

fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer

Consortium study. Proc ASCO 23:2057, 2004.

132. Ishioka GY, Disis ML, Morse MA, Cunningham CC, Lenz H-J, Figlin RA, Chesnut

RW, Fikes J: A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small

cell lung (NSCLC) and colon cancer patients. Proc ASCO 23:2525, 2004.

133. Levine AM, Quinn DI, Gorospe G, Lenz HJ, Tulpule A: Phase I trial of anti-sense

oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with

relapsed and refractory malignancies. Proc ASCO 23:3008, 2004.

134. Pegram M, Yeon CH, Ku N, Gottlieb C, Shepard M, Cossum P, John E, Iqbal S, Garcia

A, Lenz HJ. Enzyme catalyzed therapeutic activation of NB1011 (N) selectively

targets thymidylate synthase (TS)-overexpressing tumor cells: Phase I results. Proc

ASCO 23:3144, 2004.

135. Lenz HJ, Mayer RJ, Gold PJ, Mirtsching B, Stella PJ, Cohn AL, Pippas AW, Azarnia

N, Needle MN, Van Cutsem E: Activity of cetuximab in patients with colorectal cancer

refractory to both irinotecan and oxaliplatin. Proc ASCO 23:3510, 2004.

136. Zhang W, Yun J, Press OA, Gordon M, Yang DY, Mallik N, Sherrod S, Iqbal S, Lenz

HJ: Association of cyclin D1 (CCND1) gene A870G polymorphism and clinical

outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal

growth factor receptor (EGFR) inhibitor cetuximab (C225). Proc ASCO 23:3518, 2004.

137. Yun J, Zhang W, Park D, Yang D, Press O, Gordon M, Mallik N, Lenz HJ: Molecular

profiling predicts clinical outcome in patients with metastatic colorectal cancer treated

with 5-FU/oxaliplatin. Proc ASCO 23:3519, 2004.



138. Dragovich T, Lenz HJ, Rocha Lima CMS, Kozuch P, Hochster H, O’Neil B, Atiq O,

Pipas JM, Kashala O, Schenkein DP: Bortezomib ± irinotecan in relapsed/refractory

colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study. Proc ASCO

23:3591, 2004.

139. Agafitei RD, Schneider S, Iqbal S, Yang D, Groshen S, Lenz HJ: Effect of celecoxib

on neurotoxicity in patients with metastatic colorectal cancer treated with 5-

FU/oxaliplatin (CIFOX). Proc ASCO 23:3600, 2004.

140. Gordon MA, Zhang W, Yang DY, Gil J, Yun J, Press O, Mallik N, Lenz HJ: McSOD

and GPx-1 polymorphisms in relation to local recurrence in patients with rectal cancer

treated with chemoradiation. Proc ASCO 23:3604, 2004.

141. Mallik N, Zhang W, Yang DY, Iqbal S, Yun J, Press O, Gordon M, Lenz H-J:

Polymorphisms in IL-8 and the GSTP1 are associated with survival of metastatic

colorectal cancer patients treated with CPT-11. Proc ASCO 23:3606, 2004.

142. Press OA, Zhang W, Yang DY, Yun J, Gordon M, Mallik N, Lenz H-J: Survival

differences related to estrogen receptor beta (ERβ) polymorphism and age in female

patients with metastatic colon cancer. Proc ASCO 23:3618, 2004.

143. Park DJ, Yun J, Yang DY, Iqbal S, Press O, Groshen S, Gordon M, Zhang W, Lenz H-

J: Genomic profiling as predictor of toxicity in patients with advanced colorectal

cancer treated with platinum-based chemotherapy. Proc ASCO 23:3627, 2004.

144. Aparicio A, Iqbal S, Yang D, Groshen S, Park D, Garcia A, Lenz HJ: Pilot trial of 5-

FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed

on 5-FU/LV/CPT-11 (IFL). Proc ASCO 23:3773, 2004.

145. Yen Y, Doroshow J, Leong L, Lim D, Wagman L, Morgan R, Frankel P, Lenz H,

Gandara D, Shibata S: Phase II study of oxaliplatin in patients with unresectable,

metastatic or recurrent hepatocellular cancer. Proc ASCO 23:4169, 2004.

146. Yang D, Schneider S, Danenberg KD, Danenberg PV, Lenz H-J: Gene expressions of

VEGF and Survivin as molecular markers of lymph node involvement in patients with

locally advanced rectal cancer. Proc ASCO 23:9526, 2004.

147. Iqbal S, Stoehlmacher J, and Lenz HJ: Tailored chemotherapy for colorectal cancer: a

new approach to therapy. Cancer Invest. 22(5):762-773, 2004.

148. Zhang W, Vallboehmer D, Yun J, Press O, Gordon M, Rhodes K, Yang D, Iqbal S,

Lenz H-J. Pharmacogenetic study of EGFR-positive metastatic colorectal cancer

patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab

(C225). ASCO Proc Gastro Intestinal Cancers Symposium p.168:A169, 2005.

149. Saltz LB, Lenz H-J, Kindler H, Hochster H, Wadler S, Hoff P, Kemeney N,

Hollywood E, Gonen M, Chen H. Interim report of randomized phase II trial of

cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in

irinotecan-refractory colorectal cancer. ASCO Proc Gastro Intestinal Cancers

Symposium p.169:A169b, 2005.

150. Kemeney NW, Niedzwiecki D, Hollis DR, Lenz H-J, Warren RD, Naughton MJ,

Weeks JC, Herndon JE, Zhang K, Mayer RJ. Final analysis of hepatic arterial infusion

(HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a CALGB

randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular

markers. ASCO Proc Gastro Intestinal Cancers Symposium p. 176:A183, 2005.



151. Lenz H-J, Mayer RJ, Gold P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Windt

P, Van Cutsem E. Activity of cetuximab in patients with colorectal cancer refractory to

a flouropyrimidine, irinotecan, and oxaliplatin. ASCO Proc Gastro Intestinal Cancers

Symposium p.196:A225, 2005.

152. Synold TW, Morgan RJ, Newman EM, Lenz HJ, Gandara DR, Colevas AD, Lewis

MD, Doroshow JH. A phase I pharmacokinetic and target validation study of the novel

anti-tubulin agent E7389: A California Cancer Consortium trail. Proc ASCO 23: 3036,

2005.

153. Morgan RJ, Doroshow JH, Frankel P, Leong LA, Chow W, Fleming G, Garcia AA,

Lenz HJ, Gandara D. A phase II trial of bryostatin in combination with cisplatin in

patients with recurrent or persistent epithelial ovarian cancer: A California Cancer

Consortium (CCC) trial. Proc ASCO 23:5140, 2005..

154. Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Pippas A, Windt P, Van Cutsem E.

Consistent response to treatment with cetuximab monotherapy in patients with

metastatic colorectal cancer. Proc ASCO 23:3536, 2005.

155. Pippas AW, Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Windt P, Van Cutsem E.

Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab

monotherapy. Proc ASCO 23:3595, 2005.

156. Gordon MA, Zhang W, Karaman M, Yun J, Press O, Rhodes K, Vallboehmer D, Iqbal

S, Hacia J, Lenz HJ. Gene expression profiling associated with risk of recurrence in

patients with colorectal cancer. Proc ASCO 23:3602, 2005.

157. Hendifar AE, Zhang W, Yang DY, Khoueiry AE, Iqbal S, Lenz HJ. Polymorphisms of

transforming growth factor-β1 (TGF- β1) and recurrence in stage II and III colon


158. Kulke M, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K,

Baum CM, Fuchs CS. A phase 2 study to evaluate the efficacy and safety of SU11248

in patients (pts) with unresectable neuroendocrine tumors (NETs). Proc ASCO 23:4008,

2005.

159. Vallboehmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Iqbal

S, Danenberg K, Lenz HJ. Molecular determinants of cetuximab efficacy. Proc ASCO

23:3551, 2005.

160. Rhodes KE, Vallboehmer D, Zhang W, Yang DY, Yun J, Press O, Gordon M, Iqbal S,

Lenz HJ. Molecular predictor of irinotecan (CPT-11) efficacy. Proc ASCO 23:3560,

2005.

161. Press OA, Zhang W, Yang DY, Yun J, Gordon M, Vallboehmer D, Rhodes KE, Iqbal

S, Lenz HJ. Gender related survival differences associated with polymorphic variants

of estrogen beta (Erβ) and epidermal growth fact receptor (EGFR) in patients with

metastatic colon cancer. Proc ASCO 23:3590, 2005.

162. Yang DY, Vallboehmer D, Rhodes KE, Zhang W, Yun J, Press OA, Gordon M, Iqbal

S, Danenberg K, Lenz HJ. Molecular prognostic factors of irinotecan efficacy. Proc

ASCO 23:3621, 2005.

163. Love N, Grothey A, Curley S, Ellis L, Lenz HJ, Paley M, Kaderman R, Ziel K, Paley

D. Perspectives of patients with colorectal cancer (PCRC): A pilot project to determine

interests in and understanding of patient education on clinical research. Proc ASCO

23:3635, 2005.



164. Ajani JA, Phan A, Yao JC, Lee FC, Singh DA, Haller D, Benson AB, Lenz HJ,

Yanagihara RH, Strumberg D. Multi-center phase II study of S-1 plus cisplatin in

patients with advanced gastric carcinoma (AGC). Proc ASCO 23:4024, 2005.

165. Saltz LB, Lenz HJ, Hochster H, Wadler S, Hoff P, Kemeney N, Hollywood E, Gonen

M, Wetherbee S, Chen H. Randomized phase II trial of

cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in

irinotecan-refractory colorectal cancer. Proc ASCO 23:3508, 2005.

166. Zhang W, Vallboehmer D, Yang D, Yun J, Press OA, Gordon M, Rhodes K, Sherrod

A, Iqbal S, Lenz HJ. Genomic profile associated with clinical outcome of EGFR-

expressing metastatic colorectal cancer patients treated with epidermal growth factor

receptor (EGFR) inhibitor cetuximab. Proc ASCO 23:3557, 2005.

167. Love Neil, Grothey A, Ellis L, Marshall J, Saltz L, Lenz H-J. Patient Perspectives on

Trade-Offs of Adjuvant Systemic Therapy for Stage II and III Colon Cancer: A Survey

of 129 People with Colorectal Cancer.” ASCO GI poster. San Francisco, CA. 1/28/06.

168. Lenz H-J, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara RH,

Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in

patients with advanced gastric carcinoma in a multi-center phase II study. Proc ASCO

24:1083, 2006.

169. Bello C, Deprimo SE, Friece C, Smeraglia J, Sherman L, Tye L, Baum C, Meropol NJ,

Lenz H-J, Kulke MH. Analysis of circulating biomarkers of sunitinib malate in

patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble

VEGF receptors 2 and 3. Proc ASCO 24:4045, 2006.

170. El-Khoueiry AB, Iqbal S, Singh DA, D’Andre S, Ramanathan RK, Shibata S, Yang

DY, Lenz H-J, Synold T, Gandara DR. A randomized phase II non-comparative study

of Ispinesib given weekly or every three weeks in metastatic colorectal cancer: A

California Cancer Consortium Study (CCC-P). Proc ASCO 24:3595, 2006.

171. Sanborn RE, Lenz H-J, Haller DG, Benson AB, Dragovich T, Robles C, Mc Mahon M,

Li H, Mori M, Mattek N, Blanke CD. A phase II study of celecoxib (C) with irinotecan

(I), 5-flourouracil (F), and leucovorin (L) in patients (pts) with advanced or metastatic

colorectal cancer (CRC). Proc ASCO 24:3588, 2006.

172. Major P, Trarbach T, Lenz H-J, Kerr D, Pendergrass K, Douillard J, Chen B, Laurent

D, Jacques C, Van Cutsem E. A meta-analysis of two randomized, double-blind,

placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer

(mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on

pregression-free survival (PFS) in high LDH pts. Proc ASCO 24: 3529, 2006.

173. Azuma M, Shi MM, Jacques CJ, Barrett C, Danenberg KD, Iqbal S, El-Khoueiry AB,

Yang D, Zhang W, Lenz H-J. Tumor VEGFA gene expression is associated with

serum lactate dehydrogenase (LDH) levels and intratumoral mRNA expression of

genes involved in glycolysis in patients with metastatic colorectal cancer (mCRC).

Proc ASCO 24:3530, 2006.

174. Nagashima F, Zhang W, Yang D, Gordon M, Schultheis A, Fazzone W, Azuma M, El-

Khoueiry A, Iqbal S, Lenz H-J. Polymorphism in sodium-channel alpha 1-subunit

(SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic

colorectal cancer treated with 5-FU/oxaliplatin. Proc ASCO 24:3533, 2006.



175. Press OA, Zhang W, Yang D, Haiman CA, Gordon M, Schultheis AM, Nagashima F,

Sherrod A, Ibal S, Lenz H-J. Methylenetetrahydrofolate reductase (MTHFR) gene

polymorphisms associated with overall survival in women with metastatic colon cancer.

Proc ASCO 24:3600, 2006.

176. Kobayashi H, Hashiguchi Y, Ueno H, Shinto E, KajiwaraY, Lenz H-J, Danenberg KD,

Danenberg PV, Mochizuki H. Pretreatment COX-2 protein expression is a predictor of

tumor regression in rectal cancer treated with preoperative short-term

chemoradiotherapy. Proc ASCO 24:3610, 2006.

177. Shimizu D, Kuramochi H, Tanaka K, Cooc J, Xiong Y, William M, Li R, Danenberg

KD, Danenberg PV, Lenz H-J. Molecular signatures generated with RNA isolated

from formalin-fixed paraffin-embedded tumor specimens differentiate metastatic and

non-metastatic primary colorectal cancer. Proc ASCO 24:3615, 2006.

178. Zhang W, Gordon M, Schultheis A, Nagashima F, Azuma M, Yang D, Iqbal S, Lenz

H-J. Two immunoglobulin G fragment C receptor polymorphisms associated with

clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with

single agent cetuximab. Proc ASCO 24:3028, 2006.

179. Rhodes KE, Zhang W, Yang DY, Gordon M, Schultheis A, Nagashima F, Iqbal S,

Lenz H-J. Abcb1, ugt1a1 and oatp-c polymorphisms predict Irinotecan (CPT-11)

toxicity. Proc ASCO 24:3074, 2006.

180. Park DJ, Zhang W, Gordon M, Yang DY, Ladner R, Iqbal S, Groshen S, Vallbohmer

D, Lenz H-J, Fazzone W. Lack of association with epidermal growth factor receptor

gene polymorphisms with clinical outcome in patients with advanced colorectal cancer

treated with platinum-based chemotherapy. Proc ASCO 24:3079, 2006.

181. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz H-J, Yen Y, Kindler HL,

Iqbal S, Longmate J, Gandara DR. Phase II study of lapatinib, a dual inhibitor of

epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in

patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC).

A California Consortium (CCC-P) Trial. Proc ASCO 24: 4010, 2006.

182. Schultheis AM, Yang D, Garcia AA, Morgan R, Gandra D, Scudder S, Oza A, HIrte H,

Fleming G, Roman L, Lenz H-J. Angiogenesis pathway gene polymorphisms

associated with clinical outcome in recurrent ovarian cancer treated with low dose

cyclophosphamide and bevacizumab: A California Consortium Trial. Proc ASCO

24:5017, 2006.

183. Tanaka K, Shimizu D, Kuramochi H, Cooc J, Williams M, Li R, Chen P, Danenberg

KD, Danenberg PV, Lenz H-J. Molecular signatures generated with RNA Isolated

from formalin-fixed paraffin-embedded tumor specimens differentiate metastatic and

non-metastatic primary breast cancer. Proc ASCO 24:614, 2006.

184. Gordon M, Zhang W, Yang D, Spicer D, Doroshow J, Margolin K, Synold T, Albain K,

Chew H, Gandara DR, Lenz H-J. Polymorphisms of DNA-repair genes associated with

clinical outcome in metastatic breast cancer (MBC) patients treated with

gemcitabine/cisplatin (GC) (California Cancer Consortium). Proc ASCO 24: 675, 2006.



185. Takimoto CH, Liu PY, Lenz H-J, Remick S, Mulkerin D, Mani S, Synold T,

Ramanathan RK, Ivy P, Davies AM. A phase I pharmacokinetic (PK) study of the

Epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced

malignancies and varying degrees of hepatic impairment. A SWOG Early Therapeutics

Committee and NCI Organ Dysfunction Working Group Trial. Proc ASCO 24:2004,

2006.

186. Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold T, Lenz H-J, Egorin MJ.

Concentration of the DNA methyltransferase inhibitor 5-flouro-2’-deoxycy-ticine

(FdCyd) & its metabolites 5-flouro-2’-deoxyuridine (FdUrd), 5-flourouracil (FU), 5-

flourouridine (FUrd), & 5-flourocytosine (FC) in plasma of patients treated with

FdCyd. Proc ASCO 24:2023, 2006.

187. Yang D, Vallbohmer D, Zhang W, Iqbal S, El-Khoueiry A, Gordon M, Park D, Azuma

M, Groshen S, Danenberg K, Lenz H-J. Intratumoral mRNA levels predict clinical

outcome in patients with metastatic colorectal cancer treated in a prospective clinical

trial with 5-FU and oxaliplatin. Proc ASCO 24:10010, 2006.

188. Shaye O, El-Khoueiry A, Garcia A, Wei D, Groshen S, Cole S, Gitlitz B, Chung C,

Lenz H-J, Iqbal S. Phase I dose and schedule finding study of pegylated liposomal

doxorubicin (D) and weekly docetaxel (T). Proc ASCO 24:12012, 2006.

189. Singh D, Taber D, Ansari R, Lenz H-J, Agamah E, Nattam S, Wade-Oliver K, Kasza

K, Volkes E, Kindler H. A phase II trial of the epothilone B analog BMS-247550 in

patients (pts) with hepatobiliary cancer (HBC): An updated analysis. Proc ASCO

24:14050, 2006.

190. Zhang W, Gordon M, Press O, Rhodes K. Vallbohmer D, Yang D, Park D, Fazzone W,

Schultheis A, Sherrod A, Iqbal S, Groshen S, Lenz H-J. Cyclin D1 and epidermal

growth factor polymorphisms associated with survival in patients with advanced

colorectal cancer treated with Cetuximab. Pharmacogenetics and Genomics. 16(7):475-

83, July 2006.

191. Love N, Bylund C, Meropol NJ, Marshall J, Curley SA, Ellis LM, Grothey A, Lenz H-

J, Saltz LB, Elder M. How well do we communicate with out patients? A survey of

patients who received adjuvant chemotherapy for colorectal cancer. Presented at: ASCO

GI poster session, 239. Orlando, FL. 1/21/07.

192. Lenz H-J, Zhang W, Yang D, Carpanu M, Hollywood E, Lue-Yat M, Azuma M,

Nagashima F, Chang H, Saltz L. Pharmacogenomic analysis of a randomized phase II

trial (BOND 2) of cetuximab/bevacizumab/irinotacan (CBI) versus

cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presented at:

ASCO GI poster session, 401. Orlando, FL. 1/21/07.

193. Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Kuramochi

H, Lenz H-J, Danenberg K, Danenberg P. Messenger RNA expression of vascular

endothelial growth factor and its receptors in primary colorectal cancer and

corresponding liver metastasis. Presented at: ASCO GI poster session, 429. Orlando,

FL. 1/21/07.

194. Rhodes K, Zhang W, Yang D, Press O, Gordon M, Vallbohmer D, Schultheis A, Lurje

G, Ladner R, Fazzonne W, Iqbal S, Lenz H-J. ABCB1, SLCO1B1 and UGT1A1 gene

polymorphisms are associated with toxicity in metastatic colorectal cancer patients

treated with first-line Irinotecan. Drug Metabolism Letters 1: 23-30, 2007.



195. DePrimo S, Harmon C, Saltz L, Lenz H-J, Marchall J, Rosen L, Belt R, Hurwitz H,

Eckhardt S, Bergsland E, Lockhart A, Lima C, Smeraglia J, Maneval E, Chao R.

Variations in circulating levels of VEGF and sVEGFR-2, sVEGFR-3 and sKIT in

metastatic CRC patients treated with Sunitinib and failure of prior chemotherapy with

or without Bevacizumab. AACR 9053. 4/14-18/2007.

196. LaBonte M, Wilson P, Fazzone W, Lenz H-J, Ladner R. The effects of histone

deacetylase inhibitors on epidermal growth factor receptor expression in colon cancer

cell lines: implications for combination therapy. AACR 683. 4/14-18/2007.

197. Fazzone W, Borucka E, Lenz H-J, Ladner R. Histone deacetylase inhibitors

downregulate thymidylate synthase expression and interact synergistically with

floouropyrimidines in colon cancer cell lines. AACR poster session 692. 4/14-18/2007.

198. Lenz H-J. Clinical research Track: Phase I-III trials Phase III clinical plenary session:

Breakthroughs in clinical research. AACR Discussant. 4/16/2007.

199. Love N, Bylund C, Meropol NJ, Marshall JL, Curley SA, Ellis LM, Grothey A, Lenz

H-J, Saltz LB, Elder MA. How well do we communicate with patients concerning

adjuvant systemic therapy? A survey of 150 colorectal cancer survivors. Proc ASCO

25:4020, 2007.

200. Hoffman AC, Hoffman C, Danenberg KD, Lenz H-J, Danenberg PV. Heparanase and

Survivin-potential markers of aggressiveness of colon cancers. Proc ASCO 25:14524,

2007.

201. Lurje G, Schultheis AM, Hendifar AE, Shouri S, Zhang W, Gordon MA, Nagashima F,

Chang HM, Yang D, Lenz H-J. VEGF and VEGF receptor-2 (VEGFR2) gene

polymorphisms predict tumor recurrence in stage II and III colon cancer. Proc ASCO

25:4004, 2007.

202. Yang D, Schultheis AM, Lurje G, Iqbal S, Chang H, Zhang W, Gordon M, Nagashima

F, Lenz H-J. Tissue factor promoter polymorphisms as a prognostic factor in patients

with metastatic colon cancer. Proc ASCO 25:4108, 2007.

203. Omori A, Stephens C, Cooc J, Danenberg PV, Danenberg K, Lenz H-J, Pasche B.

Microarray analysis of formalin-fixed paraffin embedded specimens shows distinct

gene expression patterns in tumors containing the transforming growth factor beta

receptor 6A polymorphism (TGFBR1*6A). Proc ASCO 25:4111, 2007.

204. Azuma M, Yang D, Carpanu M, Hollywood E, Leu-Yat M, Zhang W, Danenberg KD,

Danenberg PV, Saltz L, Lenz H-J. Molecular markers associated with response and

clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus

cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2).

Proc ASCO 25:4113, 2007

205. Gordon MA, Zhang W, Yang D, Nagashima F, Chang H, Lurje G, Borucka E, Lenz H-

J. Use of sex-specific genomic profile to predict clinical outcome in metastatic

colorectal cancer (mCRC) patients treated with 5-flourouracil/oxaliplatin. Proc ASCO

25:4122, 2007.

206. Zhang W, Yang D, Capanu M, Hollywood E, Leu-Yat M, Borucka E, Azuma M,

Gordon M, Saltz L, Lenz H-J. Pharmacogenomic analysis of a randomized phase II

trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus

cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO

25:4128, 2007.



207. Nagashima F, Zhang W, Gordon M, Chang HM, Lurje G, Borucka E, Yang D, Ladner

R, Rowinsky E, Lenz H-J. EGFR, Cox-2, and EGF polymorphisms associated with

progression-free survival of EGFR-expressing metastatic colorectal cancer patients

treated with single-agent cetuximab (IMCL-0144). Proc ASCO 25:4129, 2007.

208. Ladner R, Gordon MA, Zhang W, Yang D, Nagashima F, Chang H, Lurje G, Borucka

E, Lenz H-J. Polymorphisms in estrogen receptor beta, interleukin-8, and interleukin-8

receptor associated with clinical outcome in metastatic colorectal cancer (mCRC)

patients treated with 5-flourouracil/oxaliplatin. Proc ASCO 25:4130, 2007.

209. Iqbal S, Goldman B, Lenz HJ, Fegnolio-Preiser CM, Blanke CD. S0413: A phase II

SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with

advanced or metastatic gastric cancer. Proc ASCO 25:4621, 2007.

210. El-Khoueiry AB, Rankin C, Lenz H-J, Philip PA, Rivkin SE, Blanke CD. SWOG

0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts)

with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. Proc ASCO

25:4639, 2007.

211. Chang H, Azuma M, Goldman B, Nagashima F, Iqbal S, Danenberg K, Benedetti J,

Zhang W, Blanke C, Lenz H-J. Gene expression levels of HER2 and IL-8 and

polymorphisms in IL-8 associated with clinical outcome in advanced or metastatic

gastric cancer treated with lapatinib in SWOG 0413 trial. Proc ASCO 25:4647, 2007.

212. Lara P, Redman M, Lenz H-J, Gordon M, Shibata T, Fukuda H, Tamura T, Saijo N,

Natale R, Gandara D. Cisplatin (Cis)/etoposide (VP 16) compared to cis/irinotecan

(CPT 11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG)

and comparative toxicity analysis of JCOG 9511 and SWOG 0124. Proc ASCO

25:7524, 2007.

213. Philip PA, Benedetti J, Fegnolio-Preiser C, Zalupski M, Lenz H-J, O’Reilly E, Wong

R, Atkins J, Abruzzese J, Blanke C. Phase III study of gemcitabine [G] plus cetuximab

[C] versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic

adenocarcinoma [Pca]: SWOG S0205 study. Proc ASCO 25:LBA4509, 2007.

214. Shaye OS, Chang HM, Yang DY, Shriki J, Schultheis AM, Zhang W, Lurje G, Iqbal S,

Lenz H-J, El-Khoueiry AB. Polymorphisms in angiogenesis related genes predict

clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with

first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab

(FOLFOX/BV or XELOX/BV). Proc ASCO 25:10576, 2007.

215. Love N, Meropol NJ, Ravdin PM, Bylund C, Ellis LM, Grothey A, Lenz H-J, Marshall

JL, Paley D, Elder M. Which adjuvant systemic treatments would medical oncologist

wish to receive if they had colon cancer. A survey of 150 physicians. ASCO GI poster

session. Orlando, FL. 1/25-27/08.

216. Wilson PM, Yang D, Shi MM, Zhang W, Jacques C, Barret J, Danenberg K, Trarbach

T, Folprecht G, Meinhardt G, Lenz H-J. Intratumoral mRNA expression of genes

involved in angiogenesis and H1F1 pathway predict outcome to VEGFR tyrosine

kinase inhibitor (TK1) in patients enrolled in CONFIRM1 and CONFIRM2. ASCO GI

poster session. Orlando, FL. 1/25-27/08.

217. Lenz H-J, Zhang W, Shi MM, Jacques C, Barrett J, Danenberg K, Hoffman AC,

Trarbach T, Folprecht G, Meinhardt G, Yang D. ERCC-1 gene expression levels

predict outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and

CONFIRM2. ASCO GI poster session. Orlando, FL. 1/25-27/08.



218. Zhang W, Rankin C, Danenberg K, Benedetti JK, Danenberg P, Ulrich CM, Holmes

RS, Makar KW, Blanke C, Smalley SR, Lenz H-J. An update of pharmacogenetic

analysis of adjuvant rectal cancer patients treated with 5-flourouracil and pelvic

radiation in a phase III intergroup trial (INT-0144, SWOG 9304). ASCO GI poster


219. Ning Y, Zhang W, El-Khoueiry A, Danenberg K, Yang D, Singh H, Lurje G, Pohl A,

Manegold P, Iqbal S, Lenz H-J. K-RAS mutation status predicts clinical outcome in

metastatic colorectal cancer (mCRC) patients treated with first line 5-FU or

capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or

XELOX/BV respectively). ASCO GI poster session. Orlando, FL. 1/25-27/08.3

220. Manegold PC, El-Khoueiry AB, Lurje G, Singh H, Yang D, Zhang w, Chang H, Shriki

J, Pohl A, Iqbal S, Lenz H-J. ICAM-1, GRP-78 and NFkB gene polymorphisms

associated with clinical outcome in patients (pts) with metastatic colorectal cancer

(mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin

and bevacizumab (FOLFOX/BV or XELOX/BV). ASCO GI poster session. Orlando,

FL. 1/25-27/08.

221. Husain H, Lurje G, Yang D, Zhang W, Hendifar AE, Ashouri S, Pohl A, Manegold P,

Iqbal S, El-Khoueiry A, Lenz H-J. Ethnicity is associated with recurrence in patients

with resected gastric cancer. ASCO GI poster session. Orlando, FL. 1/25-27/08.

222. Pohl A, Lurje G, Zhang W, Yang D, Hendifar AE, Manegold PC, Ning Y, Iqbal S, El-

Khoueiry A, Lenz H-J. Polymorphisms in interleukin-1 b (IL-1b) and IL-1 receptor

antagonist (IL-1Ra) predict tumor recurrence in stage II colon cancer. ASCO GI poster


223. Lurje G, Husain H, Hendifar A, Zhang W, Yang D, Pohl A Manegold P, Ning Y, Iqbal

S, El-Khoueiry A, Lenz H-J. Thrombin-receptor 1 (PAR-1), Endostatin (ES), and

Interleukin-8 (IL-8) gene polymorphisms predict tumor recurrence in patients with

surgically resected gastric cancer. ASCO GI poster session. Orlando, FL. 1/25-27/08.

224. Yang D, Lenz C, Togawa K, Lurje G, Pohl A, Manegold P, Ning Y, Groshen S, Lenz

H-J. Age and ethnicity predict overall survival in patients with metastatic gastric

cancer. ASCO GI poster session. Orlando, FL. 1/25-27/08.

225. Hendifar A, Lurje G, Lenz F, Pohl A, Manegold P, Togawa K, Husain H, Lenz H-J,

Yang D. Sex, age and ethnicity are associated with survival in metastatic colorectal

cancer. ASCO GI poster session. Orlando, FL. 1/25-27/08.

226. El-Khoueiry AB, Iqbal S, Feit K, Lenz H-J, Okereke C, Krivelevich I, Goldberg T,

Conti P, Rossignol D. A phase I study of E7820 in combination with Cetuximab in

patients (pts) with advanced solid tumors. Proc ASCO 26:3568, 2008.

227. Wilson PM, Yang D, Shi MM, Zhang W, Jacques C, Barrett JC, Danenberg K,

Trarbach T, Folprecht G, Meinhardt G, Lenz H-J. Use of intratumoral mRNA

expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to

VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and

CONFIRM2. Proc ASCO 26:4002, 2008.

228. Hendifar AE, Lurje G, Lenz F, Pohl A, Manegold PC, Togawa K, Husain H, Lenz H-J,

Yang D. Sex, age and ethnicity are associated with survival in metastatic colorectal


229. Love N, Meropol NJ, Ravdin PM, Bylund C, Ellis LM, Grothey A, Lenz H-J, Marshall

JL, Curly SA, Paley D, Elder M. Which adjuvant systemic treatment (AdjRx) would



medical oncologist (MOs) wish to receive if they had colon cancer (CCa)? A survey of

150 physicians. Proc ASCO 26:4049, 2008.

230. Zhang W, Rankin CJ, Danenberg K, Benedetti J, Danenberg P, Ulrich C, Holmes R,

Makar K, Blanke C, Smalley S, Lenz H-J. An update of pharmacogenetic analysis of

adjuvant rectal cancer patients treated with 5-flourouracil and pelvic radiation in a

phase III intergroup trial (INT-0144, SWOG 9304). Proc ASCO 26: 4115, 2008.

231. Lenz H-J, Zhang W, Shi M, Jacques C, Barrett JC, Danenberg KD, Hoffman AC,

Trarbach T, Folprecht G, Meinhardt G, Yang D. ERCC-1 gene expression levels and

outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and

CONFIRM2. Proc ASCO 26:4131, 2008.

232. Manegold PC, El-Khoueiry AB, Lurje G, Singh H, Yang D, Zhang W, Chang H, Shriki

J, Pohl A, Iqbal S, Lenz H-J. ICAM-1, GRP-78, and NFkB gene polymorphisms and

clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with

first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab

(FOLFOX/BV or XELOX/BV). Proc ASCO 26: 4134, 2008.

233. Pohl A, Lurje G, Zhang W, Yang D, Hendifar A, Manegold PC, Ning Y, Iqbal S, El-

Khoueiry AB, Lenz H-J. Use of polymorphisms in interleukin-1 β (IL-1 β) and IL-1

receptor antagonist (IL-1Ra) to predict tumor recurrence in stage II colon cancer. Proc

ASCO 26:4138, 2008.

234. Gold PJ, Goldman B, Iqbal S, Leichman LP, Lenz H-J, Blanke C. Cetuximab as

second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest

Oncology Group Study. Proc ASCO 26:4536, 2008.

235. Lurje G, Husain H, Hendifar A, Zhang W, Yang D, Pohl A, Manegold P, Ning Y, Iqbal

S, El-Khoueiry A, Lenz H-J. Use of thrombin-receptor 1 (PAR-1), endostatin (ES), and

interleukin-8 (IL-8) gene polymorphisms to predict tumor recurrence in patients with

surgically resected gastric cancer. Proc ASCO 26: 4559, 2008.

236. Natale R, Lara P, Chansky K, Crowley J, Jett J, Carleton J, Kuebler J, Lenz H-J, Mack

P, Gandara D. S014: A randomized phase III trial comparing irinotecan/cisplatin (IP)

with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage

small cell lung cancer (E-SCLC). Proc ASCO 26:7512, 2008

237. Iqbal S, Lenz H-J, Yang D, Ramanthan R, Bahary N, Shibata S, Morgan R, Gandara

D. A randomized phase II study of BAY 43-9006 in combination with gemcitabine in

metastatic pancreatic carcinoma: A California Cancer Consortium study (CCC-P). Proc

ASCO 26:11082, 2008.

238. Lenz H-J. Biomarkers in Colorectal Cancer. Clinical Spotlight, Supplement to

Oncology Times. (guest editor) 6/10/08.

239. Abbruzzese JL, Lenz H-J, Hanna W, Kindler HL, Scullin D, Nemunaitis J, Kudva G,

Zhang J, Zergebel C, Urrea P. Open-label phase II study of S-1 as second-line therapy

for patients with metastatic pancreatic cancer. ASCO GI poster session. San Francisco,

CA. 1/15-17/09.

240. Thomas CR, Goldman BH, Benedetti JK, Lenz H-J, Baker T, Hammond-Thelin L,

Mehta VK, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Cetuximab (225) plus

Cisplatin (CDDP), Irinotecan (CPT11) and Thoracic Radiotherapy (TRT) as Definitive

Treatment for Locally Advanced, Clinically Unresectable Esophageal Cancer. SWOG

0414, ASTRO 2009.



241. El-Khoueiry, A, Lenz HJ, Posey J, Wood T, Fischer B, Sankar V, Syed S, Kollia G,

Masson E, Walters I. Effects of hepatic impairment on the pharmacokinetics of

brivanib in a phase 1, open-label, multidose study in patients with hepatocellular

carcinoma and other solid tumors. EASL poster session. Copenhagen, Denmark 4/22-

26/09.

242. Yang D, Pohl A, Zhang W, Lurje G, Ning Y, El-Khoueiry A, Khambata-Ford S, Langer

C, Iqbal S, Lenz H. Pharmacogenetic analysis in metastatic colorectal cancer (mCRC)

patients (pts) treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC

experience. Poster Discussion. Proc ASCO 27: 4022, 2009.

243. Ning Y, Lurje G, Danenberg K, Cooc J, Yang D, Pohl A, Zhang W, Lenz H. VEGF

and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer.

Poster Session. Proc ASCO 27: 4040, 2009.

244. Lenz H, Lurje G, Haiman CA, Yang D, Pohl A, Ning Y, El-Khoueiry A, Iqbal S,

Zhang W. Colorectal cancer susceptibility variants and clinical outcome in adjuvant

and metastatic colorectal cancer. Poster Session. Proc ASCO 27: 4051, 2009.

245. El-Khoueiry AB, Pohl A, Danenberg K, Cooc J, Zhang W, Yang D, Singh H, Shriki J,

Iqbal S, Lenz HJ. Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-

1 associated with progression-free survival (PFS) in patients (pts) with metastatic

colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin

and bevacizumab (FOLFOX/BV or XELOX/BV). Poster Session. Proc ASCO 27:

4056, 2009.

246. Winder T, Zhang W, El-Khoueiry A, Yang D, Pohl A, Lurje G, Rowinsky E,

Khambata-Ford S, Langer C, Awad M, Lenz H. Association of a germ-line variant in

the K-ras 3' untranslated region with response and progression-free survival in patients

with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with

cetuximab (EPIC) independent of K-RAS mutation status. Poster Session. Proc ASCO

27: 4061, 2009.

247. Pohl A, Zhang W, Yang D, Lurje G, Ning Y, Khambata-Ford S, Langer C, Kahn M,

Teo JL, Lenz HJ. Association of CD133 polymorphisms and clinical outcome in

metastatic colorectal cancer (mCRC) patients (pts) treated with either first-line 5-FU +

bevacizumab (BV) or second-line irinotecan (IR)/cetuximab (CB) or IR alone. Poster

Session. Proc ASCO 27: 4062, 2009.

248. Singh H, Pohl A, El-Khoueiry A, Lurje G, Zhang W, Yang D, Ning Y, Shriki J, Iqbal

S, Lenz H. Use of genetic variants to predict clinical outcome in patients (pts) with

metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine in

combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). Poster

Session. Proc ASCO 27: 4070, 2009.

249. Leichman L, Goldman BH, Benedetti JK, Billingsley KG, Thomas CR, Iqbal S, Lenz

H, Blanke C, Gold PJ, Corless CL. Oxaliplatin (OXP) plus protracted infusion 5-

fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for

potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group

(SWOG) phase II trial with molecular correlates (S0356). Poster Discussion. Proc

ASCO 27: 4513, 2009.

250. Chhibar RS, Yang D, Zhang W, Lurje G, Pohl A, Ning Y, El-Khoueiry A, Iqbal S,

Lenz HJ. Effect of gender and age on overall survival in patients with esophageal

cancer. Poster Session. Proc ASCO 27: 4541, 2009.



251. Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Yang D, Hagen JA, DeMeester SR,

DeMeester TR, Lenz HJ. Polymorphisms in epidermal growth factor (EGF) and

proteinase activated receptor 1 (PAR-1) associated with tumor recurrence in localized

adenocarcinoma (EA) of the esophagus treated with surgery alone. Poster Session. Proc

ASCO 27: 4564, 2009.

252. Lara P, Chansky K, Shibata T, Fukuda H, Tamura T, Saijo N, Redman M, Lenz HJ,

Natale R, Gandara DR. Cisplatin + irinotecan versus cisplatin + etoposide in extensive

stage small cell lung cancer (E-SCLC): Final "common arm": Comparative outcomes

analysis of JCOG 9511 and SWOG 0124. Poster Discussion. Proc ASCO 27: 8027,

2009.

253. Zhang W, Dahlberg SE, Yang D, Sandler AB, Brahmer JR, Schiller JH, Carbone DP,

Johnson DH, Lenz H. Genetic variants in angiogenesis pathway associated with

clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination

with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599.

Poster Discussion. Proc ASCO 27: 8032, 2009.

254. Iqbal S, Yang D, Cole S, El-Khoueiry AB, Boswell W, Agafitei R, Lujan R, Lenz HJ.

Phase II study of capecitabine and gemcitabine in patients with metastatic colorectal

cancer (mCRC). Proc ASCO 27: e15077, 2009.

255. Hendifar AE, Yang D, Iqbal S, Lenz H, El-Khoueiry A. Gender disparities in

hepatocellular cancer survival. Proc ASCO 27: e15517, 2009.

256. Ottochian M, Yang D, El-Khoueiry A, Iqbal S, Pohl A, Zhang W, Ning Y, Lenz HJ.

Association of gender, age, and ethnicity with survival in patients with. pancreas

cancer. Proc ASCO 27: e15587, 2009.

257. Virk N, Yang D, Lenz HJ, El-Khoueiry AB, Danenberg KD, Iqbal S. Molecular

profiling in patients (pts) with upper gastrointestinal (UGI) cancers correlated with

clinical outcome. Proc ASCO 27: e22042, 2009.

258. Holmes RS, Rankin C, Makar KW, Benedetti JK, Smalley SR, Blanke CD, Lenz HJ,

Ulrich CM. Polymorphisms in folate-metabolizing enzymes and response to 5-

fluorouracil amount stage II or III rectal cancer patients. INT-0144 SWOG 9304,

ASTRO 2009.

259. Lenz HJ. Pharmacogenomics in colon cancer. European Journal of Cancer. 7(4);

SP150, 2009.

260. Ricker C, Ault G, El-Khoueiry A, Iqbal S, Spicer D, Lenz HJ. Familial Adenomatous

Polyposis (FAP) in 9 Hispanic Women Characteristics of Lynch Syndrome in 13

Hispanic Families. The Collaborative Group of the Americas on Inherited Colorectal

Cancer – 13th Annual CGA-ICC Meeting. Poster Session. Honolulu, Hawaii. 10/17-

18/2009.

261. Winder T, Zhang W, Yang D, Ning Y, Bohanes PO, Pohl A, Lurje G, Lenz H.

Association of germline polymorphism in the CD44 gene with clinical outcome in

localized astric adenocarcinoma. Proc ASCO 27: 2, 2009.

262. Philip PA, Goldman BH, Ramanathan RK, Lenz H, Lowy AM, Whitehead RP, Iqbal S,

Chung VM, Benedetti JK, Blanke C. Phase I trial of combination gemcitabine, erlotinib

(NSC-718784), and IMC-A12 (NSC-742460 as first-line treatment in patients with

metastatic pancreatic cancer: Southwest Oncology Group study S727. Proc ASCO 27:

233, 2009.



263. Thomas CR, Goldman BH, Benedetti JK, Lenz H, Beeker T, Abbruzzese JL, Blanke C.

Cetuximab plus cisplatin, irinotecan, and thoracic radiotherpy (TRT) as definitive

treatment for locally advanced, unresectable esophageal cancer (EC): A SWOG

(S0414) phase II trial. Proc ASCO 27: 72, 2009.

264. Raghavan D, Tangen CM, Moinpour C, Gotay C, Albain KS, Louie S, Lenz HJ, Quinn

DI, Hussain M, Thompson I. Paclitaxel-gemcitabine (P-G) for patients (pts) with

advanced urothelial cancer (UC), aged > 70 years (yrs): SWOG 0028. Poster Session,

2010.

265. O’Donnell R, El-Khoueiry AB, Lenz H, Gandara DR. A phase I trial of escalating

doses of the anti-igf-1R monoclonal antibody (mAb) cixutumumab (IMC-A12) and

sorafenib for treatment of advanced hepatocellular carcinoma (HCC). Proc ASCO 28:

TPS212, 2010.

266. Philip PA, Goldman BH, Ramanathan RK, Lenz H, Lowy AM, Whitehead RP, Iqbal S,

Chung VM, Benedetti JK, Blanke CD. SWOG SO727: A randomized phase II trial of

combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus

gemcitabine plus erlotinib as first-line tratment in patients (pts) with metastatic

pancreatic cancer. Proc ASCO 28: TPS223, 2010.

267. LaBonte MJ, Yang D, Zhang W, Wilson PM, Ladner RD, Winder T, Bohanes PO, Ning

Y, Lenz H. Correlation of cyclin D1, A870G, polymorphism, and clinical outcome in

patients with HER2-positive, metastatic breast cancer treated with lapatimib plus

capecitabine. Proc ASCO 28: 1015, 2010.

268. Iqbal S, El-Khoueiry AB, Yang D, Cole S, Boswell W, Shriki J, Ning Y, Agafitei RD,

Menendez X, Lenz H. A phase I study of celecoxib (C) and patupilone (EP09006) in

patients (pts), with metastatic colorectal cancer (mCRC). Proc ASCO 28: 2533, 2010.

269. El-Khoueiry AB, Iqbal S, Lenz H, Roman L, Gitlitz BJ, Yang D, Cole S, Shriki J,

Hughlett C, Garcia A. A phase I study of two different schedules of nab-paclitaxel

(Nab-p) with ascending doses of vandetanib (V) inpatients (pts) with advanced solid

tumors. Proc ASCO 28: 3059, 2010.

270. Sawyer MB, Iqbal S, Lenz H, Rocha Lima CS, Rossignol DP, Krivelevich I, Fan J, El-

Khoueiry AB. Phase II study of E782 in combination with cetuximab in subjects (pts)

with metastatic and refractory colorectal Cancer (CRC). Proc ASCO 28: 3537, 2010.

271. Lenz H, Zhang W, Yang D, El-Khoueiry AB, Ning Y, Pohl A, Bohanes PO,

Danenberg KD, Winder T. Association of GRP78 Polymorphisms with response and

TTP in patients with mCRC treated with FOLFOX/BV. Proc ASCO 28: 3590, 2010.

272. Shibata S, Longmate J, Chung VM, Lenz H, Kummar S, Sarantopoulos J, Harrison

ML, Synold TW, Ivy SP, Newman EM. A phase I and pharmacokinetic single agent

study of pazopanib (P) in patients (Pts) with advanced malignancies and varying

degrees of liver dysfunction (LD). Proc ASCO 28: 2571, 2010.

273. Kummar S, Chen AP, Ji JJ, Allen D, Egorin MJ, Gandara DR, Lenz H, Morgan R,

Newman EM, Doroshow JH. A phase I study of ABT-888(A) in combination with

metronomic cyclophosphamide (C) in adults with refractory solid tumors and

lymphomas. Proc ASCO 28: 2605, 2010.

274. Winder T, Zhang W, Yang D, Ning Y, Bohanes PO, Hu-Lieskovan S, Mauro DJ,

Langer C, Rowinsky EK, Lenz H.Use of germ-line polymorphisms in genes involved

in the IGF pathway to predict efficacy of cetuximab independent of K-ras in mcRC

patients (IMCL-0144). Proc ASCO 28: 3562, 2010.



275. Vallbohmer D, Grimminger PP, Yang D, Danenberg KD, Danenberg P, Arnold D,

Machiels JH, Roedel C, Velenik V, Lenz H. Biomarkers for cetuximab-based

neoadjuvant radiochemotherapy in advanced rectal cancer. Proc ASCO 28: 3563, 2010.

276. Ladner RD, Ulrich CM Rankin CJ, Danenberg KD, Danenberg PV, Smalley SR, Makar

KW, Benedetti JK, Blanke CD, Lenz H. Association of intratumoral gene expression

levels of thymidine phosphorylase (TP) and VERF with clinical outcome in stage II/III

rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III

intergruop tiral (SWOG 9304). Proc ASCO 28: 3640, 2010.

277. Hu-Lieskovan S, Yang D, Grimminger PP, Arnold D, Dellas K, Machiels JH, Roedel

C, Velenik V, Lenz H, Vallbohmer D. Use of EGF a+61G and TS-5;URT 2R/3R

polymorphisms to predict complete pathologic response in locally advanced rectal

cancer patients undergoing preoperative cetuximab-based chemoradiation followed by

surgery. Proc ASCO 28: 3641, 2010.

278. Leichman, LP, Goldman B, Thomas CR, Billingsley KG, Corless CL, Lenz H, Iqbal S,

Benedetti JK, Gold PJ, Blanke CD. An Updated Report on the Rathologic Complete

Response and Survival Outcome of Southwest Oncology Group (SWOG S0536): A

Phase II Trial of Oxaliplatin (oxp) Plus Protracted Infusion 5-Fluorouracil (PIFU) and

Extranal Beam Radiation (EBRT) Prior to Surgery(s) for Potentially Curable

Esophageal Adenocarcinoma (EA) with Molecular Correlates. J Radiation Oncol

78(3):61, 2010.

279. Lenz HJ, Zhang W, Gladkov O, Chao Y, Urba S, Kemner AM, Kaneko, T, Franklin N,

Yang D, Moon H. Lapatinib + capecitabine in advanced gastric cancer: an open-label,

phase 2 study. ESMO Poster Session, LPT109747 abstract. Milan, Italy. 10/ 9/ 2010.

280. Giamas G, Filipovic A, Jocob J, Shifa BA, Green AR, Ellis IO, Lenz H-J, Stebbing J.

Kinome screening for regulators of estrogen receptor identifies a novel kinase as a new

therapeutic target in breast cancer. CTRC-AACR S3-7. Cancer Res; 70(24 Suppl.)

12/15/2010.

281. Bohanes PO, Goldman BH, Benedetti J, Blanke CD, Leichman LP, Iqbal S, Thomas Jr.

CR, Corless CL, Gold PJ, Lenz HJ. Association of expression (GE) with outcome in

stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative

platinum-based chemoradiation (CRT) in a phase II cooperative study (SWOG) 0356.

ASCO GI poster session. San Francisco, CA. 1/20-22/11.

282. Pishvaian M, Sakaeva D, Hsieh RK, Rha SY, Caderillo-Ruiz G, Miller Jr. WH, Kemner

AM, Nagarwala YM, Zhang W, Lenz H. A global, multicenterphase II trial of lapatinib

plus capecitabine in gastric cancer. ASCO GI poster session. San Francisco, CA. 1/20-

22/11.

283. Mulcahy MF, Small Jr. W, Talamonti M, Obel JC, Rocha Lima CS, Safran H, Lenz

HJ, Chiorean EG, Link CJ. Effect of the addition of algenpantucel-L immunotherapy to

standard adjuvant therapy on survival in patients with resected pancreas cancer. ASCO

GI poster session. San Francisco, CA. 1/20-22/11.

284. Zhang W, Labonte MJ, Yang D, Ning Y, Gerger A, Bohanes PO, Winder T, El-

Khoueiry AB, Iqbal S, Lenz HJ. Use of genetic variants in formyl peptide receptor 2

(FPR2 to predict tumor recurrence in stage II colon cancer. ASCO GI poster session.

San Francisco, CA. 1/20-22/11.



285. Gerger A, Bohanes PO, Yang D, Winder T, Ning Y, Labonte MJ, Mauro DJ, Langer C,

Rowinsky EK, Lenz HJ. Human epidermal growth factor receptor-2 (HER2) Iie665Val

single nucleotide plymorphism (SNP) is associated with gender-specific outcome in

patients with metastatic colorectal cancer (mCRC)treated with cetuximab in a phase II

study (IMCL-0144. ASCO GI poster session. San Francisco, CA. 1/20-22/11.

286. Hardacre J, Mulcahy M, Talamonti M, Obel J, Rocha Lima C, Safran H, Lenz HJ,

Chiorean E, Vahanian N, Link CJ. Addition of algenpantucel-L immunotherapy to

standard adjuvant therapy may improve survival and disease free survival (DFS) in

resected pancreas cancer patients. ASCO GI poster session: A85, 2011.

287. Ning Y, LaBonte MJ, Zhang W, Bohanes P, Gerger A, Yang D, Lenz HJ. CXCR2

antagonist represses tumor cell metastasis and angiogenesis and is synergistic with

oxalilplatin in colorectal cancer cell line and xenograft models. In: Proceedings of the

102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-

6; Orlando, Florida. Philadelphia (PA): AACR;Abstract #2586.

288. Newman Em, Morgan RJ, Beumer JH, Blanchard SM, El-Khoueiry AB, Kummar S,

Carroll MI, Synold TW, Lenz HJ, Doroshow JH. Phase I and pharmacokinetic

evaluation of the DNA methyltransferase inhibitor 5-fluoro-2’deoxycytidine: A

California Cancer Consortium Study. In: Proceedings of the 102nd Annual Meeting of

the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida.

Philadelphia (PA): AACR;Abstract #1283.

289. Winder T, Giamas G, Zhang W, Yang D, Bohanes PO, Ning Y, Gerger A, Labonte MJ,

Stebbing J, Lenz H. Use of insulin-like growth factor (IGF) pathway polymorphism

IGF1R_rs2016347 to predict tumor recurrence in estrogen receptor–positive breast

cancer patients. In: Proceedings of the 47th Annual Meeting of the American Society of

Clinical Oncology; 2011 June 3-7; Chicago, Illinois: ASCO poster session;Abstract

#538.

290. Ning Y, Zhang W, Yang D, Weber D, Souami F, Bohanes PO, Gerger A, Labonte MJ,

Benhaim L, Lenz H. Analysis of polymorphisms in sodium channel, voltage-gated,

type I, alpha subunit (SCN1A) as predictors of clinical outcome and toxicity in

advanced ovarian cancer patients enrolled in a phase III trial treated with patupilone. In:

Proceedings of the 47th Annual Meeting of the American Society of Clinical Oncology;

2011 June 3-7; Chicago, Illinois: ASCO poster session;Abstract #5051.

291. El-Khoueiry AB, Iqbal S, Lenz HJ, Gitlitz BJ, Yang D, Cole S, Duddalwar V, Garcia

A. A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending

doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC).

In: Proceedings of the 47th Annual Meeting of the American Society of Clinical

Oncology; 2011 June 3-7; Chicago, Illinois: ASCO poster session;Abstract #4124.

292. Zurita AJ, Heymach J, Khajavi M, Tye L, Huang X, Kulke M, Lenz H, Meropol NJ,

Carley W, DePrimo SE, Harmon CS. Circulating protein and cellular biomarkers of

sunitinib in patients with advanced neuroendocrine tumors. In: Proceedings of the 47th

Annual Meeting of the American Society of Clinical Oncology; 2011 June 3-7;

Chicago, Illinois: ASCO poster session;Abstract #4079.



293. Iqbal S, Labonte MJ, Yang D, Zhang W, Bohanes PO, Ning Y, Benhaim L, El-

Khoueiry R, Wilson PM, Gerger A, El-Khoueiry AB, Lenz H. Polymorphisms in EGF

a+61G, GSTP1 Ile105Val, and MTHFR A1298C to predict response and survival in a

phase II study for patients with metastatic or unresectable gastric (G) or

gastroesophageal junction (GEJ) cancer treated with capecitabine, oxaliplatin

(XELOX), and cetuximab. In: Proceedings of the 47th Annual Meeting of the

American Society of Clinical Oncology; 2011 June 3-7; Chicago, Illinois: ASCO poster

session; Abstract #4121.

294. Labonte MJ, Yang D, Zhang W, Wilson PM, Gerger A, Bohanes PO, Ning Y, Benhaim

L, El-Khoueiry R, Nagarwala YM, Kemner AM, Pishvaian MJ, Hsieh RK, Gladkov O,

Urba S, Rha SY, Sakaeva D, Iqbal S, El-Khoueiry AB, Lenz H. Use of MTHFR

A1298C polymorphism to predict response in a phase II international clinical trial of

patients with advanced gastric (GC) or gastroesophageal junction (GEJ)

adenocarcinoma treated with first-line lapatinib plus capecitabine. In: Proceedings of

the 47th Annual Meeting of the American Society of Clinical Oncology; 2011 June 3-7;

Chicago, Illinois: ASCO poster session;Abstract # 4076.

295. Bohanes PO, Goldman BH, Leichman LP, Blanke CD, Iqbal S, Thomas CR, Corless

CL, Billingsley KG, Danenberg KD, Zhang W, Benedetti JK, Gold PJ, Lenz H.

Association of excision repair cross-complementation group 1 (ERCC1) gene

expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients

treated with preoperative platinum-based chemoradiation (CRT) in a phase II

cooperative group study (SWOG S0356). In: Proceedings of the 47th Annual Meeting

of the American Society of Clinical Oncology; 2011 June 3-7; Chicago, Illinois: ASCO

poster session; Abstract # 4023.

296. Lenz H, Ning Y, Zhang W, Yang D, Cole S, Agafitei RD, Menendez X, Cheng P, Iqbal

S, El-Khoueiry AB. Association of single-nucleotide polymorphisms (SNPs) in sodium

channel, voltage-gated, type I, alpha subunit (SCN1A) with toxicity in metastatic

colorectal cancer (mCRC) patients (pts) in a phase I study of patupilone (EPO906) and

celebrex (C). In: Proceedings of the 47th Annual Meeting of the American Society of

Clinical Oncology; 2011 June 3-7; Chicago, Illinois: ASCO; Abstract # e14039.

297. Zhang W, Yang D, Harbison C, Khambata-Ford S, Malone DP, Ning Y, Bohanes PO,

Gerger A, Labonte MJ, Benhaim L, El-Khoueiry AB, Iqbal S, Lenz H. FCGR2A

H131R and FCGR3A V158F polymorphism status in mCRC patients treated with

single-agent cetuximab (IMCL 0144 and CA225045) or with second-line irinotecan

plus cetuximab (EPIC): A pooled statistical analysis. In: Proceedings of the 47th


Chicago, Illinois: ASCO;Abstract #e14025.

298. Yang D, Benhaim L, Zhang W, Bohanes PO, Ning Y, Gerger A, Labonte MJ, Groshen

SG, El-Khoueiry AB, Iqbal S, Lenz H. Gender and cause-specific survival in patients

with stage III colon cancer: A SEER study. In: Proceedings of the 47th Annual Meeting

of the American Society of Clinical Oncology; 2011 June 3-7; Chicago, Illinois: ASCO;

Abstract #e14006.



299. Benhaim L, Gerger A, Zhang W, Yang D, Bohanes PO, Ning Y, Winder T, Labonte

MJ, Wilson PM, El-Khoueiry R, El-Khoueiry AB, Iqbal S, Lenz H. Cancer stem cell

gene variants associated with colon cancer recurrence. In: Proceedings of the 47th


Chicago, Illinois: ASCO poster session;Abstract #3612.

300. Ladner RD, Zhang W, Labonte MJ, Yang D, Ning Y, Gerger A, Bohanes PO, Winder

T, El-Khoueiry AB, Iqbal S, Petasis N, Lenz H. Prediction of tumor recurrence in stage

II colon cancer through genetic variants in formyl peptide receptor 2 (FPR2). In:


2011 June 3-7; Chicago, Illinois: ASCO poster session;Abstract #3604.

301. Gerger A, Zhang W, Yang D, Bohanes PO, Ning Y, Winder T, Labonte MJ, Wilson

PM, Benhaim L, El-Khoueiry R, Absenger G, El-Khoueiry AB, Iqbal S, Lenz H.

Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer

treated with first-line bevacizumab and oxaliplatin-based chemotherapy. In:


2011 June 3-7; Chicago, Illinois: ASCO poster session; Abstract #3592.

302. Lin EH, Lenz H, Saleh MN, Badarinath S, Knost JA, MacKenzie MJ, Polite BN,

Kavan P, Chen EX, Leichman LP, Pathiraja K, Lu KB; A fixed-sequence, open-label

study to determine the activity of SCH 717454 (robatumumab) as assessed by positron

emission tomography in patients with relapsed or recurrent colorectal cancer. In:


2011 June 3-7; Chicago, Illinois: ASCO poster session; Abstract #3584.

303. Wilson PM, Bohanes PO, Rankin CJ, Benedetti JK, Ulrich CM, Smalley SR, Makar

KW, Zhang W, Winder T, Ning Y, Gerger A, Benhaim L, El-Khoueiry R, Labonte MJ,

Blanke CD, Lenz H. The final results of the SWOG S9304 phase III intergroup trial’s

pharmacogenetic analysis: Association of polymorphisms with survival and toxicity in

stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU) and pelvic radiation

(RT). In: Proceedings of the 47th Annual Meeting of the American Society of Clinical

Oncology; 2011 June 3-7; Chicago, Illinois: ASCO poster session; Abstract #3542.

304. Sarantopoulos J, Lenz H, LoRusso P, Shibata S, Kummar S, Mulkerin D, Ramanathan

RK, Mita MM, O'Rourke P, Remick SC, Goel S, Gutierrez M, Ramalingam SS, Murgo

A, Davies AM, Mani S, Boni J, Shapiro M, Ivy SP, Takimoto CH. Phase I

pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced

malignancies and normal and impaired liver function: An NCI Organ Dysfunction

Working Group (ODWG) study. In: Proceedings of the 47th Annual Meeting of the

American Society of Clinical Oncology; 2011 June 3-7; Chicago, Illinois: ASCO poster

session; Abstract #3072.

305. Saif MW, Lichinitser M, Gordon MS, Tan BR, Scheulen ME, Pandya NB,

Sarantopoulos J, Rinehart JJ, Verschraegen CF, Lenz H, Zergebel C, Saito K. A phase

I study evaluating the pharmacokinetics of components of S-1 in pts with varying

degrees of renal function. In: Proceedings of the 47th Annual Meeting of the American

Society of Clinical Oncology; 2011 June 3-7; Chicago, Illinois: ASCO; Abstract

#e13089.



306. Kwak EL, Shapiro GI, Cohen SM, Becerra CR, Lenz HJ, Gooden S, Robohn M, Le-

Maulf F, Chand VK, Lafrate AJ. A Phase II trial of afatinib (BIBW 2992) in patients

with tumours prospectively creened for EGFR and/or HER2 gene amplification or

EGFR-activating mutations. In: Proceedings of the 2011 European Multidisciplinary

Cancer Congress; 2011 Sept 26; Stockholm, Sweden: ECCO/ESMO Poster Session

1.417.

307. Grothey A, Sobrero AF, Siena S, Falcone Ychou M, Lenz HJ, Yoshino T, Cihon F,

Wagner A, Van Cutsem E. Results of a phase III randomized, double-blind, placebo-

controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care

(BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer

(mCRC) who have progressed after standard therapies. 2012 Gastrointestinal Cancers

Symposium Poster Session C; Jan 19-21; San Francisco, CA; Abstract # LBA385.

308. Philip PA, Goldman BH, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, Iqbal

S, Gaur R, Benedetti JK, Blanke CD. Phase I randomized phase II trial of gemcitabine,

erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in

patients with metastatic pancreatic cancer (SWOG-0727). 2012 Gastrointestinal

Cancers Symposium Poster Session B;Jan 19-21; San Francisco, CA; Abstract #198.

309. Wakatsuki T, Bohanes PO, Zhang W, Gerger A, Yang D, Ning Y, Winder T, Labonte

MJ, Wilson P, Benhaim L, El-Khoueiry AB, Iqbal S, Giamas G, Stebbing J, Lenz HJ.

Use of genetic variants of LMTK3 to predict tumor recurrence in female localized

gastric adenocarcinoma. 2012 Gastrointestinal Cancers Symposium Poster Session

A;Jan 19-21; San Francisco, CA; Abstract #63.

310. Labonte MJ, Goldman BH, Zhang W, Blanke CD, Philip PA, Wong R, O'Reilly EM,

Benedetti JK, Lenz HJ. Use of EGF A61G polymorphism to predict overall survival in

a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with

locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205). 2012

Gastrointestinal Cancers Symposium Poster Session B;Jan 19-21;San Francisco;

Abstract #203.

311. Loupakis F, Zhang W, Gerger A, Yang D, Bohanes PO, Labonte MJ, Benhaim L,

Wakatsuki T, Ning Y, Wilson P, El-Khoueiry R, El-Khoueiry AB, Iqbal S, Barzi A,

Giamas G, Stebbing J, Lenz HJ. LMTK3 polymorphism in patients with metastatic

colon cancer. 2012 Gastrointestinal Cancers Symposium Poster Session C;Jan 19-21;

San Franscisco, CA; Abstract #471.

312. Zhang W, Gerger A, Labonte MJ, Yang D, Bohanes PO, Ning Y, Winder T, Wilson P,

Benhaim L, El-Khoueiry R, El-Khoueiry AB, Iqbal S, Giamas G, Stebbing J, Lenz HJ.

Association of gender-related tumor recurrence with a polymorphic variant of LMTK3

in stage II and III colon cancer. 2012 Gastrointestinal Cancers Symposium Poster

Session C;Jan 19-21; San Francisco, CA; Abstract #454.

313. Hobday TJ, Qin R, Reidy DL, Moore MJ, Strosberg JR, Kaubisch A, Shah MH,

Kindler HL, Lenz HJ, Chen HX, Erlichman C. Multicenter phase II trial of

temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor

(PNET). 2012 Gastrointestinal Cancers Symposium Poster Session B;Jan 19-21; San

Francsico, CA; Abstract #260.



314. Giamas G, Zhang H, Zhang W, Filipovic A, Lenz HJ, Stebbing J. Identification of

noval kinases involved in Estrogen receptor-a (Era) signalling and the development of

endocrine resistance in breast cancer. In: Proceedings of the 103rd Annual Meeting of

the American Association for Cancer Research; 2012 March 31 – April 4; Chicago, IL:

AACR;Abstract #64.

315. Zhang H, Paez D, Giamas G, Filipovic A, Yang D, Bohanes P, Ning Y, Gerger A,

Labonte MJ, Stebbing J, Lenz HJ. Genetic variants in human epidermal growth factor

receptor (HER) family gene predict tumor recurrence in breast cancer. In: Proceedings

of the 103rd Annual Meeting of the American Association for Cancer Research; 2012

March 31 – April 4; Chicago, IL: AACR poster session;Abstract #2670.

316. Skinner E, Goldman B, Sakr W, Petrylak P, Lenz H, Lee CT, Wilson SS, Lerner SP,

Tangen CM, Thompson IM. SWOG S0353: Phase II trial of inductionplus 1 year

monthly maintenance intravesicle gemcitabine for paitens with recurrence following 2

prior courses of BCG. American Urological Association Annual Meeting;May 19-23,

2012.

317. Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O,

Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM,

Sargent DJ, Cihon F, Wagner A, Laurent D, Grothey A. Phase III CORRECT trial of

regorafenib in metastatic colorectal cancer (mCRC). In: Proceedings of the 48th Annual

Meeting of the American Society of Clinical Oncology; 2012 June 1 - 5; Chicago,

Illinois: ASCO; Abstract #3502.

318. Sarantopoulos J, Hoering A, Synold TW, Mahalingam D, Wang D, Lenz HJ, O'Rourke

P, Sexton R, Van Veldhuizen PJ, Mita MM, Wong L, Mita AC, El-Khoueiry AB,

Chung VM, Gandara DR, Tejwani S, Takebe N, Takimoto CHM, Ivy SP, Kurzrock R.

Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced

malignancies and varying levels of liver dysfunction: S0711, a SWOG early

therapeutics committee study. In: Proceedings of the 48th Annual Meeting of the

American Society of Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO

poster Session; Abstract #3078.

319. El-Khoueiry AB, Rankin CJ, Iqbal S, Micetich KC, Kayaleh O, Lenz HJ, Blanke CD.

SWOG 0941: A phase II study of sorafenib and erlotinib in patients (pts) with advanced

gallbladder cancer or cholangiocarcinoma. In: Proceedings of the 48th Annual Meeting

of the American Society of Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois:

ASCO poster session; Abstract #4049.

320. Philip PA, Goldman BH, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, Iqbal

S, Gaur R, Benedetti JK, Blanke CD. Dual blockade of epidermal growth factor

receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in

metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine,

erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727). In:


2012 June 1 - 5; Chicago, Illinois: ASCO poster session; Abstract #4019.



321. Catenacci DVT, Bahary N, Edelman MJ, Nattam SR, de Wilton Marsh R, Kaubisch A,

Wallace JA, Cohen DJ, Stiff PJ, Sleckman BG, Thomas SP, Lenz HJ, Henderson L,

Zagaya C, Vannier M, Karrison T, Stadler WM, Kindler HL. A phase IB/randomized

phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh)

pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim

analysis of a University of Chicago phase II consortium study. In: Proceedings of the

48th Annual Meeting of the American Society of Clinical Oncology; 2012 June 1 - 5;

Chicago, Illinois: ASCO poster session; Abstract #4022.

322. Hardacre JM, Mulcahy MF, Small W, Talamonti MS, Obel JC, Rocha Lima CMS,

Safran H, Lenz HJ, Chiorean EG, Vahanian NN, Link CJ. Addition of algenpantucel-L

immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer. In:


2012 June 1 - 5; Chicago, Illinois: ASCO poster session; Abstract #4049.

323. Hobday TJ, Qin R, Reidy DL, Moore MJ, Strosberg JR, Kaubisch A, Shah MH,

Kindler HL, Lenz HJ, Chen H, Erlichman C. Multicenter phase II trial of temsirolimus

(TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results

of a planned interim efficacy analysis. In: Proceedings of the 48th Annual Meeting of

the American Society of Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO

poster session; Abstract #4047.

324. Genyk Y, Matsuoka L, El-Khoueiry AB, Iqbal S, Buxbaum J, Selby R, Vandam J,

Lenz HJ. R0 resection of locally advanced pancreatic cancer encasing major visceral

arteries using arterial reconstruction: Short- and long-term results. In: Proceedings of

the 48th Annual Meeting of the American Society of Clinical Oncology; 2012 June 1 -

5; Chicago, Illinois: ASCO; Abstract #e14679.

325. Gordon MA, Gundacker H, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke

CD, Elatre W, Weng P, Lenz HJ, Press MF. Assessment of HER2 gene amplification

in adenocarcinomas of the stomach or gastroesophageal junction in the INT-

0116/SWOG9008 clinical trial. In: Proceedings of the 48th Annual Meeting of the

American Society of Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO

poster session; Abstract #4010.

326. Wakatsuki T, Zhang W, Yang D, Loupakis F, Azuma M, Gerger A, Graziano F, Ning

Y, Labonte MJ, El-Khoueiry R, Bohanes PO, Benhaim L, Páez D, Watanabe M,

Koizumi W, Lenz HJ. Ethnic gene profile of genes involved in angiogenesis to predict

regional bevacizumab efficacy difference in gastric cancer. In: Proceedings of the 48th

Annual Meeting of the American Society of Clinical Oncology; 2012 June 1 - 5;

Chicago, Illinois: ASCO poster session; Abstract #4026.

327. Cremolini C, Loupakis F, Yang D, Salvatore L, Zhang W, Wakatsuki T, Schirripa M,

Lonardi S, Antoniotti C, Aprile G, Masi G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni

M, Maus MKH, Bocci G, Tonini G, Falcone A, Lenz HJ. Prospective evaluation of

candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC)

patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV). In: Proceedings

of the 48th Annual Meeting of the American Society of Clinical Oncology; 2012 June 1

- 5; Chicago, Illinois: ASCO poster session; Abstract #3518.



328. Iqbal S, El-Khoueiry AB, Yang D, Páez D, Duddalwar V, Zhang W, Agafitei RD,

Lujan R, Cole S, Ning Y, El-Khoueiry R, Loupakis F, Wakatsuki T, Lenz HJ. A phase

II study of capecitabine-oxaliplatin and cetuximab in patients (pts) with

advanced/metastatic gastric cancer (G) or gastroesophageal junction (GEJ)

adenocarcinoma. In: Proceedings of the 48th Annual Meeting of the American Society

of Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO poster session; Abstract

#4096.

329. Barzi A, Wakatsuki T, Zhang W, Yang D, Loupakis F, Ning Y, El-Khoueiry R,

Labonte MJ, Azuma M, Bohanes PO, Benhaim PO, Gerger A, Koizumi W, Watanabe

M, Stebbing J, Giamas G, Lenz HJ. Prognostic value of lemur tyrosine kinase-3

(LMTK3) polymorphism in Japanese (J) patients (PTS) with localized gastric

adenocarcinoma (GAC). In: Proceedings of the 48th Annual Meeting of the American

Society of Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO poster session;

Abstract #4088.

330. Zhang W, Benhaim L, Yang D, Gerger A, Bohanes PO, Páez D, Loupakis F, Wakatsuki

T, Labonte MJ, Ning Y, El-Khoueiry R, Zhang H, Stebbing J, Giamas G, Lenz HJ.

Genetic variants of kinases suppressors of ras (KSR1) to predict survival in patients

with ER-alpha positive metastatic breast cancer. In: Proceedings of the 48th Annual

Meeting of the American Society of Clinical Oncology; 2012 June 1 - 5; Chicago,

Illinois: ASCO; Abstract #e11018.

331. Páez D, Labonte MJ, Paré L, Yang D, Bohanes PO, Gerger A, Zhang W, Benhaim L,

Ning Y, Wakatsuki T, Loupakis F, Lenz HJ. Use of leucine-rich and immunoglobulin-

like domains germ-line polymorphisms to predict clinical outcome in metastatic

colorectal cancer. In: Proceedings of the 48th Annual Meeting of the American Society

of Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO; Abstract #e14052.

332. Ning Y, Winder T, Zhang W, Yang D, Loupakis F, Wakatsuki T, Bohanes PO, EI-

Khoueiry R, Barzi A, Iqbal S, EI-Khoueiry AB, Lenz HJ. Association of genetic

variants in plastin family genes with tumor recurrence in stage II/III colon cancer. In:


2012 June 1 - 5; Chicago, Illinois: ASCO; Abstract # e14031.

333. Wilson P, Páez D, Gerger A, Zhang W,Yang D, Labonte MJ, Benhaim L, Bohanes PO,

Ning Y,Wakatsuki T, Loupakis F, Lenz HJ. Use of germ-line variants in the WNT/β-

CATENIN pathway to predict tumor recurrence in adjuvant colon cancer. In:


2012 June 1 - 5; Chicago, Illinois: ASCO; Abstract # e14034.

334. Loupakis F, Yang D, Zhang W, Cremolini C, Wakatsuki T, Salvatore L, Antoniotti C,

Aprile G, Schirripa M, Ricci V, Lucchesi S, Masi G, Maus MKH, Lonardi S, Ning Y,

El-Khoueiry R, Falcone A, Lenz HJ. Primary side of origin affects the outcome of

mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of

BRAF status and mucinous histology. In: Proceedings of the 48th Annual Meeting of





335. Antoniotti C, Loupakis F, Cremolini C, Zhang W,Yang D, Wakatsuki T, Schirripa M,

Salvatore L, Ricci V, Graziano F, Masi G, Ruzzo A, Labonte MJ, Ning Y, El-Khoueiry

R, Falcone A, Lenz HJ. Prospective study of EGFR intron 1 CA tandem repeats to

predict factor benefit from cetuximab and irinotecan. In: Proceedings of the 48th


Chicago, Illinois: ASCO poster session; Abstract # 3540.

336. Yang D, Bohanes PO, Zhang W, Harbison C, Trifan OC, Ning Y, Benhaim L,

Wakatsuki T, El-Khoueiry AB, Lenz HJ. Association of HER2 and IGF1 germline

polymorphisms with outcome in metastatic colorectal cancer (mCRC) patients (pts)

treated with second-line irinotecan (IR) with or without cetuximab (CB): The EPIC

experience. In: Proceedings of the 48th Annual Meeting of the American Society of

Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO poster session; Abstract #

3615.

337. Labonte MJ, Bohanes PO, Yang D, Loupakis F, Wilson P, Gerger A, Ning

Y,Wakatsuki T, Zhang W, Benhaim L, Ladner RD, El-Khoueiry AB, El-Khoueiry R,

Iqbal S, Lenz HJ. Novel colon cancer tumor suppressor gene, β-defensin 1, to predict

recurrence in patients with stage II and III colon cancer. In: Proceedings of the 48th


Chicago, Illinois: ASCO poster session; Abstract # 3622.

338. Schirripa M, Loupakis F, Cremolini C, Yang D, Labonte MJ, Zhang W, Salvatore L,

Wakatsuki T, El-Khoueiry R, Antoniotti C, Aprile G, Maus MKH, Lucchesi S,

Allegrini G, Vita FD, Zhang H, Giamas G, Stebbing J, Falcone A, Lenz HJ. KSR1

gene polymorphism in mCRC patients treated with first-line FOLFIRI and

bevacizumab. In: Proceedings of the 48th Annual Meeting of the American Society of

Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO poster session; Abstract #

3546.

339. Thomas SP, Badarinath S, Greenberg RH, Huh SY, Sivarajan KM, Feng S, Scherer S,

Curry CL, Langer C, Lenz HJ. MAVERICC: A randomized phase II study of

mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker

stratification in previously untreated metastatic colorectal cancer (mCRC). In:


2012 June 1 - 5; Chicago, Illinois: ASCO poster session; Abstract # TPS3635.

340. Ladner RD, Gerger A, Zhang W, Labonte MJ, Yang D, Lenz F, Lenz C, Bohanes PO,

Ning Y,Winder T, Wilson P, Benhaim L, El-Khoueiry R, El-Khoueiry AB, Iqbal S,

Lenz HJ. Association of genetic variants in obesity-related genes with tumor

recurrence in stage II/III colon cancer. In: Proceedings of the 48th Annual Meeting of



341. Bohanes PO, Yang D, Loupakis F, Labonte MJ, Gerger A, Ning Y,Wakatsuki T, Zhang

W, Benhaim L, Páez D, El-Khoueiry AB, El-Khoueiry R, Lenz HJ. Integrin genetic

variants and stage-specific tumor recurrence in patients with stage II and III colon

cancer. In: Proceedings of the 48th Annual Meeting of the American Society of Clinical

Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO poster session; Abstract # 3604.



342. Benhaim L, Loupakis F, Zhang W, Gerger A, Bohanes PO, Páez D, Cremolini C,

Wakatsuki T, Yang D, Ning Y, El-Khoueiry R, Zhang H, Salvatore L, Schirripa M,

Falcone A, Giamas G, Stebbing J, Lenz HJ. Genetic variants of kinases suppressors of

ras in KRAS-BRAF wild-type metastatic colorectal cancer patients treated with

cetuximab and irinotecan. In: Proceedings of the 48th Annual Meeting of the American

Society of Clinical Oncology; 2012 June 1 - 5; Chicago, Illinois: ASCO poster session;

Abstract # 3597.

343. Sobrero A, Grothey A, Van Cutsem E, Siena S, Falcone A, Ychou M, Humblet Y,

Bouche O, Mineur L, Barone C, Adenis A, Ternero J, Yoshino T, Lenz HJ, Goldberg

R, Sargent D, Cihon F Jeffers M, Wagner A, Laurent D. Phase 3 CORRECT trial of

regorafenib in metastatic colorectal cancer (MCRC). In: Proceeedings of the

International Symposium: 14th World Congress on GI Cancer. 2012 June 27-30;

Barcelona, Spian: ESMO oral session; Annuals of Oncology 23;(4).Abstract# 0 -0023.

344. Cremolini C, Loupakis F, Yang D, Salvatore L, Zhang W, Wakatsuky T, Schirripa M,

Lonardi S, Antoniotti C, Aprile G, Masi G, Graziano F, Ruzzo A, Lucchesi S, Maus M

Bocci G, Falcone A, Lenz HJ. In: Proceeedings of the International Symposium: 14th

World Congress on GI Cancer. 2012 June 27-30; Barcelona, Spain: ESMO poster

session; Annuals of Oncology 23;(4).Abstract# P-0262.

345. Antoniotti C, Loupakis F, Cremolini C, Zhang W, Yang D, Wakatsuky T, Schirripa M,

Salvatore L, Ricci V, Graziano F, Masi G, Labonte MJ, Ning Y, Falcone A, Lenz HJ.

Prospective study of EGFR Intron 1 CA Tandem repeats as predictive factor of benefit

from cetuximab and irinotecan. In: Proceeedings of the International Symposium: 14th

World Congress on GI Cancer. 2012 June 27-30; Barcelona, Spain: ESMO poster

session; Annuals of Oncology 23;(4).Abstract# P-0263.

346. Loupakis F, Yang D, Feng S, Cremolini C, Zhang W, Antoniotti C, Langer C, Hurwitz

H, Saltz L, Falcone A, Lenz HJ. Premary Tumor location is a major independent

prognostic factor for MCRC patients. In: Proceeedings of the International Symposium:

14th World Congress on GI Cancer. 2012 June 27-30; Barcelona, Spain: ESMO poster

discussions; Annuals of Oncology 23;(4).Abstract# PD-0009.

347. Schirripa M, Loupakis F, Cremolini C, Dongyun Y, Labonte MJ, Zhang W, Salvatore

L, Wakatsuky T, Antoniotti C, Aprile G, Lucchesi S, Giamas G, Stebbing J, Falcone A,

Lenz HJ. KSR1 gele polymorphism in MCRC patients treated with first-line folfiri and

bevacizumab. In: Proceedings of the International Symposium: 14th World Congress on

GI Cancer. 2012 June 27-30; Barcelona, Spain: ESMO poster discussions; Annuals of

Oncology 23;(4).Abstract# PD-0015.

348. Yoshino T, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Lenz HJ,

Cihon F, Wagner W, Grothey A. Results of a phase III randomized, double-blind,

placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive

care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer

(mCRC) who have progressed after standard therapies. 2012 July 26-28; Osaka, Japan:

Plenary Session Discussant; The 10th Annual Meeting of JSMO; Abstract# PLS-4.

349. Lenz HJ. Personalized Treatment Options for Patients with Colorectal Cancer. In:

Proceedings of the 40th ISOBM Congress. 2012October 13-17; Jerusalem, Israel: Oral

session. Tumor Biol;33(Suppl 1):S15-S80,O13.4. Abstract#289.



350. Benhaim L, Gerger A, Bohanes PO, Paez D, Wakatsuki T, Yang D, Labonte MJ, Wu z,

Ning Y, Loupakis F, El-Khoueiry R, Laurent-Puig P, Lenz H-J. Gender specific

profiling in SCN1A polymorphisms and time to recurrence in patients with stage II/III

colorectal cancer. 2013 Gastrointestinal Cancers Symposium Poster Session A;Jan 19-

21; San Francisco, CA; Suppl 34;Abstract #393.

351. Starodub A, Thomas SP, Lee F, Harish V, Koh HA, Mitchell EP, Mandanas RA, Huh

SY, Badarinath S, Mittan A, Leon L, Vogt T, Langer C, Lenz HJ. Biomarker

distribution and characteristics for the first 100 patients in MAVERICC, a randomized

phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV in previously

untreated metastatic colorectal cancer (mCRC). 2013 Gastrointestinal Cancers

Symposium Poster Session A;Jan 19-21; San Francisco, CA; Suppl 34;Abstract #483.

352. Jeffers M, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y,


Goldberg RM, Sargent D, Cihon F, Wagner A, Laurent D, Grothey A. Mutational

analysis of biomarker samples from the CORRECT study: Correlating mutation status

with clinical response to regorafenib. 2013 Gastrointestinal Cancers Symposium Poster

Session A;Jan 19-21; San Francisco, CA; Suppl 34;Abstract #381.

353. Wakatsuki T, Paez D, Labonte MJ, Yang D, Azuma M, Ning Y, Volz N, Stintzing S,

Bohanes PO, El-Khoueiry R, Koizumi W, Watanabe M, Lenz HJ. Association between

genetic variations involved in tumor dormancy related genes and clinical outcomes in

Japanese patients with gastric cancer. 2013 Gastrointestinal Cancers Symposium Poster

Session A;Jan 19-21; San Francisco, CA; Suppl 34;Abstract #43.

354. Barzi A, Shabihkhani M, Yu S, Yang D, Ji L, Lenz HJ. Racial disparities and the

outcome of metastatic (met) colorectal cancer (CRC). 2013 Gastrointestinal Cancers

Symposium Poster Session A;Jan 19-21; San Francisco, CA; Suppl 34;Abstract #373.

355. Genyk Y, Barzi A, El-Khoueiry AB, Matsuoka L, Sutton V, Buxbaum J, Iqbal S, Van

Dam J, Selby R, Lenz HJ. The feasibility of R0 resection of locally advanced

pancreatic cancer (LAPC) encasing major visceral arteries (T4 lesions) using arterial

resection and reconstruction: Short- and long-term outcomes. 2013 Gastrointestinal

Cancers Symposium Poster Session A;Jan 19-21; San Francisco, CA; Suppl 34;Abstract

#243.

356. Grothey A, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y,


Goldberg RM, Sargent DJ, Cihon F, Wagner A Laurent D, Cupit L. Time course of

regorafenib-associated adverse events in the phase III CORRECT study. 2013

Gastrointestinal Cancers Symposium Poster Session A;Jan 19-21; San Francisco, CA;

Suppl 34;Abstract #467.

357. Maus MKH, Stephens C, Astrow AH, Grimminger PP, Yang D, Loupakis F, Hsiang J,

Zeger G, Huang X, Lenz HJ. Correlation of messenger RNA expression patterns of

ERCC1, TS, EGFR, and VEGFR2 with KRAS and BRAF mutational status in

advanced colorectal cancer: Implications for targeted therapies. 2013 Gastrointestinal


#383.



358. Yang D, Usher J, LoCoco J, Pritesh C, Lenz HJ, El-Khoueiry AB. Impact of gender on

survival of patients (pts) with hepatocellular carcinoma (HCC): SEER analysis. In:


2013 May 31 - June 4; Chicago, Illinois: ASCO poster session; Abstract # 4128.

359. Shabihkhani M, Yu S, Yang D, Lenz HJ, Barzi A. Hispanic race and outcome of

metastatic (MET) colorectal cancer (CRC): Biology or health care (HC) setting? In:


2013 May 31 – June 4; Chicago, Illinois: ASCO poster session; Abstract # e17559.

360. El-Khoueiry AB, Ning Y, Yang D, Cole S, Kahn M, Zoghbi M, Berg J, Fujmori M,

Inada T, Kouji H, Lenz HJ. A phase I first-in-human study of PRI-724 in patients (pts)

with advanced solid tumors. In: Proceedings of the 49th Annual Meeting of the

American Society of Clinical Oncology; 2013 May 31 – June 4; Chicago, Illinois:

ASCO oral session; Abstract # 2501.

361. Zhang W, Ning Y, Yang D, Wakatsuki T, Stintzing S, Volz NB, Li JE, Labonte MJ, El-

Khoueiry RE, Barzi A, El-Khoueiry AB, Kahn M, Lenz HJ. Prediction of tumor

recurrence by tumor location in stage II and III colon cancer patients through common

germ-line variants of genes involved in wnt signaling pathway. In: Proceedings of the

49th Annual Meeting of the American Society of Clinical Oncology; 2013 May 31 –

June 4; Chicago, Illinois: ASCO Abstract # e14714.

362. Ladner RD, Kahn M, Stintzing S, Zhang W, Wakatsuki T, Ning Y, Volz NB, Labonte

MJ, Wilson PMD, Kardosh A, Lenz HJ. Risk of tumor-related death in stage I-II colon

based on gender and tumor location. In: Proceedings of the 49th Annual Meeting of the


ASCO Abstract # e14538.

363. Bokemeyer C, Kohne C, Bondarenko I, Heydebreck A, Grote HJ, Stroh C, Lenz HJ.

Treatment outcome according to tumor ERCC1 expression status in OPUS study

patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4

with/without cetuximab. In: Proceedings of the 49th Annual Meeting of the American

Society of Clinical Oncology; 2013 May 31 – June 4; Chicago, Illinois: ASCO Abstract

# 3537.

364. Schultheis AM,Volz NB, Zhang W, Yang D, Ning Y, Stintzing S,Wakatsuki T, El-

Khoueiry RE, Li JE, Kardosh A, Barzi A, El-Khoueiry AB, Lenz HJ. Use of genetic

variants in immune response genes to predict clinical outcome in mCRC patients

treated with cetuximab-based therapy. In: Proceedings of the 49th Annual Meeting of

the American Society of Clinical Oncology; 2013 May 31 – June 4; Chicago, Illinois:

ASCO Abstract # 3567.

365. Semrad TJ, Lenz HJ, Gong I-Y, Tanaka MS, Eddings C, Mahaffey N, Mack PC,

Beckett L, Lara P. Pharmacodynamic separation (PDS) of gemcitabine (Gem) and the

epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (Pts) with

advanced pancreatic cancer: Phase II results. In: Proceedings of the 49th Annual

Meeting of the American Society of Clinical Oncology; 2013 May 31 – June 4;

Chicago, Illinois: ASCO Abstract # e15073.

366. Barzi A, Directo M, Dasu S, Lenz HJ, Sadeghi S. Saving lives and costs through

screening (Sc) for colorectal cancer (CRC): Implications for limited-resource healthcare

systems (LRHS). In: Proceedings of the 49th Annual Meeting of the American Society

of Clinical Oncology; 2013 May 31 – June 4; Chicago, Illinois: ASCO Abstract # 6545.



367. Luu TH, Frankel PH, Lim D, Cristea MC, Beumer JH, Appleman LJ, Lenz HJ,

Gandara DR, Piekarz R, Newman EM. Phi-53: (NCI#7251): Phase I trial of belinostat

(PXD101) in combination with 13-cis-retinoic acid (13c-RA) in advanced solid tumor

malignancies—A California Cancer Consortium NCI/CTEP sponsored trial. In:


2013 May 31 – June 4; Chicago, Illinois: ASCO Abstract # 2526.

368. Li JE, Zhang W, Loupakis F, Yang D, Wakatsuki T, Ning Y, Stintzing S, El-Khoueiry

RE, Volz NB, Marmorino F, Schirripa M, Salvatore L, Antoniotti C, Cremolini C,

Lenz HJ. EGFL7 polymorphism to predict tumor response in metastatic colorectal

cancer (mCRC) patients (pts) treated with FOLFIRI and bevacizumab (BV). In:



369. Stintzing S, Zhang W, Wakatsuki T, Ning Y, Volz NB, Li JE, Labonte MJ, Wilson P,

Kardosh A, Loupakis F, Salvatore L, Schirripa M, Lenz HJ. Genes involved in EGFR-

degradation to predict for efficacy in metastatic colorectal cancer patients treated with

cetuximab. In: Proceedings of the 49th Annual Meeting of the American Society of

Clinical Oncology; 2013 May 31 – June 4; Chicago, Illinois: ASCO Abstract # 3557.

370. Naughton MJ, Schrag D, Venook AP, Niedzwiecki D, Anderson RT, Lenz HJ, Grubbs

SS. Quality of life (QOL) and toxicity among patients in CALGB 80405. In:



371. Volz NB, Zhang W, Yang D, Ning Y, Stintzing S, Wakatsuki T, El-Khoueiry RE, Li

JE, Kardosh A, Loupakis F, Marmorino F, Antoniotti C, Lenz HJ. Use of genetic

variants in pericyte-driven tumor vessel maturation genes to predict treatment efficacy

in mCRC patients treated with FOLFIRI/bevacizumab. In: Proceedings of the 49th

Annual Meeting of the American Society of Clinical Oncology; 2013 May 31 – June 4;

Chicago, Illinois: ASCO Abstract # 3566.

372. Ning Y, Zhang W, Yang D, Loupakis F, Wakatsuki T, Stintzing S, Volz NB, Li JE, El-

Khoueiry RE, Labonte MJ, Cremolini C, Marmorino F, Barzi A, El-Khoueiry AB,

Lenz HJ, Kahn M. Use of genetic variants in wnt signaling pathway to predict gender

and tumor location dependent survival in metastatic colorectal cancer (mCRC) patients

(pts) treated with first-line FOLFIRI and bevacizumab (BEV). In: Proceedings of the


June 4; Chicago, Illinois: ASCO Abstract # 3568.

373. Hanna DL, Maus MKH, Stephens C, Grimminger PP, Astrow SH, Yang D, Loupakis F,

Hsiang J, Zeger G, Barzi A, Lenz HJ. Correlation of ERCC1 mRNA expression with

KRAS mutation status in colorectal, pancreatic, and lung adenocarcinoma. In:



374. Koczywas M, Lenz HJ, Mortimer JE, El-Khoueiry AB, Frankel PH, Gandara DR,

Cristea MC, Chung VM, Lim D, Reckamp DL, Lau DHM,Ye W, Doyle AL, Carroll

MI, Newman EM. PHI-55: (NCI#7427): A phase I study of halichondrin B analog

(E7389) in combination with cisplatin (CDDP) in advanced solid tumors: A CCC,

NCI/CTEP-sponsored trial (grant U01 CA 062505). In: Proceedings of the 49th Annual





375. Rossi GR, Hardacre JH, Mulcahy MF, Talamonti MS, Obel JC, Rocha Lima CMS,

Safran H, Lenz HJ, Chiorean EG,Vahanian NN, Link CJ. Effect of algenpantucel-L

immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and

correlation with improved overall survival. In: Proceedings of the 49th Annual Meeting

of the American Society of Clinical Oncology; 2013 May 31 – June 4; Chicago,

Illinois: ASCO Abstract # 3007.

376. Wilson P, Wakatsuki T, Loupakis F, Zhang W, Yang D, Stintzing S, Ning Y, Volz NB,

El-Khoueiry RE, Li JE, Labonte MJ, Sunakawa Y, Maus MKH, Ladner RD, Barzi A,

Iqbal S, El-Khoueiry AB, Lenz HJ. Association of a polymorphism in amphiregulin

with worse prognosis in metastatic colorectal cancer patients treated with cetuximab.


Oncology; 2013 May 31 – June 4; Chicago, Illinois: ASCO Abstract # e14543.

377. Maus MKH, Hanna DL, Stephens C, Grimminger PP, Epstein M, Astrow SH, Yang D,

Loupakis F, Hsiang J, Zeger G, Wakatsuki T, Barzi A, Lenz HJ. Gene expression

profiles and tumor locations in colorectal cancer (left vs. right vs. rectum). In:



378. Hobday TJ, Qin R, Moore MJ, Reidy DL, Strosberg JR, Kindler HL, Shah MH, Lenz

HJ, Kaubisch A, Chen HX, Erlichman C. Multicenter phase II trial of temsirolimus

(TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). In:



379. Hochster HS, Messersmith WA, O'Neil BH, Groshen SG, Lenz HJ, Cohen DJ,

Denlinger CS, Gold PJ, Eckhardt SG, Locker GY, Ames P, McKinley M, Leichman

LP. The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan

(IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer

(CRC). In: Proceedings of the 49th Annual Meeting of the American Society of


380. Iqbal S, Wakatsuki T, Bohanes PO, Zhang W, Gerger A, Azuma M, Stotz M, Yang D,

Ning Y, Volz NB, Stintzing S, El-Khoueiry RE, Labonte MJ, Li JE, Maus MKH,

Koizumi W, Watanabe M, Barzi A, Lenz HJ, El-Khoueiry AB. Iiteglinα4 (ITGα4)

rs7562325 polymorphism was associated with better survivals in Austrian but not in

Japanese patients with gastric cancer. In: Proceedings of the 49th Annual Meeting of



381. Wakatsuki T, Zhang W, Yang D, Azuma M, Ning Y, Volz NB, Stintzing S, El-

Khoueiry RE, Li JE, Wilson P, Labonte MJ, Maus MKH, Sunakawa Y, Koizumi W,

Watanabe M, Iqbal S, Barzi A, El-Khoueiry AB, Shah MA, Lenz HJ. Association of

AREG exon 1 polymorphism with worse prognosis in Japanese and U.S. patients with

gastric cancer. In: Proceedings of the 49th Annual Meeting of the American Society of

Clinical Oncology; 2013 May 31 – June 4; Chicago, Illinois: ASCO Abstract # e15022.



382. El-Khoueiry RE, Wakatsuki T, Ning Y, Zhang W, Yang D, Azuma M, Gerger A, Stotz

M, Labonte MJ, Wilson P, Volz NB, Stintzing S, Maus MKH, Sunakawa Y, Koizumi

W, Watanabe M, Li JE, Barzi A, El-Khoueiry AB, Lenz HJ. Association of

transcription factor 7-like 2 (TCF7L2) polymorphisms with worse survival in three

independent cohorts from the United States, Austria, and Japan in patients with gastric

cancer. In: Proceedings of the 49th Annual Meeting of the American Society of Clinical

Oncology; 2013 May 31 – June 4; Chicago, Illinois: ASCO Abstract # 4111.

383. Labonte MJ, Wakatsuki T, Zhang W, Yang D, Azuma M, Gerger A, Stotz M, Ning Y,

Volz NB, Stintzing S, Li JE, El-Khoueiry RE, Wilson P, Koizumi W, Watanabe M,

Maus MKH, Barzi A, Iqbal S, El-Khoueiry AB, Lenz HJ. Prognostic outcome of

gastric cancer patients with cancer stem cell SNPs in Asian versus western countries.


Oncology; 2013 May 31 – June 4; Chicago, Illinois: ASCO Abstract # 4110.

384. Catenacci DVT, Bahary N, Nattam SR, De Wilton Marsh R, Wallace JA, Rajdev L,

Cohen DJ, Sleckman BJ, Lenz HJ, Stiff PJ, Thomas SP, Xu P, Henderson L, Horiba

MN, Vannier M, Karrison T, Stadler WM, Kindler HL. Final analysis of a phase

IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a

hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer

(PC): A University of Chicago phase II consortium study. In: Proceedings of the 49th



385. Lenz HJ, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y,

Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Goldberg RM,

Sargent DJ, Cihon F, Wagner A, Laurent D, Jeffers M, Grothey A. Analysis of plasma

protein biomarkers from the CORRECT phase III study of regorafenib for metastatic

colorectal cancer. . In: Proceedings of the 49th Annual Meeting of the American


# 3514.

386. Van Cutsem E, Sobrero A, Siena S, Falcone A,Ychou M, Humblet Y, Bouche O,

Mineur Barone L,C , Adenis A, Argilés G, Yoshino T, Lenz HJ, Goldberg RM,

Sargent DJ, Cihon F, Wagner A, Laurent D, Cupit L, Grothey A. Regorafenib (REG) in

progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the

phase III CORRECT trial. In: Proceedings of the 49th Annual Meeting of the American


# 3636.

387. Grothey A, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur

L, Barone C, Adenis A, Argiles G, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ,

Cihon F, Wagner A, Cupit L, Laurent D, Van Cutsem E. Time profile of adverse events

(AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in

the phase III CORRECT study. In: Proceedings of the 49th Annual Meeting of the



388. Prager G, Schuler A, Ay C, Pausz C, Lenz HJ, Pabinger I, Zielinski C. Integrin genetic

variants and risk of thromboembolic events in patients with colorectal cancer. 2014

Gastrointestinal Cancers Symposium Poster Session A;Jan 16-18; San Francisco, CA;

Suppl 3;Abstract # 462.



389. Ciardiello F, Lenz HJ, Kohne CH, Heinemann V, Tejpar , Esser R, Beier F, Stroh C,

Duecker K, Van Cutsem E. Effect of KRAS and NRAS mutational status on first-line

treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer

(mCRC): New results from the CRYSTAL trial. 2014 Gastrointestinal Cancers

Symposium Poster Session A;Jan 16-18; San Francisco, CA; Suppl 3;Abstract #

LBA443.

390. Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y,

Sunakawa Y, Shinichi Y, Sebio A, El-Khoueiry RE, Bimer P, Preusser M, Lenz HJ.

Influence of genetic variants of genes potentially associated with colorectal brain

metastases on overall survival. 2014 Gastrointestinal Cancers Symposium Poster

Session A;Jan 16-18; San Francisco, CA; Suppl 3;Abstract # 487.

391. Barzi A, Stern MC, Zhang J, Lenz HJ, Iqbal S, Liu L. Gastric Cancer (GC) in

California Cancer Registry (CCR): One disease, many faces. 2014 Gastrointestinal


# 30.

392. Sunakawa Y, Wakatuki T, Zhang W, Yang D, Azuma M, Ning Y, Stintzing S,

Stremitzer S, Yamauchi S, Sebio A, Volz NB, El-Khoueiry R, Koizumi W, Watanabe

M, Lenz HJ. Use of genetic variants in c-MET to predict clinical outcome in localized

gastric cancer (GC) patients (pts) treated with surgery. 2014 Gastrointestinal Cancers

Symposium Poster Session A;Jan 16-18; San Francisco, CA; Suppl 3;Abstract # 50.

393. El-Khoueiry AB, O’Donnell R, Mack PC, Blanchard S, Bahary N, Jiang Y, Yen Y,

Wright JJ, Chen H, Lenz HJ, Gandara DR. A phase I trial of cixutumumab (C) (IMC-

A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).

2014 Gastrointestinal Cancers Symposium Poster Session A;Jan 16-18; San Francisco,

CA; Suppl 3;Abstract # 293.

394. Tejpar S, Lenz HJ, Kohne CH, Heinemann V, Ciardiello F, Esser R, Beier F, Stroh C,

Duecker K, Bokemeyer C. Effect of KRAS and NRAS mutations on treatment

outcomes in patients with metastatic colorectal cancer (mCRC) treatment first-line with

cetuximab plus FOLFOX4: New results from the OPUS study. 2014 Gastrointestinal


# LBA444.

395. Berlin J, Ramanathan R, Strickler JH, Subramaniam DS, Hurwitz H, Kang YK, Kim

TY, Shepherd SP, Xiong H, Hetman R, Nickner C, Dudley MW, Giranda VL, Lenz

HJ. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients

with advanced solid tumors. In: Proceedings of the 50th Annual Meeting of the



396. Rossi GR, Rocha Lima CMS, Hardacre JM, Mulcahy MF, Talamonti MS, Obel JC,

Safran H, Lenz HJ, Chiorean EG, Vahanian NN, Link CJ. Correlation of anti-

calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of

algenpantucel-L immunotherapy for patients with resected pancreatic cancer. In:





397. Larson G, Stephens C, Astrow SH, Jack Hsiang, Lenz HJ. KRAS screening for

clinically important mutants via a multiplex allele-specific PCR assay for exons 2, 3,

and 4. In: Proceedings of the 50th Annual Meeting of the American Society of Clinical

Oncology; 2014 May 30 – June 3; Chicago, Illinois: ASCO Abstract # e14569.

398. Stintzing S, Stremitzer S, Heinemann V, Jung A, Sunakawa Y, Matsusaka S, Yamauchi

S, Zhang W, Yang D, Ning Y, Sebio A, Hanna DL, Siamak S, Lenz HJ. Amphiregulin

(AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA

levels: Data from FIRE3 (AIO KRK-0306). In: Proceedings of the 50th Annual



399. Yang D, Stremitzer S, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi

S, Matsusaka S, El-Khoueiry RE, Stift J, Wrba F, Gruenberger T, Lenz HJ. Association of outcome with genes involved in tumor dormancy in patients with

resected colorectal liver metastases. In: Proceedings of the 50th Annual Meeting of the



400. Yamauchi S, Loupakis F, Matsusaka S, Zhang W, Yang D, Ning Y, Stintzing S,

Sunakawa Y, Stremitzer S, Sebio A, El-Khoueiry RE, Pasquini G, Marmorino F,

Schirripa M, Fujimoto Y, Ueno M, Mizunuma N, Lenz HJ. Association of single

nucleotide polymorphisms in genes involved in autophagy with overall survival in

patients with metastatic colorectal cancer. In: Proceedings of the 50th Annual Meeting


Illinois: ASCO Abstract # e14506.

401. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi

S, Matsusaka S, El-Khoueiry RE, Stift J, Wrba F, Gruenberger T, Lenz HJ.

Association outcome with genes involved in immune response and checkpoints in

patients with resected colorectal liver metastases. In: Proceedings of the 50th Annual



402. Stintzing S, Stremitzer S, Heinemann V, Falcone A, Loupakis F, Cremolini C,

Antoniotti C, Sunakawa Y, Matsusaka S, Yamauchi S, Zhang W, Yang D, Ning Y,

Sebio A, Hanna DL, Siamak S, Lenz HJ. Biomarker validation study: Genes involved

in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of

efficacy in metastatic colorectal cancer patients treated with cetuximab. In: Proceedings

of the 50th Annual Meeting of the American Society of Clinical Oncology; 2014 May

30 – June 3; Chicago, Illinois: ASCO Abstract # 3571.

403. Renfro LA, Loupakis F, Adams RA, Seymour MT, Schmoll HJ, Douillard JY, Hurwitz

H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Falcone A, Tebbutt MC, Hecht

JR, Punt CJA, Goldberg RM, Saltz L, De Gramont A, Sargent DJ, Lenz HJ. Body

mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled

analysis of 21 first-line trials in the ARCAD database. In: Proceedings of the 50th





404. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O'Neil BH, Shaw

JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL,

Bertagnolli MM, Blanke CD. CALGB/SWOG 80405: Phase III trial of irinotecan/5-

FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with

bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt)

untreated metastatic adenocarcinoma of the colon or rectum (MCRC). In: Proceedings


30 – June 3; Chicago, Illinois: ASCO Abstract # LBA3.

405. Siamak S, Sunakawa Y, Loupakis F, Yang D, Zhang W, Ning Y, Stintzing S,

Stremitzer S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry RE, Rossini CAD,

Cremolini C, Falcone A, Lenz HJ. CCL2 polymorphism as a predictive marker for

bevacizumab (Bev) in combination with FOLFIRI as first-line treatment in metastatic

colorectal cancer (mCRC) patients (pts). In: Proceedings of the 50th Annual Meeting of



406. Hanna DL, Garcia AS, Zhang W, Yang D, Loupakis F, Stintzing S, Stremitzer S, Ning

Y, Sunakawa Y,Yamauchi S, Matsusaka S, Cremolini C, El-Khoueiry RE, Falcone A,

Lenz HJ. Common genetic variants in genes involved in the Hippo pathway: Novel

biomarkers in metastatic colorectal cancer patients treated with irinotecan plus

cetuximab. In: Proceedings of the 50th Annual Meeting of the American Society of


407. Garcia AS, Marmorino F, Gerger A, Zhang W,Yang D, Ning Y, Stintzing S, Stremitzer

S, Sunakawa Y,Yamauchi S, Matsusaka S, Salvatore L, Cremolini C, El-Khoueiry RE,

Falcone A, Lenz HJ. Genetic variant in the down syndrome candidate region 1

(DSCR1) gene: A novel biomarker in metastatic colorectal cancer. In: Proceedings of

the 50th Annual Meeting of the American Society of Clinical Oncology; 2014 May 30

– June 3; Chicago, Illinois: ASCO Abstract # e14544.

408. Ning Y, Zhang W,Yang D, Stintzing S, Sunakawa S, Stremitzer S, Sebio A,Yamauchi

S,Matsusaka S, Zoratto F, Loupakis F, El-Khoueiry RE, Barzi A, El-Khoueiry AB,

Kahn M, Lenz HJ. Genetic variants of CBP and SOX9 to predict clinical outcome in

metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and

bevacizumab (FOLFIRI/BEV). In: Proceedings of the 50th Annual Meeting of the



409. Ning Y, Stintzing S, Heinemann V, Zhang W,Yang D, Sunakawa Y, Stremitzer S,

Sebio A,Yamauchi S, Matsusaka S, El-Khoueiry R, Barzi A, El-Khoueiry AB, Lenz

HJ. Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location-

dependent clinical outcome in FIRE-3 trial: A validation study. In: Proceedings of the





410. Garcia AS, Zhang W, Yang D, Stremitzer S, Stintzing S, Ning Y, Sunakawa Y,

Yamauchi S, Matsusaka S, El-Khoueiry RE, Barzi A, Iqbal S, El-Khoueiry AB, Lenz

HJ. Germline polymorphisms in genes involved in the Hippo pathway to predict

recurrence in locally advanced colon cancer. In: Proceedings of the 50th Annual



411. Zhang W, Schumacher F, Loupakis F, Van Den Berg D, Cremolini C, Stintzing S, Ning

N, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, El-Khoueiry R,

Falcone A, Lenz HJ. High-throughput exome array for identification of novel

polymorphisms associated with clinical outcome in mCRC patients treated with first-

line FOLFOXIRI/BEV versus FOLFIRI/BEV (TRIBE trial; NCT00719797). In:



412. Preusser M, Stremitzer S, Berghoff AS,Volz NB, Zhang W, Yang D, Stintzing S, Ning

Y, Sunakawa Y,Yamauchi S, Sebio A, Matsusaka S, El-Khoueiry RE, Birner P, Lenz

HJ. Influence of genetic variants of genes potentially associated with brain metastases

on overall survival in 70 colorectal cancer patients. In: Proceedings of the 50th Annual



413. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y,Yamauchi

S, Matsusaka S, El-Khoueiry RE, Stift J, Wrba F, Gruenberger T, Lenz HJ. Influence

of genetic variations of the angiopoietin and pericyte pathways in resected colorectal

liver metastases. In: Proceedings of the 50th Annual Meeting of the American Society


414. Gerger A, Herzog S, Szkandera J, Pichler M, Stotz M, Schaberl-Moser R, Samonigg H,

Lax S, Leitner G, Renner W, Berghold A, Lenz HJ. LGR5 rs17109924 to predict

chemoresistance to 5FU-based chemotherapy in adjuvant colon cancer. In: Proceedings


30 – June 3; Chicago, Illinois: ASCO Abstract # 3580.

415. Yang D, Loupakis F, Cremolini C, Antoniotti C, Schirripa M, Salvatore L, Moran M,

Astrow SH, Falcone A, Lenz HJ. mRNA expression levels of candidate genes and

clinical outcome in mCRC patients treated with FOLFOXIRI plus bevacizumab (bev)

or FOLFIRI plus bev in the TRIBE study. In: Proceedings of the 50th Annual Meeting


Illinois: ASCO Abstract # 3640.

416. Ciardiello F, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh

C,Van Cutsem E. Treatment outcome according to tumor RAS mutation status in

CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to

FOLFIRI with/without cetuximab. In: Proceedings of the 50th Annual Meeting of the





417. Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier

F, Duecker K,Tejpar S. Treatment outcome according to tumor RAS mutation status in

OPUS study patients with metastatic colorectal cancer (mCRC) randomized to

FOLFOX4 with/without cetuximab. In: Proceedings of the 50th Annual Meeting of the



418. Sunakawa Y, Zhang W, Yang D, Wakatsuki T, Ning Y, Stintzing S, Stremitzer S, Sebio

A,Yamauchi S, Matsusaka S, El-Khoueiry RE, Iqbal S, Barzi A, Azuma M, Watanabe

M, Koizumi W, Lenz HJ. Association of polymorphisms in the CCL2/CCR2 axis with

clinical outcome in localized advanced gastric cancer (AGC) patients (pts) from the

United States and Japan. In: Proceedings of the 50th Annual Meeting of the American


# 4052.

419. Barzi A, Stern MC, Zhang J, Deapen D, Lenz HJ, Liu L. Gastric cancer (GC) among

California Asians: Analysis of California Cancer Registry (CCR). In: Proceedings of


– June 3; Chicago, Illinois: ASCO Abstract # 4086.

420. Sunakawa Y, Volz NB, Zhang W, Yang D, Wakatsuki T, Ning Y, Stintzing S,

Stremitzer S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry RE, Iqbal S, Barzi A,

Azuma M,Watanabe M, Koizumi W, Lenz HJ. Genetic variants in tumor immune

checkpoints as prognostic markers in patients (pts) with localized advanced gastric

cancer (AGC). In: Proceedings of the 50th Annual Meeting of the American Society of


421. El-Khoueiry AB, O'Donnell R, Mack PC, Blanchard S, Bahary N, Jiang Y, Wright JJ,

Chen HX, Lenz HJ, Gandara DR. A phase I trial of of cixutumumab (C) (IMC-A12)

and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC). In:



422. Matsusaka S, Loupakis F, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y,

Yamauchi S, Stremitzer S, Sebio A, El-Khoueiry RE, Pasquini G, Marmorino F,

Schirripa M, Inoshita N, Ishikawa Y, Ueno M, Mizunuma N, Lenz HJ. Association of

the prognostic role of CXCR4/CXCL12 polymorphism with treatment outcomes after

bevacizumab-based chemotherapy in metastatic colorectal cancer. In: Proceedings of


– June 3; Chicago, Illinois: ASCO Abstract # e22008.

423. Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony M, O’neil b, Shaw J, Polite B

Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky R, Bertagnolli M, Venook A.

CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or

oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab

(CET) for patients (pts) with expanded ras analyses untreated metastatic

adenocarcinoma of the colonor rectum (MCRC). 38th ESMO Congress 2014 September

26-30; Madrid, Spain: Abstract # 8058.



424. Venook A, Niedzwiecki D, Lenz H, Mohoney M, Innocenti F, O’Neil B, Hochster H,

Goldberg R, Schilsky R, Mayer R, Polite B, Atkins J, Shaw J, Bertagnolli M, Blanke C.

CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment

strategy. 38th ESMO Congress 2014 September 26-30; Madrid, Spain: Abstract #

LBA10.

425. Van Cutsem E, Tabernero J, Yoshino T, Sassi M, Oum’Hamed Z, Studeny M, Lenz HJ.

LUME – Colon 1: double–blind, randomised Phase III study of nintedanib plus best

supportive care (BSC) versus placebo plus BSC in patients with refractory colorectal

cancer. 38th ESMO Congress 2014 September 26-30; Madrid, Spain: Poster session:

Abstract # 610Tip.

426. Tabernero J, Van Geel R, Bendell JC, Spreaflico A, Schuler M, Yoshino T, Delord JP,

Yamada Y, Lolkema MP, Faris JE, Eskens F A.L.M, Sharma S, Yaeger R, Lenz HJ,

Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Demuth T, Schellens J H.M. Phase I

study of the selective BRAF v600 inhibitor encorafenib (LGX818) combined with

cetuximab and with or without the a-specific P13K inhibitor alpelisib (BYL719) in

patients with advanced BRAF mutant colorectal cancer. Plenary Session 8 on

“Targeting RAS and Other Driver Oncogenes”. 26th EORTC-NCI-AACR Symposium on

Molecular Targets and Cancer Therapeutics, 2014 November 18-21: Barcelona, Spain:

Abstract.

427. Lenz HJ, Tabernero J, Yoshino T, Oum'Hamed Z, Vlassak S, Sassi M, Van Cutsem E.

LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best

supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer

(CRC) refractory to standard therapies. 2015 Gastrointestinal Cancers Symposium

Poster Session C;Jan 15-17; San Francisco, CA; Suppl 3; Abstract #TPS794.

428. Lenz HJ, Van Cutsem E, Verma UN, Saltzman M, Fuloria J, Khojasteh A, Wiesenfeld

M, Cihon F, Wagner A, Grothey A. Subgroup analysis of patients enrolled in the

United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib

(REG) in metastatic colorectal cancer (mCRC). 2015 Gastrointestinal Cancers

Symposium Poster Session C;Jan 15-17; San Francisco, CA; Suppl 3; Abstract #767.

429. Larson G, Israyelyan A, Lenz HJ, Astrow SH. Expanded KRAS and NRAS assays

increase detection of mutations that predict for resistance to therapy in colorectal cancer

patients. 2015 Gastrointestinal Cancers Symposium Poster Session C;Jan 15-17; San

Francisco, CA; Suppl 3; Abstract #519.

430. Kidd MT, Wilcox E, Rogers J, Eng C, Saadat S, Lenz HJ, Hubbard JM, Grothey A.

Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal

cancer (mCRC). 2015 Gastrointestinal Cancers Symposium Poster Session C;Jan 15-

17; San Francisco, CA; Suppl 3; Abstract #678.

431. Yamauchi S, Okazaki S, Barzi A, Zhang W, Yang D, Cao S, Ning Y, Sunakawa Y,

Stremitzer S, Matsusaka S, El-Khoueiry R, Mendez A, Parekh A, Lenz HJ.

Association between single nucleotide polymorphisms (SNPs) of genes involved in

spindle assembly checkpoint (SAC) and clinical outcomes in advanced gastric cancer

(AGC) patients (pts) treated with taxane-based chemotherapy. 2015 Gastrointestinal

Cancers Symposium Poster Session A;Jan 15-17; San Francisco, CA; Suppl 3; Abstract

#79.



432. Matsusaka S, Loupakis F, Zhang W, Cao S, Yang D, Ning Y, Stremitzer S, Sunakawa

Y, Yamauchi S, El-Khoueiry R, Parekh A, Mizunuma N, Lenz HJ. Polymorphism of

the chemokine CXCR4 to predict treatment benefit of first-line bevacizumab-based

chemotherapy in patients with metastatic colorectal cancer. 2015 Gastrointestinal

Cancers Symposium Poster Session C;Jan 15-17; San Francisco, CA; Suppl 3; Abstract

#635.

433. Stremitzer S, Stintzing S, Heinemann V, Zhang W, Yang D, Ning Y, Sunakawa Y,

Sebio A, Yamauchi S, Matsusaka S, Parekh A, Mendez A, El-Khoueiry, Lenz HJ.

Variations in Y chromosome-related genes and clinical outcome in metastatic

colorectal cancer. 2015 Gastrointestinal Cancers Symposium Poster Session C;Jan 15-

17; San Francisco, CA; Suppl 3; Abstract #634.

434. Sunakawa Y, Ichikawa W, Tsuji A, Moran M, Astrow SH, Yang D, Zhang W,

Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y,

Takeuchi M, Lenz HJ, Fujii M, Nakajima T. EGFR ligands and ERCC1 mRNA

expression to predict clinical outcome in Japanese (JPN) patients (pts) with metastatic

colorectal cancer (mCRC) harboring overexpressed EGFR and KRAS exon 2 wild-type

(KRAS wt) treated with cetuximab (cet) plus oxaliplatin-based chemotherapy (JACCRO

CC-05/06 AR). 2015 Gastrointestinal Cancers Symposium Poster Session C;Jan 15-17;

San Francisco, CA; Suppl 3; Abstract #618.

435. Sunakawa Y, Stintzing S, Heinemann V, Loupakis F, Cremolini C, Cao S, Yang D,

Zhang W, Parekh A, Yamauchi S, Ning Y, Stremitzer S, Matsusaka S, Mendez A, El-

Khoueiry RE, Lenz HJ. Macrophage polarization related gene variants to predict

clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with

bevacizumab (bev) in combination with FOLFIRI. 2015 Gastrointestinal Cancers

Symposium Poster Session C;Jan 15-17; San Francisco, CA; Suppl 3; Abstract #621.

436. Ng K, Venook AP, Sato K, Hollis BW, Niedzwiecki D, Ye C, Chang I-W, O'Neil BH,

Innocenti F, Lenz HJ, Blanke CD, Mayer RJ, Fuchs CS, Meyerhardt JA. Vitamin D

status and survival of metastatic colorectal cancer patients: Results from

CALGB/SWOG 80405 (Alliance). 2015 Gastrointestinal Cancers Symposium Poster

Session C;Jan 15-17; San Francisco, CA; Suppl 3; Abstract #507.

437. Kopetz S, McDonough S, Morris VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA,

Allegra CJ, Lieu CH, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie K, Hochster HS.

S1406: Randomized phase II study of irinotecan and cetuximab with or without

vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). 2015

Gastrointestinal Cancers Symposium Poster Session C;Jan 15-17; San Francisco, CA;

Suppl 3; Abstract #TPS790.

438. Grothey A, Falcone A, Humblet Y, Bouche O, Mineur L, Adenis A, Tabernero J,

Yoshino T, Lenz HJ, Goldberg RM, Xu L, Wagner A, Van Cutsem E. Subgroup

analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib

(REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4

months. 2015 Gastrointestinal Cancers Symposium Poster Session C;Jan 15-17; San

Francisco, CA; Suppl 3; Abstract #710.



439. Ichikawa W, Sunakawa Y, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M,

Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Takagane A, Tani S,

Yamaguchi T, Masuishi T, Takeuchi M, Lenz HJ. Association of EGFR CA simple

sequence repeat 1 (CA-SSR1) variant with cetuximab (cet)-induced skin toxicity (ST)

in Japanese metastatic colorectal cancer (mCRC) patients (pts) with overexpressed

EGFR and KRAS exon 2 wild-type (KRASwt) (JACCRO CC-05/06 AR). 2015

Gastrointestinal Cancers Symposium Poster Session C;Jan 15-17; San Francisco, CA;

Suppl 3; Abstract #582.

440. Ferencz TR, Hochster H, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N,

Yamazaki K, Shimada Y, Komatsu Y, Sobrero A, Peeters M, Van Cutsem E, Zaniboni

A, Tran B, Wahba M, Atalla G, Lenz HJ, Ohtsu A, Mayer RJ. Efficacy and safety from

RECOURSE: a multicenter, randomized, double-blind, phase 3 study of TAS-102

versus placebo with best supportive care in patients with metastatic colorectal cancer

refractory to standard therapies. 2015 ACCP Global Conference on Clinical Pharmacy.

Oct 17-21; Abstract #35743.

441. Schellens JHM, Van Geel R, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord

JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ,

Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Demuth T, Tabernero, J. Final

biomarker analysis of the phase I study of the selective BRAF V600 inhibitor

encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K

inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer.

. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer

Research; 2015 April 18 – 22; Philadelphia, PA: AACR;Abstract Presentation #CT136.

Lenz HJ, Schumacher F, Loupakis F, Cremolini C, Ning Y, Stremitzer S, Sunakawa Y,

Matsusaka S, Okazaki S, Zhang W, Falcone A. Effect of genetic variation on overall

survival in a clinical trial of metastatic colorectal cancer (mCRC). In: Proceedings of

the 51st Annual Meeting of the American Society of Clinical Oncology; 2015 May 29 –

June 2; Chicago, Illinois: ASCO Abstract #3562.

442. Lenz HJ, Tabernero J, Yoshino T, Oum'Hamed Z, Vlassak S, Sassi M, Cutsem EV.

LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best

supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer

(CRC) refractory to standard therapies. In: Proceedings of the 51st Annual Meeting of


ASCO Abstract #TPS3625.

443. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. Colonoscopy versus less invasive approaches

for colorectal cancer (CRC) screening (Scr): A strategic perspective. In: Proceedings of

the 51st Annual Meeting of the American Society of Clinical Oncology; 2015 May 29 –

June 2; Chicago, Illinois: ASCO Abstract #6523.

444. Cleary JM, Mayer RJ, Cutsem EV, Yamashita F, Yoshisue K, Ieiri I, Ohtsu A, Lenz

HJ. Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with

metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3

RECOURSE trial. In: Proceedings of the 51st Annual Meeting of the American Society




445. Graver S, Stremitzer S, Sunakawa Y, Edelmann W, Kockx M, Schartl M, Scherer SJ,

Lenz HJ, Mazzone M. Immune response triggered by a novel molecular crosstalk of

major hallmarks of cancer: Angiogenesis, mismatch repair, and immune pathways. In:

Proceedings of the 51st Annual Meeting of the American Society of Clinical Oncology;


446. Matsusaka S, Wu AH, Cao S, Mizunuma N, Chin K, Zhang W, Yang D, Ning Y,

Stremitzer S, Sunakawa Y, Okazaki S, Parekh A, El-Khoueiry RE, Mendez A, Lenz

HJ. Prognostic impact of Forkhead box-F1 (FOXF1) polymorphisms on the clinical

outcome in gastric cancer patients. In: Proceedings of the 51st Annual Meeting of the



447. Okazaki S, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y,

Stremitzer S, Matsusaka S, Elkhoueiry R, Mendez A, Parekh A, Lenz HJ. TLR6

polymorphism associated with overall survival in metastatic colorectal cancer (mCRC)

patients treated with FOLFIRI/bevacizumab enrolled in FIRE3. In: Proceedings of the

51st Annual Meeting of the American Society of Clinical Oncology; 2015 May 29 –


448. Sunakawa Y, Stintzing S, Heinemann V, Cremolini C, Falcone A, Cao S, Yang D,

Zhang W, Yamauchi S, Ning Y, Stremitzer S, Matsusaka S, Parekh A, Graver S,

Mendez A, Okazaki S, El-Khoueiry R, Scherer SJ, Loupakis F, Lenz HJ. Variations in

genes regulating tumor-associated macrophages (TAMs) to predict outcome of

bevacizumab (bev)-based treatment in patients with metastatic colorectal cancer

(mCRC): Results from TRIBE and FIRE3 trials. In: Proceedings of the 51st Annual



449. McWilliams RR, Ko AH, Chiorean EG, Kwak EL, Lenz HJ, Nadler PI, Wood DL,

Fujimori M, Morita K, Inada T, Kouji H. A phase Ib dose-escalation study of PRI-724,

a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced

pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or

FOLFOX. In: Proceedings of the 51st Annual Meeting of the American Society of


450. Kim GP, Van Cutsem E, Lenz HJ, Verma UN, Saltzman M, Fuloria J, Khojasteh A,

Wiesenfeld M, Cihon F, Wagner A, Grothey A. Subgroup analysis of patients enrolled

in the United States in the CORRECT phase 3 trial of the multikinase inhibitor

regorafenib (REG) in metastatic colorectal cancer (mCRC). : Proceedings of the 51st



451. Leichman CG, McDonough SL, Smalley SS, Billingsley KG, Lenz HJ, Beldner MA,

Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. S0713: A phase II

study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX)

and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally

advanced rectal cancer (LARC). In: Proceedings of the 51st Annual Meeting of the





452. Parekh A, Ning Y, Stintzing S, Loupakis F, Zhang W, Yang D, Sunakawa Y,

Stremitzer S, Matsusaka S, Okazaki S, Elkhoueiry R, Mendez A, Barzi A, Schirripa M,

Heinemann V, Lenz HJ. Genetic variant of TWEAK to predict clinical outcome in

mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV)

in FIRE-3 and TRIBE cohorts. In: Proceedings of the 51st Annual Meeting of the



453. Ning Y, Zhang W, Hanna DL, Mendez A, Yang D, Sunakawa Y, Stremitzer S,

Matsusaka S, Okazaki S, Parekh A, El-Khoueiry RE, Flores B, Hauch S, Barzi A, El-

Khoueiry AB, Lenz HJ. Circulating tumor cell (CTC) EMT and stem cell biomarker

expression predict overall survival (OS) in mCRC by a combined immunomagnetic

qRT-PCR approach. In: Proceedings of the 51st Annual Meeting of the American


# 11018.

454. Zhang W, Curtis C, Stintzing S, Heinemann V, Parekh A, Yang D, Cao S, Ning Y,

Sunakawa Y, Stremitzer S, Matsusaka S, Okazaki S, El-Khoueiry RE, Mendez A, Barzi

A, El-Khoueiry AB, Lenz HJ. Profiling of differentially expressed genes in right and

left side mCRC patients using nCounter customized gene expression assay. In:

Proceedings of the 51st Annual Meeting of the American Society of Clinical Oncology;

2015 May 29 – June 2; Chicago, Illinois: ASCO Abstract # e14586.

455. Teufel M, Schwenke S, Seidel H, Beckmann G, Reischl J, Vonk R, Lenz HJ,

Tabernero J, Siena S, Grothey A, Cutsem EV, Jeffers M, Wilhelm S, Wagner A,

Laurent D, Kobina S, Rutstein MD, Wirapati P, Guinney J, Tejpar S. Molecular

subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer

(mCRC) enrolled in the CORRECT trial. In: Proceedings of the 51st Annual Meeting of



456. Ng K, Venook AP, Sato K, Yuan C, Hollis BW, Niedzwiecki D, Ye C, Chang IW,

O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Mayer RJ, Fuchs CS, Meyerhardt JA.

Vitamin D status and survival of metastatic colorectal cancer patients: Results from

CALGB/SWOG 80405 (Alliance). In: Proceedings of the 51st Annual Meeting of the



457. Benhaim L, Zhang W, Wakatsuki T, Gerger A, Yang D, Paez D, Ning Y, El-Khoueiry

RE, Loupakis F, Bohanes PO, Stintzing S, Heinemann V, Lenz HJ. Genetic variants of

kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in

patients with mCRC: Prospective analysis in the FIRE 3 trial. In: Proceedings of the

51st Annual Meeting of the American Society of Clinical Oncology; 2015 May 29 –




458. Parekh A, Sunakawa Y, Cao S, Matsusaka S, Yang D, Zhang W, Wakatsuki T, Ning Y,

Stremitzer S, Mendez A, Okazaki S, Elkhoueiry R, Iqbal S, Barzi A, Azuma M,

Watanabe M, Koizumi W, Wu AH, Lenz HJ. Estrogen receptor beta (ERβ) gene

polymorphisms as a predictor of overall survival in patients with gastric cancer (GC)

from Japan and Los Angeles County (LAC). In: Proceedings of the 51st Annual

Meeting of the American Society of Clinical Oncology. 2015 May 29 – June 2;


459. Innocenti F, Owzar K, Jiang C, Sibley A, Niedzwiecki D, Lenz HJ, Bertagnolli MM,

Friedman PN, Furukawa Y, Kubo M, Ratain MJ, Blanke CD, Venook AP, McLeod HL.

A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic

colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB

80405. In: Proceedings of the 51st Annual Meeting of the American Society of Clinical

Oncology. 2015 May 29 – June 2; Chicago, Illinois: ASCO Abstract # 3599.

460. Becerra C, Stephenson J, Jonker DJ, Cohn AL, Asmis TR, Bekaii-Saab TS, Conkling

PR, Garbo LE, Lenz HJ, Richards DA, Spira AI, Mikhail S, Goodwin RA, Yoon HH,

Hume S, Hitron M, Li C. Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608

combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ)

adenocarcinoma. In: Proceedings of the 51st Annual Meeting of the American Society

of Clinical Oncology. 2015 May 29 – June 2; Chicago, Illinois: ASCO Abstract # 4069.


Yoshino T, Lenz HJ, Goldberg RM, Xu L, Wagner A, Van Cutsem E. Subgroup

analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib

(REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4

months. . In: Proceedings of the 51st Annual Meeting of the American Society of

Clinical Oncology. 2015 May 29 – June 2; Chicago, Illinois: ASCO Abstract # E14579.

462. Elez E, Schellens J, Van Geel R, Bendell J, Spreafico A, Schuler M, Yoshino T, Delord

JP, Yamada Y, Lolkema M, Faris JE, Eskens F, Sharma S, Yaeger R, Lenz HJ,

Wainberg Z, Avsar E, Chatterjee A, Jaeger S, Demuth T, Tabernero J. Results of a

phase 1B study of the selective BRAF V600 inhibitor encorafenib in cambination with

cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced

BRAF-mutant metastatic colorectal cancer. In: Proceedings of ESMO 17th World

Congress on GI Cancer. 2015 July 1-4; Barcelona, Spain: Annuals of Oncology

26;(4).ESMO Abstract# LBA-08.

463. Falcone A, Laurent S, Gravalos C, Benavides M, Longo Munoz F, Ychou M, Ciardiello

F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y, Tebbutt N, Loehrer PJ, Lenz HJ,

Mayer RJ, Ohtsu A, Van Cutsem E. Phase 3 RECORSE trial of TAS-102 versus

placebo with best supportive care in patients with metastatic colorectal cancer:

European subgroup. In: Proceedings of ESMO 17th World Congress on GI Cancer.

2015 July 1-4; Barcelona, Spain: Annuals of Oncology 26;(4). ESMO Abstract# P -284.



464. Shinozaki E, Laurent S, Gravalos C, Benavides M, Longo Munoz F, Mizuguchi H,

Wahba M, Ychou M, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y,

Loehrer P, Lenz HJ, Tebutt N, Mayer RJ, Van Cutsem E, Ohtsu A. Timing of adverse

events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients

(pts) with metastatic colorectal cancer (mCRC). In: Proceedings of the 18th ECCO –

40th ESMO European Cancer Congress. 2015 Sept 25 – 29; Vienna, Austria.

ESMO/ECCO Abstract# 2151.

465. Falcone A, Garcia-Carbonero R, Tabernero J, Sobrero A, Peeters M, Zaniboni A,

Hochster H, Lenz HJ, Tran B, Yamaguchi K, Muro K, Denda T, Tsuji Y, Wahba M,

Benedetti F, Ohtsu A, Mayer RJ, Van Cutsem E. Low rates of hospitalizations with

TAS-102 in European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts)

with metastatic colorectal cancer (mCRC). In: Proceedings of the 18th ECCO – 40th

ESMO European Cancer Congress. 2015 Sept 25 – 29; Vienna, Austria. ESMO/ECCO

Abstract# 2150.

466. Sobrero A, Grothey A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur

L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H, Goldberg RM, Xu L, Wagner

A, Van Custem E. Subgroup analysis of patints with metasttic colorectal cancer (mCRC

treated with regorafenib (REG) in the CORRECT trial who had progression-free

survival (PFS) longer than 4 months. 17th National Congress of Medical Oncology,

2015 Oct 23 – 25: Rome, Italy. ESMO, Abstract# E13.

467. Lenz HJ, Lee FC, Yau L, Koh HA, Knost JA, Mitchell EP, Bosanac I, Mancao C,

Parikh A. MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs

FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in

patients (pts) with metastatic colorectal cancer (mCRC). 2016 Gastrointestinal Cancers

Symposium, Oral Abstract and Poster session C; Jan 21-23, 2016. San Francisco, CA;

Abstract # 493.

468. Cheng WH, Sadeghi S, Lenz HJ, Hay JW, Barzi A. Comparative effectiveness of

FOLFIRINOX (FOL) versus gemcitabine and nab-paclitaxel (GNP) for the first-line

treatment of metastatic pancreatic cancer. 2016 Gastrointestinal Cancers Symposium

Poster Session C; Jan 21-23; San Francisco, CA; Suppl 4S; Abstract # 306.

469. Xu Y, Hay JW, Lenz HJ, Sadeghi S, Barzi A. Comparative effectiveness of

panitumumab (P) and cetuximab (C) in metastatic colorectal cancer (mCRC) with wild-

type KRAS (WTKRAS). 2016 Gastrointestinal Cancers Symposium Poster Session C;

Jan 21-23; San Francisco, CA; Suppl 4S; Abstract # 652.

470. Okazaki S, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S,

Martin D. Berger MD, West JD, Miyamoto Y, Suenaga M, Lenz HJ. Association of

TLR9 polymorphism with overall survival in metastatic colorectal cancer patients

treated with FOLFIRI plus bevacizumab enrolled in FIRE3. 2016 Gastrointestinal

Cancers Symposium Poster Session C; Jan 21-23; San Francisco, CA; Suppl 4S;

Abstract # 498.



471. Bendell JC, Tan BR, Reeves JA, Xiong H, Somer BG, Lenz HJ, Hochster HS,

Scappaticci F, Sommer N, Day B, Hurwitz H. Overall response rate (ORR) in STEAM,

a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-

bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients

(pts) with metastatic colorectal cancer (mCRC). 2016 Gastrointestinal Cancers

Symposium Poster Session C; Jan 21-23; San Francisco, CA; Suppl 4S; Abstract # 492.

472. Berger MD, Stintzing S, Heinemann V, Yang D, Sunakawa Y, Ning Y, Matsusaka S,

Okazaki S, Miyamoto Y, Suenaga M, West JD, Zhang W, Petasis N, Lenz HJ. Serum

amyloid α (SAA-1) SNP rs12218 to predict outcome for mCRC patients treated with

FOLFIRI and bevacizumab: Data from FIRE-3 trial. 2016 Gastrointestinal Cancers

Symposium Poster Session C; Jan 21-23; San Francisco, CA; Suppl 4S; Abstract # 586.

473. Verma U, Arriaga YE, Lenz HJ, Henderson CA, Fuloria J, Cartwright TH, Khojasteh

A, Stella PJ, Saltzman M, Cohn AL, Philip PA, Kappeler C, Kalmus J, Grothey A, Van

Cutsem E, Hochster HS, Arena FP. Regorafenib for previously treated metastatic

colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in

the international, open-label phase IIIb CONSIGN study. 2016 Gastrointestinal


Abstract # 735.

474. Mayer RJ, Ohtsu A, Yoshino T, Falcone A, Garcia-Carbonero R, Tabernero J, Sobrero

AF, Peeters M, Benedetti F, Makris L, Ambe H, Zaniboni A, Shimada Y, Yamazaki K,

Komatsu Y, Hochster HS, Lenz HJ, Tran B, Van Cutsem E. TAS-102 versus placebo

plus best supportive care in patients with metastatic colorectal cancer refractory to

standard therapies: Final survival results of the phase III RECOURSE trial. 2016

Gastrointestinal Cancers Symposium Poster Session C; Jan 21-23; San Francisco, CA;

Suppl 4S; Abstract # 634.

475. Van Cutsem E, Benedetti FM, Mizuguchi H, Mayer RJ, Falcone A, Garcia-Carbonero

R, J Tabernero, Sobrero AF, Peeters M, Zaniboni A, Yoshino T, Shimada Y, Yamazaki

K, Komatsu Y, Hochster HS, Lenz HJ, Tran B, Ohtsu A. TAS-102 versus placebo

(PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An

age-based analysis of the recourse trial. 2016 Gastrointestinal Cancers Symposium


476. Van Cutsem E, Benedetti FM, Mizuguchi H, Mayer RJ, Falcone A, Garcia-Carbonero

R, J Tabernero, Sobrero AF, Peeters M, Zaniboni A, Yoshino T, Shimada Y, Yamazaki

K, Komatsu Y, Hochster HS, Lenz HJ, Tran B, Ohtsu A. TAS-102 versus placebo

(PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An

age-based analysis of the recourse trial. 2016 Gastrointestinal Cancers Symposium


477. Sunakawa Y, Yang D, Cao S, Roberts C, Wang E, Moran M, Astrow SH, Thompson D,

Hsiang J, Zhang W, Tsuji A, Takahashi T, Denda T, Kochi M, Shimada K, Takeuchi

M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ. Alteration of ADCC-related genes as a

novel predictor of efficacy of cetuximab (cet)-based chemotherapy in patients (pts) with

metastatic colorectal cancer (mCRC) (JACCRO CC-05/06 AR). 2016 Gastrointestinal


Abstract # 589.



478. Van Cutsem E, Lenz HJ, Furuse J, Tabernero J, Heinemann V, Ioka T, Bazin I, Ueno

M, Csõszi T, Wasan H, Melichar B, Karasek P, Macarulla T, Guillén Ponce C, Kalinka-

Warzocha E, Horvath Z, Prenen H, Schlichting M, Mehdi F, Bendell JC. Evofosfamide

(TH-302) in combination with gemcitabine in previously untreated patients with

metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary

analysis of the randomized, double-blind phase III MAESTRO study. 2016



479. Lenz HJ, Lee FC, Yau L, Koh HA, Knost JA, Mitchell EP, Bosanac I, Mancao C,

Parikh A. MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs

FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic

colorectal cancer (mCRC): Outcomes by tumor location and KRAS status. In:

Proceedings of the 52nd Annual Meeting of the American Society of Clinical Oncology;

2016, June 3 - 7; Chicago, Illinois: ASCO Poster discussion session, Abstract #3515.

480. Sadeghi S, Quinn DI, Lenz HJ, Barzi A. FOBT compared to FIT in reducing colorectal

cancer (CRC) incidence. In: Proceedings of the 52nd Annual Meeting of the American

Society of Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Abstract

#e18119.

481. Barzi A, Yang D, Lenz HJ, Sadeghi S. Outcomes with adjuvant chemo-radiation

(ACRT) in patients (pts) with localized gastric cancer (GC): Analysis of National

Cancer Data Base (NCDB). In: Proceedings of the 52nd Annual Meeting of the

American Society of Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO

Poster Session, Abstract #4044.

482. Duddalwar V, Quinn DI, Lenz HJ, Barzi A, Sadeghi S. Comparative effectiveness of

CT colonography (CT-C) as a screening (Scr) tool for colorectal cancer (CRC). In:


2016, June 3 - 7; Chicago, Illinois: ASCO Abstract #e13049.

483. Barzi A, Quinn DI, Idos G, Lenz HJ, Sadeghi S. The opportunity cost (OC) of low

adherence with screening (scr) recommendations for colorectal cancer (CRC). In:


2016, June 3 - 7; Chicago, Illinois: ASCO Poster Session, Abstract #1553.

484. Melnikova V, Vibat CRT, Ning Y, Agafitei RD, Hanna DL, Hancock S, Erlander MG,

Lenz HJ, Barzi A. Quantitative urinary KRAS for treatment decisions in patients with

metastatic colorectal cancer (mCRC). In: Proceedings of the 52nd Annual Meeting of

the American Society of Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO

Abstract #e15011.

485. Chang Shen JU, Usher J, Samberg D, Ishiba T, Danenberg K, Lenz HJ, Barzi A. PD-

L1 and HER2 expression in gastric cancer (GC) patients (pts) using cell-free RNA

(cfRNA). In: Proceedings of the 52nd Annual Meeting of the American Society of

Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Abstract #e15539.



486. Ishiba T, Usher JL, Elshimali Y, Vodala S, Sturdevant T, Dang M, Grino M, Gonzalez

R, Jaimes YS, Tyagi R, Pinsk JKi, Barzi A, Raez LE, Hoffmann AC, Lenz HJ, Uetake

H, Danenberg PV, Danenberg K. Frequencies and expression levels of programmed

death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. In:



487. Ko AH, Chiorean EG, Lee Kwak E, Lenz HJ, Nadler PI, Wood DL, Fujimori M, Inada

T, Kouji H, McWilliams RR. Final results of a phase Ib dose-escalation study of PRI-

724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced

pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or

FOLFOX. In: Proceedings of the 52nd Annual Meeting of the American Society of

Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Abstract #e15721.

488. Yang D, Zhang W, Cao S, Loupakis F, Schirripa M, Stintzing S, Lenz HJ. Identifying

SNPs associated with progression-free survival (PFS) and overall survival (OS) in

patients with KRAS wildtype and mutant metastatic colorectal cancer (mCRC) using

Random Survival Forests (RSF). In: Proceedings of the 52nd Annual Meeting of the



489. Matsusaka S, Ning Y, Yang D, Zhang W, Hanna DL, Cao S, Suenaga M, Okazaki S,

Berger MD, Lenz HJ. Epidermal growth factor receptor mRNA expression in

circulating tumor cells as a potential mechanism of molecular escape from regorafenib

therapy. In: Proceedings of the 52nd Annual Meeting of the American Society of

Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Poster Discussion

Session, Abstract #11517.


Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, West JD, Hanna DL, Barzi A,

Zhang W, Lenz HJ. MKNK1 SNP rs8602 to predict outcome for mCRC patients

treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. In:



491. Sunakawa Y, Wang E, Roberts C, Yang D, Liu Q, Thompson D, Botros I, Moran M,

Astrow SH, Hsiang J, Zhang W, Tsuji A, Denda T, Shimada K, Kochi M, Takeuchi M,

Fujii M, Nakajima T, Ichikawa W, Lenz HJ. Immune-related genes to predict clinical

outcome of cetuximab (cet) treatment for metastatic colorectal cancer (mCRC):

Immuno-Oncology assay research. In: Proceedings of the 52nd Annual Meeting of the



492. Gopez R, Schirripa M, Zhang W, Cao S, Okazaki S, Dongyun Yang, Fotios Loupakis,

Berger MD, Ning Y, Miyamoto Y, Suenaga M, West JD, Hanna HL, Barzi A, Falcone

A, Stintzing S, Heinemann V, Lenz HJ. IRS1 and IRS2 polymorphisms and outcome in

mCRC patients enrolled in the FIRE-3 trial. In: Proceedings of the 52nd Annual

Meeting of the American Society of Clinical Oncology; 2016, June 3 - 7; Chicago,

Illinois: ASCO Poster Session, Abstract #11600.



493. Cao S, Yang D, Stintzing S, Loupakis F, Zhang W, Ning Y, Schirripa M, Suenaga M,

Okazaki S, Miyamoto Y, Barzi A, Lenz HJ. Identifying predictive SNPs in patients

with metastatic colorectal cancer (mCRC) using Random Survival Forests. In:




Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, West JD, Barzi A, Hanna DL,

Zhang W, Lenz HJ. Polymorphisms of genes encoding for vitamin D binding protein

and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and

bevacizumab: Data from FIRE-3 trial. In: Proceedings of the 52nd Annual Meeting of



495. Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y,

Barzi A, Miyamoto Y, Suenaga M, Gopez R, West JD, Hanna DL, Lonardi S, Bergamo

F, Cremolini C, Falcone A, Lenz HJ. NOS2 polymorphisms in the prediction of benefit

from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial. In:



496. Nixon AB, Sibley A, Hatch AJ, Liu Y, Chen Jiang C, Mulkey F, Starr MD, Brady JC,

Niedzwiecki D, Innocenti F, Venook AP, Hochster HS, Lenz HJ, O'Neil BH, Owzar K,

Hurwitz H. Blood-based biomarkers in patients (pts) with metastatic colorectal cancer

(mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab

(Cetux), or bev plus Cetux: Results from CALGB 80405 (Alliance). In: Proceedings of

the 52nd Annual Meeting of the American Society of Clinical Oncology; 2016, June 3 -

7; Chicago, Illinois: ASCO Poster Session, Abstract #3597.

497. Miyamoto Y, Stintzing S, Loupakis Zhang W, Cao S, Ning Y, Okazaki S, Berger MD,

Suenaga M, Schirripa M, Matsusaka S, Yang D, West JD, Gopez R, Hanna DL, Barzi

A, Baba H, Heinemann V, Lenz HJ. Genetic variations associated with cancer

cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results

from FIRE-3 and TRIBE. In: Proceedings of the 52nd Annual Meeting of the American

Society of Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Poster Session,

Abstract #3590.

498. Ning Y, Stintzing S, Zhang W, Yang D, Hanna DL, Okazaki S, Berger MD, Miyamoto

Y, West JD, Suenaga M, Schirripa M, Barzi A, Heinemann V, Lenz HJ. Genetic

variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated

with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort. In:



499. Mayer RJ, Van Cutsem E, Yoshino T, Falcone A, Garcia-Carbonero R, Argiles G,

Pastorino A, Peeters M, Winkler R, Wahba M, Makris L, Zaniboni A, Shimada Y,

Yamazaki K, Komatsu Y, Hochster HS, Lenz HJ, Tran B, Ohtsu A. Supportive

treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs

placebo with best supportive care in patients with metastatic colorectal cancer. In:





500. Zhang W, Suenaga M, Schirripa M, Cao S, Yang D, Berger MD, West JD, Ning Y,

Wakatsuki T, Mashima T, Okazaki S, Miyamoto Y, Hanna DL, Marmorino F,

Salvatore L, Moretto R, Borelli B, Barzi A, Loupakis F, Lenz HJ. Genetic variants

of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic

colorectal cancer. In: Proceedings of the 52nd Annual Meeting of the American Society

of Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Poster Session,

Abstract #3580.

501. Sunakawa Y, Wang E, Roberts C, Yang D, Liu Q, Thompson D, Botros I, Moran M,

Astrow SH, Hsiang J, Zhang W, Stintzing S, Tsuji A, Takahashi T, Denda T, Takeuchi

M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ. Association of gene signature to

identify molecular subtypes with clinical outcomes of 1st-line cetuximab (cet)

treatment for metastatic colorectal cancer (mCRC). In: Proceedings of the 52nd Annual


Illinois: ASCO Poster Session, Abstract #3592.

502. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Berger MD, West JD, Ning Y,

Salvatore L, Rossini D, Antoniotti C, Inoue R, Matsusaka S, Okazaki S, Miyamoto Y,

Hanna DL, Barzi A, Loupakis F, Lenz HJ. Genetic variants of ATM and XRCC3 to

predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. In:



503. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Berger MD, West JD, Cremolini

C, Lonardi S, Battaglin F, Ning Y, Horiike Y, Yamamoto N, Okazaki S, Miyamoto Y,

Hanna DL, Barzi A, Loupakis F, Falcone A, Lenz HJ. Genetic variants of Pin1 to

predict benefit from irinotecan and oxaliplatin based treatment in patients with

metastatic colorectal cancer (mCRC). In: Proceedings of the 52nd Annual Meeting of



504. Ohtsu A, Yoshino T, Falcone A, Garcia-Carbonero R, Argiles G, Sobrero AF, Peeters

M, Makris L, Benedetti F, Zaniboni A, Shimada Y, Yamazaki K, Komatsu Y, Hochster

HS, Lenz HJ, Tran B, Wahba M, Yoshida K, Van Cutsem E, Mayer RJ. Onset of

neutropenia as an indicator of treatment response in the phase III RECOURSE trial of

TAS-102 vs placebo in patients with metastatic colorectal cancer. In: Proceedings of


7; Chicago, Illinois: ASCO Poster Session, Abstract #3556.

505. Schirripa M, Yang D, Loupakis F, Antoniotti C, Cremolini C, Cao S, Okazaki S, Berger

MD, Ning Y, Miyamoto Y, Suenaga M, Moretto R, Bergamo F, Battaglin F, Lonardi S,

Gopez R, West JD, Zhang W, Falcone A, Lenz HJ. Females versus males: Clinical

features and outcome differences in large molecularly selected cohort of mCRC

patients. In: Proceedings of the 52nd Annual Meeting of the American Society of

Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Poster Session, Abstract

#3540.



506. Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz HJ, Morse MA,

Desai J, Hill A, Axelson MD, Moss RA, Lin CS, Goldberg M, Andre T. Nivolumab ±

ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC)

with and without high microsatellite instability (MSI-H): CheckMate-142 interim

results. In: Proceedings of the 52nd Annual Meeting of the American Society of Clinical

Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Oral Abstract Session, Abstract

#3501.

507. Mayer RJ, Ohtsu A, Yoshino T, Falcone A, Garcia-Carbonero R, Argiles G, Damiani

A, Peeters M, Makris L, Zaniboni A, Shimada Y, Yamazaki K, KomatsuY, Hochster

HS, Lenz HJ, TranB,Winkler R, Bebeau P, Wahba MM, Van Cutsem E. Efficacy and

safety results in patients with impaired renal and hepatic function in the RECOURSE

trial. In: Proceedings of the 52nd Annual Meeting of the American Society of Clinical

Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Poster Session, Abstract #3547.

508. Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Berger MD,

West JD, Gopez R, Miyamoto Y, Suenaga M, Schirripa M, Barzi A, Hanna DL,Tsuji

A, Ichikawa W, Heinemann V, DePaolo W, Lenz HJ. Polymorphisms in toll-like

receptor (TLR) genes in the prediction of outcome for cetuximab-based treatment in

patients with metastatic colorectal cancer (mCRC). In: Proceedings of the 52nd Annual


Illinois: ASCO Abstract #3588.

509. West JD, Zhang W, Stintzing S, Sunakawa Y, Yang D, Cao S, Ning Y, Berger MD,

Gopez R, Miyamoto Y, Okazaki S, Suenaga M, Schirripa M, Barzi A, Hanna DL, Tsuji

A, Ichikawa W, Heinemann V, Lenz HJ. Genetic variants in immune response genes to

predict clinical outcome in mCRC patients treated with FOLFIRI/cetuximab (FIRE-3)

or with first line cetuximab-based chemotherapy (JACCRO CC-05/06 AR). In:



510. Tabernero J, Van Geel R, Guren TK,Yaeger RD, Spreafico A, Faris JE, Yoshino T,

Yamada Y, Won Kim T, Bendell JC, Schuler MH, Lenz HJ, Eskens F, Desai J,

Hochster HS, Avsar E, Demuth T, Sandor V, Elez E, Schellens JHM. Phase 2 results:

Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in

patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). In: Proceedings

of the 52nd Annual Meeting of the American Society of Clinical Oncology; 2016, June

3 - 7; Chicago, Illinois: ASCO Poster Session, Abstract #3544.

511. Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C,O'Neil BH, Shaw JE,

Atkins JN, Horvath LE, Polite BN, Meyerhardt JA, O'Reilly EM, Richard M. Goldberg

RM, Hochster HS, Blanke CD, Schilsky RL, Mayer RJ, Bertagnolli MM, Lenz HJ.

Impact of primary (1º) tumor location on overall survival (OS) and progression-free

survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of

CALGB/SWOG 80405 (Alliance). In: Proceedings of the 52nd Annual Meeting of the

American Society of Clinical Oncology; 2016, June 3 - 7; Chicago, Illinois: ASCO Oral

Abstract Session, Abstract #3504.



512. Van Cutsem E, Lenz HJ, Furuse J, Tabernero J, Heinemann V, Ioka T, Bazin I, Ueno

M, Csõszi T, Wasan H, Melichar B, Karasek P, Macarulla TM, Guillen C, Kalinka-

Warzocha E, Horvath Z, Prenen H, Schlichting M, Ibrahim A, Bendell JC. MAESTRO:

A randomized, double-blind phase III study of evofosfamide (Evo) in combination with

gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally

advanced unresectable pancreatic ductal adenocarcinoma (PDAC). In: Proceedings of


7; Chicago, Illinois: ASCO Oral Abstract Session, Abstract #4007.

513. Tabernero J, Mayer Robert J, Ohtsu A, Yoshino T, Garcia-Carbonero R, Pastorino A,

Peeters M, Winkler R, Makris L, Wahba M, Zaniboni A, Shimada Y, Yamazaki K,

Komatsu Y, Hochster H, Lenz HJ, Falcone A, Tran A, Van Cutsem E. RECOURSE

trial: impact of adverse events on quality of life and duration of TAS-102(trifluridine

and tipiracil) treatment. In: Proceedings 18th World Congress on GI Cancer. 2016 June

30-July 4; Barcelona, Spain: Annuals of Oncology 27;(2), ESMO Poster Discussion,

Abstract# PD-025.

514. Tabernero J, Van Geel R, Guren T, Yaeger R, Spreafico A, Faris J, Yoshino T, Yamada

Y, Kim Tae W, Bendell J, Schuler M, Lenz HJ, Eskens F, Desai J, Hochster H, Avsar

E, Demuth T, Sandor V, Elez E, Schellens J. Combination of encorafenib and

cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal

cancer (BRAFm CRC): phase 2 results. In: Proceedings 18th World Congress on GI

Cancer. 2016 June 29 –July 4; Barcelona, Spain: Annuals of Oncology 27;(2), ESMO

Orals, Abstract# O-026.

515. Okazaki S, Loupakis F, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Berger MD,

Miyamoto Y, Suenaga M, Gopez R, Borelli BB, Cremolini C, Falcone A, Lonardi S,

Salvatore L, Uetake H, Kawano T, Helentjaris T, Lenz HJ. Tandem repeat variation in

HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with

metastatic colorectal cancer. In: Proceedings 41st ESMO Congress. 2016 7–11 October;

Copenhagen, Denmark: Annuals of Oncology 27;(6), ESMO, Abstract#124P.

516. Weekes C, Berlin J, Lenz HJ, O’Neil B, Messersmith W, Cohen S, Dendinger C,

Shahda S, Kapoun A, Zhang C, Jenner R, Cattaruzza F, Xu L, Dupont J, Brachmann R,

Uttamsingh S, Farooki A, Dotan E. Tandem repeat variation in HIC1 gene predicts

outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal

cancer. In: Proceedings 41st ESMO Congress. 2016 7–11 October; Copenhagen,

Denmark: Annuals of Oncology 27;(6), ESMO, Abstract#367PD.

517. Overman MJ, Kopetz S, Lonardi S, McDermott R, Leone F, Leach J, Lenz HJ,

Hendlisz A, Morse M, Garcia-Alfonso P, Desai J, Hill A, Moss RA, Goldberg MV, Lin

CS, Tang H, André T. Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and

biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without

high microsatellite instability (MSI-H): results from the CheckMate-142 study. In:

Proceedings 41st ESMO Congress. 2016 7–11 October; Copenhagen, Denmark:

Annuals of Oncology 27;(6), ESMO, Abstract#479P.



518. Yoshino T, Cleary J, Mayer R, Yoshida K, Makris L, Yamashita F, Ohtsu A, Lenz

HJ,Van Cutsem E. Pharmacokinetic and pharmacodynamic (PK/PD) analysis results

from the phase 3 RECOURSE trial of trifluridine and tipiracil (TAS-102) versus

placebo (pbo) in patients (pts) with refractory metastatic colorectal cancer (mCRC). In:




Yoshino T, Lenz HJ, Goldberg RM, Huang L, Wagner A, Van Cutsem E.

Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with

regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup

analysis of the phase 3 CORRECT trial. In: Proceedings 41st ESMO Congress. 2016 7–

11 October; Copenhagen, Denmark: Annuals of Oncology 27;(6), ESMO,

Abstract#516P.

520. Barzi A, Yang D, Lenz HJ, Sadeghi S. Multimodality treatment (MMT) and outcomes

of gastric adenocarcinoma (GC) in National Cancer DataBase(NCDB). In: Proceedings

41st ESMO Congress. 2016 7–11 October; Copenhagen, Denmark: Annuals of

Oncology 27;(6), ESMO, Abstract#623P.

521. Messersmith W, Cohen S, Shahda S, Lenz HJ, Weekes C, Dotan E, Denlinger C,

O’Neil B, Kapoun A, Zhang C, Henner R, Cattaruzza F, Xu L, Dupont J, Brachmann R,

Uttamsingh S, A. Farooki A, Berlin J. Phase 1b study of WNT inhibitor vantictumab

(VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G)

in patients (pts) with previously untreated stage IV pancreatic cancer (PC). In:



522. Mayer R, Ohtsu A, Yoshino T, Falcone A, Garcia-Carbonero R, Tabernero J, Sobrero

A, Peeters M, Benedetti F, Makris L, Ambe H, Zaniboni A, Shimada Y, Yamazaki K,

Komatsu Y, Hochster H, Lenz HJ, Tran B, Cutsem EV. TAS-102 vs Placebo Plus Best

Supportive Care in Patients with Metastatic Colorectal Cancer Refactory to Standard

Therapies: Final Results of the Phase 3 RECOURSE Trial. In: Proceedings of the 2016

13th Annual Meeting Gastrointestinal Oncology Conference of the International Society

of Gastrointestinal Oncology(ISGIO); 2016, Oct 27-28, 2016; Arlington, VA: Poster

session, Abstract.

523. Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A,

Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift

J, Wrba F, Gruenberger T, Lenz HJ. Expression of Genes Involved in Vascular

Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based

Chemotherapy in Patients Undergoing Liver Resection. DOI: 10.1158/1535-

7163.MCT-16-0275 Published November 2016, Mol Cancer Ther, 15(11):2814-2821.

Abstract#??.



524. Lenz HJ, Yoshino T, Argiles G, Iveson T, Sastre J, Harrison M, Lim HJ, Tebbutt NC,

Peeters M, Satoh T, Dittrich C, Sassi M, Loembe A-B, Van Cutsem E. Nintedanib (N)

plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of

patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis

of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment. 2017



525. Lenz HJ, Tabernero J, Yoshino T, Lonardi S, Falcone A, Limón Mirón ML, Saunders

MP, Sobrero AF, Suk Park Y, Monteagudo RF, Sang Hong Y, Tomasek J, Taniguchi

H, Ciardiello F, Sassi M, Peil B, Hastedt C, Studeny M, Van Cutsem E. Nintedanib (N)

plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients

(pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-

related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study. 2017



526. Barzi A, Siegel R, Fedewa SA, Lenz HJ, Quinn DI, Jemal A, Sadeghi S. Comparative

effectiveness of initiating colorectal cancer (CRC) screening (Scr) at age 45. 2017



527. Qureshi S, Xiu J, Sarraf Yazdy M, Shields AF, Agop P, Marshall J, Lenz HJ, Salem

ME. Molecular characterization of early vs. late onset gastroesophageal cancers. 2017



528. Berger MD, Stintzing S, Yang D, Suenaga M, Miyamoto Y, Cao S, Soni S, Gopez R,

Hanna HL, Zhang W, Heinemann V, Lenz HJ. Effect of polymorphisms of genes

encoding regulatory proteins in the coagulation cascade on outcome for mCRC patients

treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. 2017 Gastrointestinal


Abstract # 601.

529. Weinberg BA, Lenz HJ, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Liu Z, Chen S,

El Ghazaly H, Hwang JJ, Philip PA, Shields AF, Marshall J, Salem ME. Molecular

characterization of squamous cell carcinoma of the anal canal (SCCA). 2017



530. Kopetz S, McDonough SL, Van Karlyle Morris VK, Lenz HJ, Magliocco AM, Atreya

CE, Diaz LA, Allegra CJ, Wang SE, Hanyoung Lieu C, Eckhardt GS, Semrad TJ,

Kaberle K, Guthrie KA, Hochster HS. Randomized trial of irinotecan and cetuximab

with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG

1406). 2017 Gastrointestinal Cancers Symposium Poster Session C; Jan 19-21; San

Francisco, CA; Suppl 4S; Abstract # 520.

531. Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Ning Y, Okazaki S, Miyamoto

Y, Suenaga M, Schirripa M, Gopez R, Hanna DL, Zhang W, Lenz HJ. Effect of JAK2

SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and

bevacizumab: Data from FIRE-3 trial. 2017 Gastrointestinal Cancers Symposium




532. Miyamoto Y, Stintzing S, Zhang W, Cao S, Ning Y, Okazaki S, Berger MD, Suenaga

M, Schirripa M, Soni S, Matsusaka S, Yang D, Gopez R, Hanna DL, Barzi A, Baba H,

Heinemann V, Lenz HJ. Polymorphisms in adipokine-related genes to predict

treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated

with bevacizumab-based chemotherapy. 2017 Gastrointestinal Cancers Symposium


533. Marshall J, Lenz HJ, Xiu J, El-Deiry WS, Swensen J, El Ghazaly H, Gatalica Z,

Hwang JJ, Philip PA, Shields AF, Salem ME. Molecular variances between rectal and

left-sided colon cancers. 2017 Gastrointestinal Cancers Symposium Poster Session C;

Jan 19-21; San Francisco, CA; Suppl 4S; Abstract # 522.

534. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Salvatore L, Lonardi S, Moretto R,

Borelli B, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Hanna DL, Barzi A,

Wakatsuki T, Yamaguchi T, Loupakis F, Lenz HJ. Genetic variants of genes in

CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients

with refractory metastatic colorectal cancer: A report of ethnic difference. 2017



535. Hurwitz H, Tan BR, Reeves AJ, Xiong HQ, Somer BG, Lenz HJ, Hochster HS,

Scappaticci F, Palma JF, Mancao C, Lee JJ, Nicholas A, Sommer N, Bendell

JC. Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-

label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV)

vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal

cancer (mCRC). 2017 Gastrointestinal Cancers Symposium Poster Session C; Jan 19-

21; San Francisco, CA; Suppl 4S; Abstract # 657.

536. Salem ME, Xiu J, Weinberg BA, El-Deiry WS, Weiner LM, Gatalica Z, Liu Z, El

Ghazaly H, Xiao N, Hwang JJ, Philip PA, Shields AF, Lenz HJ, Marshall J.

Characterization of tumor mutation burden (TMB) in gastrointestinal (GI) cancers.

2017 Gastrointestinal Cancers Symposium Poster Session C; Jan 19-21; San Francisco,

CA; Suppl 4S; Abstract # 530.

537. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Marmorino F, Bergamo F,

Antoniotti C, Rossini D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R,

Hanna DL, Barzi A, Mashima T, Yamaguchi T, Loupakis F, Lenz HJ. Role of genetic

polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with

refractory metastatic colorectal cancer. 2017 Gastrointestinal Cancers Symposium


538. Overman MJ, Lonardi S, Leone F, McDermott RS, Morse MA, Wong KYM, Neyns B,

Leach JL, Garcia Alfonso P, Lee JJ, Hill A, Lenz HJ, Desai J, Moss RA, Cao ZA,

Ledeine JM, Tang H, Kopetz S, Andre T. Nivolumab in patients with DNA mismatch

repair deficient/microsatellite instability high metastatic colorectal cancer: Update from

CheckMate 142. 2017 Gastrointestinal Cancers Symposium Poster Session C; Jan 19-

21; San Francisco, CA; Suppl 4S; Abstract # 519.



539. Guercio BJ, Venook AP, Niedzwiecki D, Zhang S, Sato K, Fuchs CS, Lenz HJ,

Innocenti F, Fruth B, Van Blarigan E,O'Neil BH, Shaw JE, Polite BN, Hochster HS,

James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Bertagnolli MM,

Blanke CD, Meyerhardt JA. Associations of physical activity with survival and

progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance).

2017 Gastrointestinal Cancers Symposium Poster Session C; Jan 19-21; San Francisco,

CA; Suppl 4S; Abstract # 659.

540. Janku M, Barzi A, Sartore-Bianchi A, Fujii T, Cassingena A, Siravegna G, Karp DD,

Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio

F, Erlander MG, Luthra R, Kopetz S, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A.

Mutation enrichment next-generation sequencing for quantitative detection of KRAS

mutations in urine cell-free DNA from patients with advanced colorectal and other

cancers. 2017 Gastrointestinal Cancers Symposium Poster Session C; Jan 19-21; San


541. Ohtsu A, Yoshino T, Falcone A, Garcia-Carbonero R, Argiles G, Sobrero AF, Peeters

M, Makris L, Benedetti FM, Zaniboni A, Shimada Y, Yamazaki K, Komatsu Y,

Rochster HS, Lenz HJ, Tran B, Yoshida K,Van Cutsem E, Mayer RJ. Onset of

neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of

trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal

cancer. 2017 Gastrointestinal Cancers Symposium Poster Session C; Jan 19-21; San


542. Venook AP, Ou F-S, Lenz H-J, Kabbarah O, Qu X, Niedzwiecki D, Zemla T,

Goldberg RM, Hochster HS, O'Neil BH, Sanoff HK, Mayer RJ, Bertagnolli MM,

Blanke CD, Innocenti F. Primary tumor location as an independent prognostic marker

from molecular features for overall survival in patients with metastatic colorectal

cancer: analysis of CALGB/SWOG 80405 (Alliance). In: Proceedings of the 53rd

Annual Meeting of the American Society of Clinical Oncology; 2017, June 2-6;

Chicago, Illinois; ASCO Oral Abstract Session, J Clin Onc 35(15S): Abstract #3503.

543. Kopetz S, McDonough SL, Lenz H-J, Magliocco AM, Atreya CE, Diaz LA, Allegra

CJ, Singh Raghav KP, MorrisVK, Wang SE, Lieu CH, Guthrie KA, Hochster HS.

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-

mutant metastatic colorectal cancer (SWOG S1406). In: Proceedings of the 53rd


Chicago, Illinois; ASCO Oral Abstract Session, J Clin Onc 35(15S): Abstract #3505.

544. Stintzing S, Wirapati P, Lenz H-J, Neureiter D, von Weikersthal LF, Decker T, Kiani

A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, Kahl C, Kullmann F, Moehler MH,

Scheithauer W, Held S, Modest DP, Jung A, Kirchner T, Tejpar S, Heinemann V.

Consensus Molecular Subgroups (CMS) of Colorectal Cancer (CRC) and 1st Line

Efficacy of FOLFIRI Plus Cetuximab or Bevacizumab: Analysis of the FIRE-3 (AIO

KRK 0306) Study. In: Proceedings of the 53rd Annual Meeting of the American

Society of Clinical Oncology; 2017, June 2-6; Chicago, Illinois; ASCO Oral Abstract

Session, J Clin Onc 35(15S): Abstract #3510.



545. Lenz H-J, Ou F-S, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer

RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Innocenti F, Kabbarah O. Impact of

consensus molecular subtyping (CMS) on overall survival (OS) and progression free

survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of

CALGB/SWOG 80405 (Alliance). In: Proceedings of the 53rd Annual Meeting of the

American Society of Clinical Oncology; 2017, June 2-6; Chicago, Illinois; ASCO Oral

Abstract Session, J Clin Onc 35(15S): Abstract #3511.

546. Furchtgott L, Swanson D, Hayete B, Khalil I, Wuest D, Rich K, Nixon AB,

Niedzwiecki D, Meyerhardt JA, O'Reilly EM, Ou F-S, Lenz H-J, Innocenti F, Venook

AP (Alliance for Clinical Trials in Oncology). Statistical modeling of CALGB 80405

(Alliance) to identify influential factors in metastatic colorectal cancer (CRC)

dependent on primary (1o) tumor side. In: Proceedings of the 53rd Annual Meeting of

the American Society of Clinical Oncology; 2017, June 2-6; Chicago, Illinois; ASCO

Poster Session, J Clin Onc 35(15S): Abstract #3528.

547. Andre T, Lonardi S, Wong KYM, Morse M, McDermott RS, Hill AG, Hendlisz A,

Lenz H-J, Leach JW, Moss RA, Cao ZA, Ledeine J-M, Chan E, Kopetz S, Overman

MJ. Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients

(pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability

(MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study. In: Proceedings

of the 53rd Annual Meeting of the American Society of Clinical Oncology; 2017, June

2-6; Chicago, Illinois; ASCO Poster Session, J Clin Onc 35(15S): Abstract #3531.

548. Kopetz S, Lonardi S, McDermott RS, Aglietta M, Hendlisz A, Morse M, Leach JW,

Neyns B, Chan E, Chen F, Wong KYM, Lee JJ, Garcia-Alfonso P, Hill AG, Lenz H-J,

Desai J, Moss RA, Cao ZA, Overman MJ, Thierry Andre T. Concordance of DNA

mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local

and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo)

in CheckMate 142 study. In: Proceedings of the 53rd Annual Meeting of the American

Society of Clinical Oncology; 2017, June 2-6; Chicago, Illinois; ASCO Poster Session,

J Clin Onc 35(15S): Abstract #3548.

549. Salem ME, Lenz H-J, Xiu J, Hwang JJ, Philip PA, Shields AF, Marshall J. Colorectal

cancer: Impact of primary tumor location on genetic alterations. In: Proceedings of the

53rd Annual Meeting of the American Society of Clinical Oncology; 2017, June 2-6;

Chicago, Illinois; ASCO Poster Session, J Clin Onc 35(15S): Abstract #3578.

550. Miyamoto Y, Stintzing S, Heinemann V, Zhang W, Cao S, Okazaki S, Berger MD,

Suenaga M, Schirripa M, Soni S, Matsusaka S, Ning Y, Yang D, Gopez R, Melendez E,

Hanna DL, Barzi A, Baba H, Lenz H-J. Association of genetic variations in genes

implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer

(mCRC) treated with cetuximab plus chemotherapy. In: Proceedings of the 53rd





551. Suenaga M, Cao S, Stintzing S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD,

Miyamoto Y, Schirripa M, Gopez R, Melendez E, Soni S, Barzi A, Yamaguchi T,

Heinemann V, Lenz H-J. Genetic polymorphisms of CCL5 and CCR5 to predict

efficacy of cetuximab-based treatment in metastatic colorectal cancer patients

depending on primary tumor location. In: Proceedings of the 53rd Annual Meeting of

the American Society of Clinical Oncology; 2017, June 2-6; Chicago, Illinois; ASCO

Poster Session, J Clin Onc 35(15S): Abstract #3594.

552. Suenaga M, Cao S, Zhang W, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa

M, Gopez R, Melendez E, Soni S, Barzi A, Yamaguchi T, Lenz H-J. Genetic variants

in CCL5 and CCR5 genes and serum VEGF-A levels to predict efficacy of

bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy.

In: Proceedings of the 53rd Annual Meeting of the American Society of Clinical

Oncology; 2017, June 2-6; Chicago, Illinois; ASCO Poster Session, J Clin Onc

35(15S): Abstract #11564.

553. Iqbal S, McDonough S, Lenz H-J, Ilson DH, Burtness B, Singh Nangia C, Barzi A,

Schneider C, Liu J, Dotan E, Guthrie KA, Hochster HS. A randomized phase II pilot

study prospectively evaluating treatment for patients based on ERCC1 for advanced/

metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201. In:

Proceedings of the 53rd Annual Meeting of the American Society of Clinical


35(15S): Abstract #4009.

554. Barzi A, Hershman DL, Till C, Lenz H-J, Hochster HS, Unger JM. Patterns of

osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials. In:

Proceedings of the 53rd Annual Meeting of the American Society of Clinical


35(15S): Abstract #10056.

555. Berger MD, Stintzing S, Yang D, Cao S, Miyamoto Y, Suenaga M, Soni S, Gopez R,

Melendez E, Zhang W, Heinemann V, Lenz H-J. Genetic variations within the vitamin

C transporter genes to predict outcome in metastatic colorectal cancer patients treated

with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. In: Proceedings of

the 53rd Annual Meeting of the American Society of Clinical Oncology; 2017, June 2-

6; Chicago, Illinois; ASCO Oral Abstract Session, J Clin Onc 35(15S): Abstract

#11507.

556. Salem ME, Xiu J, Lenz H-J, Atkins MB, Philip PA, Hwang JJ, Gatalica Z, Xiao N,

Gibney GT, El-Deiry WS, Tan AR, Kim ES, Shields AF, Raghavan D, Marshall J.

Characterization of tumor mutation load (TML) in solid tumors. In: Proceedings of the



557. Miyamoto Y, Loupakis F, Zhang W, Cao S, Okazaki S, Berger MD, Suenaga M,

Schirripa M, Soni S, Matsusaka S, Ning Y, Yang D, Gopez R, Melendez E, Hanna DL,

Barzi A, Baba H, Falcone A, Lenz H-J. Genetic variations in semaphorin/neuropilin

signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer

(mCRC) receiving bevacizumab-based chemotherapy. In: Proceedings of the 53rd





558. Sunakawa Y, Yang D, LaFleur B, Luecke J, Thompson D, Moran M, Astrow SH,

Hsiang J, Zhang W, Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S,

Yamaguchi T, Eto T, Fujii M, Ichikawa W, Lenz H-J. Association of immune-related

genes to neutrophil-lymphocyte ratio (NLR) with survival of cetuximab treatment for

metastatic colorectal cancer (mCRC): JACCRO CC-05/06AR. In: Proceedings of the



559. Salem ME, Xiu J, Puccini A, Philip PA, Goldberg RM, Hwang JJ, Kc B, Korn WM,

hields AF, Lenz H-J, John Marshall J. Molecular characterization of intestinal (IS) and

diffuse subtypes (DS) of gastric adenocarcinomas. 2018 Gastrointestinal Cancers

Symposium Poster Session A; Jan 18-20; San Francisco, CA; J Clin Oncol 36 (Suppl

4S); Abstract #60.

560. Thomas JS, Lenz H-J, Iqbal S, Tsao-Wei DD, Barzi A, Duddalwar V, Cole S, Rehman

R, Menendez X, Krasnoperov V, Liu R, Feng Q, Gill PS, El-Khoueiry AB. A first-in-

human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular

(HCC) and cholangiocarcinoma (CCA). 2018 Gastrointestinal Cancers Symposium

Poster Session B; Jan 18-20; San Francisco, CA; J Clin Oncol 36 (Suppl 4S); Abstract

#285.

561. Andre T, Lonardi S, Wong M, Lenz H-J, Gelsomino F, Aglietta M, Morse M, Van

Cutsem E, McDermott RS, Hill AG, Sawyer MB, Hendlisz A, Neyns B, Svrcek M,

Moss RA, Ledeine J-M, Z. Cao A, Kamble S, Kopetz S, Overman MJ. Nivolumab +

ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite

instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of

the full cohort from CheckMate-142. 2018 Gastrointestinal Cancers Symposium Oral

Abstract Session C; Jan 18-20; San Francisco, CA; J Clin Oncol 36 (Suppl 4S);

Abstract #553.

562. Bekaii-Saab TS, Ou F-S, Anderson DM, Ahn DH, Boland PM, Ciombor KK, Jacobs

NL, Desnoyers RJ, Cleary JM, Meyers JP, Chiorean EG, Pedersen K, Barzi A, Sloan J,

McCune JS, Lacouture ME, Lenz H-J, Grothey A. Regorafenib dose optimization

study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib

in refractory metastatic colorectal cancer (mCRC)—An ACCRU Network study. 2018


J Clin Oncol 36 (Suppl 4S); Abstract #611.

563. Barzi A, Salem ME, Xiu J, Korn WM, Marshall J, Shields AF, Lenz H-J. Differences

in molecular profiles of males and females with colorectal cancer (CRC). 2018



564. Berger MD, Zlobec I, Yang D, Cao S, Sunakawa Y, Matsusaka S, Koelzer VH,

Inderbitzin D, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S,

Puccini A, Tokunaga R, Naseem M, Zhang W, Lugli A, Lenz H-J. Association of

genetic variations within the PD-L2 immune checkpoint gene with outcome in stage II

and III colon cancer. 2018 Gastrointestinal Cancers Symposium Poster Session C; Jan

18-20; San Francisco, CA; J Clin Oncol 36 (Suppl 4S); Abstract #626.



565. Sunakawa Y, Satake H, Usher JL, Jaimes YS, Miyamoto Y, Nakamura M, Nakayama

H, Sugano N, Takagane A, Gotoh M, Watanabe T, Ishigure K, Tanaka C, Takeuchi M,

Fujii M, Danenberg K, Lenz H-J, Sekikawa T, Ichikawa W. Initial therapy with

FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer

(mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker

for the efficacy: JACCRO CC-11. 2018 Gastrointestinal Cancers Symposium Poster

Session C; Jan 18-20; San Francisco, CA; J Clin Oncol 36 (Suppl 4S); Abstract #635.

566. Sehdev A, Niedzwiecki D, Venook AP, Lenz H-J, Innocenti F, Mahoney MR, Shaw

JE, Polite BN, Hochster HS, Atkins JN, Goldberg R, Mayer RJ, Schilsky RL,

Bertagnolli MM, Blanke CD, O'Neil BH. Association of RAS mutations with race in

metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE). 2018



567. Puccini A, Berger MD, Tokunaga R, Naseem M, Battaglin F, Cao S, Millstein J, Soni

S, McSkane M, Zhang W, Loupakis F, Stintzing S, Heinemann V, Falcone A, Lenz H-

J. Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical

outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two

independent randomized phase III trials: TRIBE and FIRE-3. 2018 Gastrointestinal

Cancers Symposium Poster Session C; Jan 18-20; San Francisco, CA; J Clin Oncol 36

(Suppl 4S); Abstract #645.

568. Puccini A, Loupakis F, Stintzing S, Berger MD, Tokunaga R, Naseem M, Battaglin F,

Cao S, Millstein J, Soni S, McSkane M, Zhang W, Heinemann V, Falcone A, Lenz H-

J. Genetic variants in methylation and demethylation pathways to predict clinical

outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line

FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials. 2018 Gastrointestinal Cancers

Symposium Poster Session C; Jan 18-20; San Francisco, CA; J Clin Oncol 36 (Suppl

4S); Abstract #646.

569. Tokunaga R, Cao S, Zhang W, Puccini A, Berger MD, Naseem M, Battaglin F, Soni S,

McSkane M, Stintzing S, Loupakis F, Heinemann V, Falcone A, Millstein J, Lenz H-J.

The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal

cancer patients with bevacizumab-based chemotherapy. 2018 Gastrointestinal Cancers


4S); Abstract #651.

570. Naseem M, Berger MD, Puccini A, Tokunaga R, Battaglin F, Barzi A, Soni S,

McSkane M, Cao S, Millstein J, Zhang W, Loupakis F, Stintzing S, Heinemann V,

Falcone A, Lenz H-J. Polymorphisms in beta-defensin pathways and clinical outcomes

in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two

randomized phase III trials. 2018 Gastrointestinal Cancers Symposium Poster Session

C; Jan 18-20; San Francisco, CA; J Clin Oncol 36 (Suppl 4S); Abstract #662.



571. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Murgioni S, Lonardi

S, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Loupakis F,

Falcone A, Lenz H-J. Single nucleotide polymorphisms in miRNA binding sites of

nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in

FOLFOXIRI plus bevacizumab in TRIBE trial. 2018 Gastrointestinal Cancers


4S); Abstract #663.

572. Barzi A, Campan M, Petterson J, Du L, Long T, Dubeau L, Lenz H-J, Ward P.

Assessment of microsatellite instability (MSI) in cell free DNA (cfDNA) of colorectal

cancers (CRC) patients (pts). 2018 Gastrointestinal Cancers Symposium Poster Session

C; Jan 18-20; San Francisco, CA; J Clin Oncol 36 (Suppl 4S); Abstract #672.

573. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Bergamo F, Zagonel V,

Rossini D, Borelli B, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A,

Yamaguchi T, Loupakis F, Lenz H-J. Matrix metalloproteinase-related gene

polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal

cancer. 2018 Gastrointestinal Cancers Symposium Poster Session C; Jan 18-20; San

Francisco, CA; Suppl 4S; Abstract #692.

574. Loupakis F, Hurwitz HI, Saltz L, Arnold D, Grothey A, Nguyen QL, Osborne S, Yau L,

Talbot J, Srock S, Lenz H-J. Efficacy outcomes with bevacizumab added to

chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-

sided tumors in metastatic colorectal cancer (mCRC). 2018 Gastrointestinal Cancers


4S); Abstract #726.

575. Kopetz S, Spira AI, Wertheim M, Kim E, Tan BR, Lenz H-J, Nikolinakos P, Rich P,

Smith DA, Helwig C, Dussault I, Ojalvo L, Gulley JL. M7824 (MSB0011359C), a

bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily

pretreated CRC: Preliminary results from a phase I trial. 2018 Gastrointestinal Cancers


4S); Abstract #764.

576. Davis SL, Cardin DB, Shahda S, Lenz H-J, Dotan E, O'Neil BH, Kapoun AM, Stagg

RJ, Berlin J, Messersmith WA, Cohen SJ. A phase 1b dose escalation study of

vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in

patients with previously untreated stage IV pancreatic cancer. 2019 Gastrointestinal

Cancers Symposium; Jan 17-19; San Francisco, CA; J Clin Oncol 37; Abstract #237077

577. Suenaga M, Cao S, Zhang W, Matsusaka S, Okazaki S, Berger MD, Miyamoto Y,

Schirripa M, Barzi A, Ueno M, Lenz H-J. Role of enterocyte-specific gene

polymorphisms in adjuvant treatment for stage III colorectal cancer. 2019

Gastrointestinal Cancers Symposium; Jan 17-19; San Francisco, CA; J Clin Oncol 37;

Abstract #239735

578. Battaglin F, Puccini A, Cao S, Millstein J, Tokunaga R, Naseem M, Soni S, Lo JH,

Ning T, Arai H, Berger MD, Barzi A, Zhang W, Heinemann V, Stintzing S, Lenz H-J.

Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4

expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic

colorectal cancer (mCRC): data from the FIRE-3 phase III trial. 2019 Gastrointestinal




579. Battaglin F, Loupakis F, Stintzing S, Cao S, Puccini A, Tokunaga R, Naseem M,

Berger MD, Soni S, Lo JH, Bergamo F, Lonardi S, Millstein J, Zhang W, Zagonel V,

Cremolini C, Falcone A, Heinemann V, Lenz H-J. Polymorphisms in the telomerase

complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC):

data from TRIBE and FIRE-3 phase III trials. 2019 Gastrointestinal Cancers

Symposium; Jan 17-19; San Francisco, CA; J Clin Oncol 37; Abstract #240615

580. Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Hwang JJ, Marshall J, Vanderwalde AM,

Shields AF, Lenz H-J, Salem ME, Philip PA, Goldberg RM, Korn WM, Kim SS.

Association of DNA damage response and repair genes (DDR) mutations and

microsatellite instability (MSI), PD-L1 expression, Tumor mutational burden (TMB) in

gastroesophageal cancers. 2019 Gastrointestinal Cancers Symposium; Jan 17-19; San

Francisco, CA; J Clin Oncol 37; Abstract #240729

581. Puccini A, Poorman K, Salem ME, Goldberg RM, Shields AF, Berger MD, Battaglin F,

Tokunaga R, Naseem M, Zhang W, Soni S, Korn WM, Philip PA, Marshall J, Lenz H-

J. Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the

stomach and colon. 2019 Gastrointestinal Cancers Symposium; Jan 17-19; San

Francisco, CA; J Clin Oncol 37; Abstract #240821

582. Hall MJ, Bodor JN, Xiu J, Feldman R, Grothey A, Goldberg RM, Worrilow WM,

Hwang JJ, Kim ES, Lenz H-J, Raghavan D, Shields AF, Marshall J, Korn WM, Salem

ME. Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR)

protein expression and somatic mutations (muts), microsatellite instability (MSI) and

tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles

(TGPs). 2019 Gastrointestinal Cancers Symposium; Jan 17-19; San Francisco, CA; J

Clin Oncol 37; Abstract #240917

583. Hatch AJ, Ou F-S, Zemla T, Starr MD, Brady JC, Liu Y, Innocenti F, Meyerhardt JA,

O'Reilly EM, Lenz H-J, Hurwitz H, Venook AP, Nixon AB. On-treatment changes of

plasma protein biomarkers in CALGB/SWOG 80405 (Alliance). 2019 Gastrointestinal


584. Tokunaga R, Cao S, Battaglin F, Lo JH, Loupakis F, Stintzing S, Naseem M, Puccini

A, Berger MD, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ,

Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz H-J. Th17 cell

pathway-related genetic variants in metastatic colorectal cancer: a meta-analysis using

TRIBE, MAVERICC, and FIRE-3. 2019 Gastrointestinal Cancers Symposium; Jan 17-

19; San Francisco, CA; J Clin Oncol 37; Abstract #241417

585. Barzi A, Cho SK, Hay JW, Lenz H-J, Ou F-S, Grothey A, Bekaii-Saab TS. Cost-

effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal

cancer. 2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Health Services

Research, Clinical Informatics, and Quality of Care. J Clin Oncol 37, 2019 (suppl; abstr

e18367).

586. Yu Sunakawa, Joshua L. Usher, Yolanda S Jaimes, Akihito Tsuji, Manabu Shiozawa,

Takanori Watanabe, Hironaga Satake, Hirofumi Ota, Mitsugu Kochi, Hisatsugu Ohori,

Dai Manaka, Masato Matsuura, Masahiro Takeuchi, Peter V. Danenberg, Masashi

Fujii, Wataru Ichikawa, Heinz-Josef Lenz, Kathleen Danenberg. Clinical verification

of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for

quantitative monitoring of treatment response in metastatic colorectal cancer

(mCRC): A biomarker study of the DEEPER trial. 2019 ASCO Annual Meeting; May



29-Jun 4; Chicago, IL; Gastrointestinal (Colorectal) Cancer - Poster 110A. J Clin Oncol

37, 2019 (suppl; abstr TPS3621).

587. Martin D. Berger, Shu Cao, Inti Zlobec, Yuji Miyamoto, Mitsukuni Suenaga, Diana L.

Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca

Battaglin, Wu Zhang, Alessandro Lugli, Heinz-Josef Lenz. Association of genetic

variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III

colon cancer. 2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Developmental

Immunotherapy and Tumor Immunobiology - Poster 277. J Clin Oncol 37, 2019 (suppl;

abstr 2633).

588. Brendan John Guercio, Alan P. Venook, Sui Zhang, Fang-Shu Ou, Donna Niedzwiecki,

Heinz-Josef Lenz, Federico Innocenti, Michael N. Pollak, Andrew B. Nixon, Michelle

R. Mahoney, Bert O'Neil, James Edward Shaw, Blase N. Polite, Crystal S. Denlinger,

James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Charles David Blanke,

Charles S. Fuchs, Jeffrey A. Meyerhardt. Associations of insulin-like growth factor

binding proteins and adiponectin with disease progression and mortality in metastatic

colorectal cancer: Results from CALGB/SWOG 80405 (Alliance). 2019 ASCO Annual

Meeting; May 29-Jun 4; Chicago, IL; Developmental Therapeutics and Tumor Biology

(Nonimmuno) - Poster 27. J Clin Oncol 37, 2019 (suppl; abstr 3035).

589. Francesca Battaglin, Shu Cao, Fotios Loupakis, Sebastian Stintzing, Aparna Raj Parikh,

Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Martin D. Berger, Hiroyuki Arai,

Joshua Millstein, Sara Lonardi, Wu Zhang, Chiara Cremolini, Christoph Mancao,

Alfredo Falcone, Volker Heinemann, Heinz-Josef Lenz. Polymorphisms in the

dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal

cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials. 2019

ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Developmental Therapeutics and

Tumor Biology (Nonimmuno) - Poster 40. J Clin Oncol 37, 2019 (suppl; abstr 3048).

590. Alberto Puccini, Joanne Xiu, Richard M. Goldberg, Axel Grothey, Anthony Frank

Shields, Mohamed E. Salem, Andreas Seeber, Francesca Battaglin, Martin D. Berger,

Wafik S. El-Deiry, Ryuma Tokunaga, Madiha Naseem, Wu Zhang, Sukeshi Patel

Arora, Moh'd M. Khushman, Michael J. Hall, Philip Agop Philip, John Marshall,

Wolfgang Michael Korn, Heinz-Josef Lenz

591. Molecular differences between lymph nodes (LNs) and distant metastases (mets) in

colorectal cancer (CRC). 2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL;

Development Therapeutics and Tumor Biology (Nonimmuno) - Poster 122. J Clin

Oncol 37, 2019 (suppl; abstr 3130).

592. Madiha Naseem, Shu Cao, Sebastian Stintzing, Fotios Loupakis, Martin D. Berger,

Alberto Puccini, Ryuma Tokunaga, Francesca Battaglin, Afsaneh Barzi, Shivani Soni,

Joshua Millstein, Mohamed E. Salem, Chiara Cremolini, Wu Zhang, Volker

Heinemann, Alfredo Falcone, Heinz-Josef Lenz. BRCA1 genetic variant to predict

survival in metastatic colorectal cancer (mCRC) patients (pts) treated with

FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials. 2019

ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Developmental Therapeutics and

Tumor Biology (Nonimmuno) - Poster 137. J Clin Oncol 37, 2019 (suppl; abstr 3145).

593. Heinz-Josef Lenz, Sara Lonardi, Vittorina Zagonel, Eric Van Cutsem, M. Luisa

Limon, Ka Yeung Mark Wong, Alain Hendlisz, Massimo Aglietta, Pilar Garcia-

Alfonso, Bart Neyns, Dana Backlund Cardin, Andrea Spallanzani, Tomislav



Dragovich, Usman Shah, Ajlan Atasoy, Jean-Marie Ledeine, Michael J. Overman.

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in

microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR)

metastatic colorectal cancer (mCRC): Clinical update. 2019 ASCO Annual Meeting;

May 29-Jun 4; Chicago, IL; Gastrointestinal (Colorectal) Cancer - Poster 13. J Clin

Oncol 37, 2019 (suppl; abstr 3521).

594. Ofer Margalit, William S. Harmsen, Einat shacham-Shmueli, Molly Petersen, Ben

Boursi, Leonard B. Saltz, Richard Adams, Tim Maughan, Jean-Yves Douillard, Eric

Van Cutsem, Herbert Hurwitz, Carsten Bokemeyer, Niall C. Tebbutt, Fairooz F.

Kabbinavar, Aimery De Gramont, Qian Shi, Heinz-Josef Lenz. Evaluating gender as a

predictive marker for response to bevacizuamb (Bev) in metastatic colorectal

carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.

2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Gastrointestinal (Colorectal)

Cancer - Poster 31. J Clin Oncol 37, 2019 (suppl; abstr 3539).

595. Hiroyuki Arai, Shu Cao, Fotios Loupakis, Sebastian Stintzing, Ryuma Tokunaga,

Francesca Battaglin, Jae Ho Lo, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour

Salhia, Shannon M Mumenthaler, Daniel J Weisenberger, Gangning Liang, Chiara

Cremolini, Volker Heinemann, Alfredo Falcone, Joshua Millstein, Heinz-Josef Lenz.

Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic

colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials. 2019

ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Gastrointestinal (Colorectal)

Cancer - Poster 37. J Clin Oncol 37, 2019 (suppl; abstr 3545)

596. Alberto F. Sobrero, Heinz-Josef Lenz, Cathy Eng, Werner Scheithauer, Gary William

Middleton, Wen-Feng Chen, Regina Esser, Johannes Nippgen, Howard A. Burris.

Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts)

with RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan ±

cetuximab in the EPIC study. 2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL;

Gastrointestinal (Colorectal) Cancer - Poster 72. J Clin Oncol 37, 2019 (suppl; abstr

3580).

597. Andreas Seeber, Florian Kocher, Joanne Xiu, Gilbert Spizzo, Alberto Puccini, Jeffrey

Swensen, Michelle Ellis, Richard M. Goldberg, Axel Grothey, Anthony Frank Shields,

Mohamed E. Salem, Francesca Battaglin, Wafik S. El-Deiry, Ryuma Tokunaga,

Madiha Naseem, Philip Agop Philip, John Marshall, Wolfgang Michael Korn, Heinz-

Josef Lenz, Zoran Gatalica. Molecular landscape of colorectal cancers harboring R-

spondin fusions. 2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL;

Gastrointestinal (Colorectal) Cancer - Poster 80. J Clin Oncol 37, 2019 (suppl; abstr

3588).

598. Francesca Battaglin, Shu Cao, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem,

Hiroyuki Arai, Martin D. Berger, Tricia Ning, Shivani Soni, Jae Ho Lo, Afsaneh Barzi,

Joshua Millstein, Wu Zhang, Volker Heinemann, Sebastian Stintzing, Heinz-Josef

Lenz. Gene expression and genetic variants in Parkinson's disease (PD) genes to

predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III

trial. 2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Gastrointestinal

(Colorectal) Cancer - Poster 87. J Clin Oncol 37, 2019 (suppl; abstr 3595).

599. Ryuma Tokunaga, Joanne Xiu, Richard M. Goldberg, Philip Agop Philip, Andreas

Seeber, Francesca Battaglin, Hiroyuki Arai, Jae Ho Lo, Alberto Puccini, Madiha



Naseem, Martin D. Berger, Shivani Soni, Wu Zhang, Wangjuh Sting Chen, Jimmy J.

Hwang, Anthony Frank Shields, John Marshall, Hideo Baba, W. Michael Korn, Heinz-

Josef Lenz. Gene mutations of SWI/SNF complex and molecular profile in colorectal

cancer. 2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Gastrointestinal

(Colorectal) Cancer - Poster 92. J Clin Oncol 37, 2019 (suppl; abstr 3600).

600. Matthew K Stein, Joanne Xiu, Michael Gary Martin, Axel Grothey, Philippe Prouet,

Jeffrey Owsley, Forrest W Williard, Evan Scott Glazer, Paxton Vandiver Dickson,

David Shibata, Danny Yakoub, Richard M. Goldberg, W. Michael Korn, Anthony

Frank Shields, Jimmy J. Hwang, Heinz-Josef Lenz, Jeremiah Lee Deneve. Molecular

comparison between peritoneal metastases (PM) and primary gastric (GC) and

gastroesophageal junction (GEJ) cancer. 2019 ASCO Annual Meeting; May 29-Jun 4;

Chicago, IL; Gastrointestinal (Noncolorectal) Cancer - Poster 158. J Clin Oncol 37,

2019 (suppl; abstr 4053).

601. Gilbert Spizzo, Alberto Puccini, Joanne Xiu, Richard M. Goldberg, Axel Grothey,

Anthony Frank Shields, Sukeshi Patel Arora, Moh'd M. Khushman, Mohamed E.

Salem, Francesca Battaglin, Wafik S. El-Deiry, Ryuma Tokunaga, Philip Agop Philip,

Michael J. Hall, John Marshall, Florian Kocher, Wolfgang Michael Korn, Heinz-Josef

Lenz, Andreas Seeber. Frequency of BRCA mutation in biliary tract cancer and its

correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).

2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Gastrointestinal

(Noncolorectal) Cancer - Poster 190. J Clin Oncol 37, 2019 (suppl; abstr 4085).

602. Andreas Seeber, Alberto Puccini, Joanne Xiu, Richard M. Goldberg, Axel Grothey,

Anthony Frank Shields, Mohamed E. Salem, Francesca Battaglin, Wafik S. El-Deiry,

Ryuma Tokunaga, Philip Agop Philip, John Marshall, Florian Kocher, Michael J. Hall,

Wolfgang Michael Korn, Heinz-Josef Lenz, Gilbert Spizzo. Association of BRCA-

mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1

expression. 2019 ASCO Annual Meeting; May 29-Jun 4; Chicago, IL; Gastrointestinal

(Noncolorectal) Cancer - Poster 238. J Clin Oncol 37, 2019 (suppl; abstr 4133).

603. Aminah Jatoi, Fang-Shu Ou, Daniel H. Ahn, Patrick McKay Boland, Kristen Keon

Ciombor, Nisha Lassi Jacobs, Boris Pasche, James M. Cleary, Jeannine S. McCune,

Katrina Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Erica N. Heying, Heinz-Josef

Lenz, Jeff A. Sloan, Mario E. Lacouture, Axel Grothey, Tanios S. Bekaii-Saab.

Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot

reactions: Results from the ReDOS trial. 2019 ASCO Annual Meeting; May 29-Jun 4;

Chicago, IL; Symptoms and Survivorship - Poster 278. J Clin Oncol 37, 2019 (suppl;

abstr 11586).

Chapters

1. Lenz, H-J. Bestimmung der Androstendionspiegel im Serum von Kindern mit Ullrich-

Turner…In: Cancer Gene Therapy, 1989.

2. Lenz H-J, Danenberg KD, Danenberg PV: Quantitative measurement of relative gene

expression in human tumors. In: Reverse Transcriptase PCR. Simon and Schuster,

1994.

3. Lenz HJ, Hill C, Danenberg K, Leichman L, Priest DG, Danenber PV. Rapid

Quantitative PCR for Determination of Relative Gene Expressions in Tissue



Specimens. In: PCR Methods and Applications, Volume 4. Cold Spring Harbor

Laboratory Press. pp. 305-, 1995.

4. Iqbal S, Lenz H-J: Principles of adjuvant and neoadjuvant therapy: applications in

gastric and pancreatic cancer. In: Surgical Oncology: Multidisciplinary Approach to

Difficult Problems (1st edition; Silberman H, Silberman AW [editors]). Oxford

University Press, New York, NY, pp574–584, 2002.

5. Schneider S, Stoehlmacher J, Lenz H-J: Pharmakogenetik in Kolorektalen

Karzinomen. Der Onkologe. Band 9, Heft 8, 2003.

6. Stoehlmacher J, Iqbal S, Lenz H-J: Polymorphisms in genes of drug targets and

metabolism, and DNA repair. In: Handbook of Anticancer Pharmacokinetics and

Pharmacodynamics (1st Edition; William Figg, Howard McLeod [editors]). Human

Press Inc., Totowa, NJ, pp231–243, 2004.

7. Vallbohmer D, Lenz H-J. Potential Response Prediction in the Neoadjuvant and

Adjuvant Therapy of Esophageal and Gastric Cancer. In: Viszeralchirurgie 40: 249–

254, 2005.

8. Park DJ, Lenz H-J: Proteasome Inhibition in Its Clinical Application in Solid Tumors.

In: The Oncogenomics Handbook. (Larochelle WJ, Shimkets RA [editors]). Human

Press, Totowa, NJ. pp. 493-508, 2006.

9. El-Khoueiry A, Lenz HJ. Future directions in the treatment of colorectal cancer. In:

Challenges in colorectal cancer, second edition. (Scholefield J, Maughan T, Abcarian

H, Grothey A, [editors]). Blackwell Publishing, Oxford, England. pp. 251-270, 2006.

10. Lenz, H-J: Pharmacogenomics and Colorectal Cancer. In: New Trends in Cancer for

the 21st Century – Advances in Experimental Medicine and Biology. (Lopez-Guerrero

JA, Blombart-Bosch A, Felipo V, [editors]). Springer, New York. Volume 587; pp.

211-231, 2006.

11. Valböhmer D, Lenz HJ. Möglichkeiten der Response Prediction. Siewert, Rothmund,

Schumpelick: Praxis der Viszeralchirurgie 2.Auflage, 2006.

12. El-Khoueiry A, Lenz HJ. Molecular biology and pharmacogenomics in GI cancers. In:

Atlas of Gastrointestinal Cancers. Current Medicine, pp. 195-210, 2006.

13. El-Khoueiry A, Lenz HJ. Second line strategies in the treatment of patients with

metastatic colorectal cancer. (Saltz LB, [editor]). In: Colorectal cancer: evidence based

chemotherapy strategies. Humana Press, New York. pp. 119-130, 2007.

14. El-Khoueiry A, Lenz H-J. Personalized Medicine in the Clinical Management of

Colorectal Cancer. In: Bioinformatics in Cancer and Cancer Therapy. (Gordon GJ,

[editor]). Humana Press, Totowa, NJ. pp.155-172, 2008.

15. El-Khoueiry A, Lenz H-J. Pharmacogenomics. In: DeVita, Hellman, and Rosenberg’s

Cancer Principles and Practice of Oncology, 8th Edition. pp. 402-406, 2008.

16. Lenz H-J. In: Esophageal Tumors: Principles and Practice. (Jobe BA, Thomas CR,

Hunter JG, [editors]). Demos Medical Publishing, New York. In press, 2008.

17. Lurje G, Lenz H-J: Role of Thymidylate Synthase Gene Variations in Colorectal

Cancer Patients. In: Genomics and Pharmacogenomics in Anticancer Drug

Development and Clinical Response. (Innocenti F, [editor]). Humana Press, Totowa,

NJ. pp. 151-172, 2008.

18. Lurje G, Lenz H-J: Rationale for Tailored Treatment. In: Esophageal Cancer:

Principles and Practice. Demos Medical Publishing, New York. pp. 219-228, 2009.



19. Park D, Lenz H-J: Cancer of the Pancreas: Adjuvant and Neoadjuvant Therapy. In:

Principles and Practice of Surgical Oncology: A Multidisciplinary Approach to

Difficult Problems. (Silberman H, Silberman AW, [editors]). Lippincott, Williams &

Wilkins, Philadelphia, PA. pp. 694-704, 2009.

20. Winder T, Lenz H-J. Molecular Prognostic Markers In Colon Cancer. In: Metastasis of

Colorectal Cancer. (Beauchemin N, Huot J, [editors]). Springer Science and Business

Media B.V., The Netherlands. Volume 14; pp. 321-342, August 2010.

21. Lurge G, Lenz H-J. Molecular Response Prediction in Multimodality Treatment for

Adenocarcinoma of the Esophagus and Esophagogastric Junction. In: Adenocarcinoma

of the Esophagogastric Junction. (Schneider PM, [editor]). Springer-Verlag, Berlin-

Heidelberg. pp. 179-186, 2010.

22. Lenz HJ. Biomarkers in Oncology. In: Prediction Markers in Clinical Development.

400 p., Humana Press 2011.

23. Paez D, Labonte MJ, Lenz HJ. Pancreatic Cancer: Medical Management (Novel

Chemotherapeutics). In: Modern Management of Benign and Malignant Pancreatic

Disease. (Jacques Van Dam, MD, PhD, [editors]). W.B. Sauders Company A Division

of Elsevier Inc. Gastroenterology clinics of North America. Volume 41:(1), pp. 189-

211, 2012.

Panels / Media Appearances

1. Colon Cancer. Colon Cancer Chat Room, Wellness Community of the Foothills,

Pasadena, CA, 7/27/1998.

2. Colorectal health. Interactive Web discussion, A Doctor in Your House.com Program,

1/27/1999.

3. Colon Cancer. GI Cancer Chat Room, Wellness Community of the Foothills, Pasadena,

CA, 4/20/1999.

4. The latest advances in the diagnosis and treatment of colorectal cancer. Panel

Discussion, The Group Room, Talk LA 1110 AM Radio, 3/5/2000.

5. Frankly speaking about colorectal cancer. Seminar, The Wellness Community of the

Foothills, Pasadena, CA, 3/7/2000.

6. IM862 in colon cancer. Interview, CBS Channel 2, 4/1/2000.

7. Cancer genetics. Internet Live Q&A, WebMD, 4/14/2000.

8. Colorectal cancer: Vital Options. The Group Room, Talk LA 1110 AM Radio, Los

Angeles, CA, 7/16/2000, 12/2/2002.

9. Colon cancer and genetic risk. DNA.com live internet chat, WebMD, 8/29/2000.

10. Frankly Speaking About Colorectal Cancer. Santa Monica Wellness Community, Santa

Monica, CA, 3/15/2003.

11. Cancer Talk- Colorectal Cancer. Vital Options. Recorded via telephone.11/22/05.

12. Colon Cancer Special in Support of Colorectal Cancer Awareness Month. The Group

Room Talk Radio, Encino, CA, 3/16/2003.

13. Colon Cancer. The Group Room Talk Radio, Encino, CA, 7/27/2003.

14. Colon and Carcinoid Tumors. The Wellness Community, Manhattan Beach, CA,

8/6/2003.

15. Cancer: The Next Frontier. The Hollywood Reporter, American Cancer Society,

11/10/2003.



16. Colorectal Cancer Awareness Month. Group Room/Vital Options Radio Talk Show

(Listener Question and Answer). Encino, CA, 3/14/2004.

17. Genetic profiling to predict response to 5-FU/platinum combinations – Colorectal

Cancer Update. Conversations with Oncology research leaders: Bridging the gap

between research and patient care, Audio Series (CD/Cassette) organized by Dr. Neil

Love during the 2nd International Congress on Colorectal Cancer, Palm Beach, FL,

(11/1/2003). Completed product received, 3/2004.

18. Colorectal Cancer Update- Research Leader Think Tank. Prognostic and predictive

factors in systemic therapy, ongoing translational studies. Organized by Dr. Neil Love.

Chicago, IL. July 30, 2004.

19. Strike Out Cancer and New Discoveries. Wellness Community. Redondo Beach, CA.

9/10/2005.

20. Colorectal Cancer Update- Think Tank. Conversations with Oncology Research

Leaders. Bridging the Gap between Research and Patient Care. Organized by Dr. Neil

Love. Chicago, IL. 2005.

21. Colorectal Cancer Update. Group Room/Vital Options Radio Talk Show. Encino, CA

10/23/2005.

22. Colorectal Cancer Awareness Month. Group Room/Vital Options Radio Talk Show

(Listener Question and Answer). Encino, CA, 3/12/2006.

23. Erbitux Media Interview. Barcelona, Spain. 6/29/2006.

24. Colorectal Awareness Broadcast. Vital Options Radio Talk Show. Encino, CA.

2/25/2007.

25. Colorectal Cancer Update: Conversations with Oncology Investigators. Bridging the

gap between reseach and patient care. Vol 6, Issue 1. 2007.

26. Merck Media Interview. Orlando, FL. 1/25/2008.

27. Pancreatic Cancer, ABC News. Los Angeles, CA. 3/5/2008.

28. Clinical Case Study Challenge and Straight Talk (faculty filming), M2

Communications. NY, NY. 3/8/2008.

29. Pancreatic Cancer, Good Morning America. Los Angeles, CA. March 2008.

30. Significance on Kras Mutation Update (CBCE). XM Satellite Radio at Annual ASCO

Meeting 2008.

31. Erbitux Video Shoot. Los Angeles, CA.October 2008.

32. Colorectal Cancer Update curriculum - Research Leader Think Tank. Prognostic and

predictive factors in systemic therapy, ongoing translational studies. Radio talk show

organized by Dr. Neil Love. Hollywood, CA. 12/23/2009.

33. Optimizing Treatment Regimens for Colorectal Cancer: Hightlights from the 2009

ASCO GI Cancer Annual Meeting(CBCE). Oncology uplugged Interview. San

Francisco, CA. 1/17/2009.

34. Colorectal Cancer Awareness Month. Vital Options The Group Room Talk Radio

Show. Sherman Oaks, CA. 3/1/2009.

35. Managing treatment side effects for colorectal cancer. Vital Options International The

Group Room Cancer Talk Radio Show. Los Angeles, CA. 3/22/2009.

36. Erbitux Media Interview. TV clip that went to air in Australia. Channel 10 News.

Melbourne, Australia. 5/17/2009.

37. ECCO/ESMO mCRC Media Debate. Panel1 second speaker (plus rebuttal) and

audience. Scene for the lauch of www.TargetMyCancer.com. 9/21-22/2009.



38. Charla con el Dr. Heinz-Josef Lenz, “Hay una revolucion molecular en cuanto al cancer

de colon”. La Capital New Paper. XX Congreso internacional Federacion Lation

Americana De Sociedades De Cancerologia. AAOC Asociacion Argentina De

Oncoligia Clinica. Mar Del Plata, Argentina. Page 12, 11/10/2011.

39. Buying Time: Funding Cutting Edge Cancer Research and Patient Needs. Inaugural

Dinner for The Danny Butler Memorial Fund, Inc. M, NY 10/12/11.

40. Interview in Ankara resulted in multipule publications (May 2012): 5 newspapers, 3

TVs and 37 mostly-rated internet sites made the article, Colon Cancer. Ankara, Turkey,

3/31-4/4/2012.

41. Frankly speaking about colorectal cancer. Workshop, The Wellness Community of the

Foothills, Pasadena, CA, 3/26/2012.

42. Vital Options 1:1 interview: Genomics of Metastasis. Chicago, IL, 6/3/2013.

43. Vital Options: produce called Advocacy in Action (AIA), Panel discussion during

ASCO. Chicago, IL, 6/3/2013.

44. ECCO/ESMO Bayer Stivarga Virtual Interactive Education Module for Multikinase

Inhibition in mCRC and GIST. Netherlands, Amsterdam. 9/30/2013.

45. OncLive Peer Exchange. Treatment of Metastatic Colorectal Cancer: Case Study

Reports Outlining Second-line and Later-live Options. SFO, CA. 1/17/2014.

46. Colorectal Cancer. A career dedicated to translational research in colorectal cancer.

Future Medicine part of FSG Interview. Published 10.227/CRC.14.43; ISSN 1758-

194X. Colorectal Cancer 4(1), 5-8, 2015.

47. Gastrointestinal Cancer Update 2015 ‹ An Enduring Audio, Print, Podcast, Web and

Mobile Interview Series for Medical Oncologists and Other Allied GI Cancer

Professionals: 2015 Edition. Radio talk show organized by Dr. Neil Love. Los Angeles,

CA. 7/24/15.

48. REAL-LIFE DECISIONS, Clinical Investigators Provide Their Perspectives on Actual

Patients with Metastatic Colorectal, Gastric and Pancreatic Cancer. Module 1: Selection

and Sequencing of Therapy for Patients with Newly Diagnosed Metastatic Colorectal

Cancer (mCRC). Research to Practice (RTP). San Francisco, CA. 1/21/2016.

49. Nintedanib Externale expert filming session with the subject colorectal cancer. 2016

Gastrointestinal Cancers Symposium. Boehringer Ingelheim International gmBh.

1/23/2016.

50. Metastatic Colorectal Cancer: Results of The Mavericc Study. Discusses in German

the findings of this phase II study of mFOLFOX6-bevacizumab vs FOLFIRI-

bevacizumab with biomarker stratification in patients with mCRC. (Abstract 493).The

ASCO Post is pleased to present this special video series of interviews. 1/26/2016.

Educational Material

1. Clinical Update: The role of epidermal growth factor receptor inhibitors in colorectal

cancer. Sponsored by American Academy of CME and Clinical Insights. Supported by

ImClone and BMS. October 2004-2005.

2. New directions in biological therapy of colorectal cancer. Supported by Genentech

BioOncology. Cancer and Abstract Summaries 5(7.) July 2004.

3. Anti-angiogenic Therapy in Oncology. Supported by Genentech BioOncology. Vol. 1,

4 of 11. December 2004.



4. Timely Issues in EGFR Targeted Therapy. ASCO Review and EGFR Clinical Primer.

An interactive CD-ROM and audio CD program. Supported by ImClone and BMS.

January 2005.

5. Targeted Therapy in Combination with Chemotherapy in Metastatic Colorectal Cancer.

Oncology Consultation 3(1) Jan 2006. Lenz H-J, Giantonio BJ. Physician’s Education

Resource, Supported by Genentech BioOncology.

6. New Treatment Paradigms in Colorectal Cancer. Clinical Implementation of Molecular

Markers. Iqbal S, Lenz HJ. Supported by Genentech and Sanofi. October 2006.

7. Colorectal Cancer update. Conversations with Oncology Investigators Bridging the Gap

between Research and Patient Care. CD-ROM and audio CD program. Lenz H-J, Hoff

PH, Hochster H, Hurwitz H. Sponsored by American Academy of CME and Research

to Practice. Vol 8/Issue I 2009.

8. Current Developments in the Treatment of Colorectal Cancer. Speakers Lenz HJ, Ryan

DP, Bearden DL. Sponsored by CancerCare Connect Education. October 26, 2011.

9. Colorectal Cancer. A career dedicated to translational research in colorectal cancer.

Future Medicine part of FSG Interview. Published 10.227/CRC.14.43; ISSN 1758-

194X. Colorectal Cancer 4(1), 5-8, 2015.

10. Gastrointestinal Cancer Update 2015 ‹ An Enduring Audio, Print, Podcast, Web and

Mobile Interview Series for Medical Oncologists and Other Allied GI Cancer

Professionals: Research to Practice, Fuch C, Lenz HJ, Editor: Love N, GICU 2015

Edition, Audio CD, Vol 6/Issue 1, Dec 2015.

Heinz-Josef Lenz, M.D. Curriculum Vitae › wp-content › uploads › 2019 › 11 ›...

Documents

Transcript of Heinz-Josef Lenz, M.D. Curriculum Vitae › wp-content › uploads › 2019 › 11 ›...